



## **EMORY UNIVERSITY AND ITS SUBSIDIARIES**

Independent Auditors' Reports as Required by the Uniform  
Guidance and State of Georgia and Related Information

Year Ended August 31, 2020

## EMORY UNIVERSITY AND ITS SUBSIDIARIES

### Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements – Years ended August 31, 2020 and 2019	3
Notes to Consolidated Financial Statements	8
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	43
<b>Supplementary Schedules</b>	
Supplementary Schedule of Expenditures of Federal Awards	45
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	73
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	74
<b>Uniform Guidance Reports</b>	
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards	76
Schedule of Findings and Questioned Costs	78



KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

## **Independent Auditors' Report**

The Board of Trustees  
Emory University:

### **Report on the Consolidated Financial Statements**

We have audited the accompanying consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statements of financial position as of August 31, 2020 and 2019, the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

#### *Management's Responsibility for the Consolidated Financial Statements*

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

#### *Auditors' Responsibility*

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### *Opinion*

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Emory University and its subsidiaries as of August 31, 2020 and 2019, and the changes in their net assets and their cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



### *Emphasis of Matters*

As discussed in note 2(u) to the consolidated financial statements, in fiscal year 2020, Emory University and its subsidiaries adopted new accounting guidance, Accounting Standards Update (ASU) No. 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*, and ASU No. 2016-02, *Leases (Topic 842)*, as amended. Our opinion is not modified with respect to these matters.

### **Other Reporting Required by Government Auditing Standards**

In accordance with Government Auditing Standards, we have also issued our report dated December 18, 2020 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia  
December 18, 2020

# EMORY UNIVERSITY

## CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AUGUST 31, 2020 AND 2019 (Dollars in thousands)

	August 31, 2020	August 31, 2019
<b>ASSETS:</b>		
Cash and cash equivalents	\$ 1,368,050	\$ 229,414
Patient accounts receivable, net	555,349	515,801
Student accounts receivable, net	81,136	21,875
Loans receivable, net	20,783	21,960
Contributions receivable, net	160,429	193,792
Other receivables, net	249,025	180,406
Prepaid expenses, deferred charges, and other assets	446,925	319,591
Investments	8,778,088	8,282,405
Interests in perpetual funds held by others	1,670,377	1,757,576
Operating lease right-of-use assets	212,499	-
Property and equipment, net	3,629,700	3,502,052
<b>Total assets</b>	<b>\$ 17,172,361</b>	<b>\$ 15,024,872</b>
<b>LIABILITIES AND NET ASSETS:</b>		
Accounts payable and accrued liabilities	\$ 799,140	\$ 747,530
CARES Act accrued liabilities	575,762	-
Deferred revenue	326,377	340,445
Interest payable	28,735	14,892
Liability for derivative instruments	270,976	238,112
Bonds and notes payable	2,562,915	1,980,060
Accrued liabilities for benefit obligations and professional liabilities	730,455	652,125
Operating lease liabilities	214,354	-
Finance lease liabilities	17,846	-
Funds held in trust for others	911,138	826,663
Annuities payable	14,677	15,287
Government advances for federal loan programs	19,494	16,638
Asset retirement obligation	82,615	79,096
<b>Total liabilities</b>	<b>6,554,484</b>	<b>4,910,848</b>
Net assets without donor restrictions, controlled by Emory	4,355,032	4,191,903
Net assets without donor restrictions related to noncontrolling interests	104,470	107,380
Total net assets without donor restrictions	4,459,502	4,299,283
Net assets with donor restrictions	6,158,375	5,814,741
<b>Total net assets</b>	<b>10,617,877</b>	<b>10,114,024</b>
<b>TOTAL LIABILITIES AND NET ASSETS</b>	<b>\$ 17,172,361</b>	<b>\$ 15,024,872</b>

See accompanying notes to consolidated financial statements.

# EMORY UNIVERSITY

## CONSOLIDATED STATEMENTS OF ACTIVITIES

YEAR ENDED AUGUST 31, 2020 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR 2019) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2020	Total August 31, 2019
<b>OPERATING REVENUE</b>				
Tuition and fees, net of scholarship allowance	\$ 455,077	-	\$ 455,077	\$ 452,423
Sales and services of auxiliary enterprises, net of scholarship allowance	62,364	-	62,364	74,666
Endowment spending distribution	204,034	-	204,034	197,908
Distribution from perpetual funds	38,797	-	38,797	37,077
Other investment income designated for current operations	59,931	3	59,934	77,927
Gifts and contributions for current use	64,853	47,620	112,473	73,467
Grants and contracts	513,925	-	513,925	495,839
Indirect cost recoveries	153,399	-	153,399	147,534
Net patient service revenue	4,191,037	-	4,191,037	4,206,383
Medical services	254,180	-	254,180	246,435
Independent operations	13,001	-	13,001	23,798
Other revenue	379,438	-	379,438	275,106
Net assets released from restrictions	48,166	(33,369)	14,797	27,803
<b>Total operating revenue</b>	<b>6,438,202</b>	<b>14,254</b>	<b>6,452,456</b>	<b>6,336,366</b>
<b>OPERATING EXPENSES</b>				
Salaries	3,367,132	-	3,367,132	3,188,145
Fringe benefits	714,223	-	714,223	684,039
Student financial aid	27,302	-	27,302	20,477
Nonsalary operating expenses:				
Professional fees and purchased services	577,758	-	577,758	572,991
Supplies and pharmaceuticals	1,099,294	-	1,099,294	1,039,738
Rent, utilities, and maintenance	369,141	-	369,141	367,291
Other operating expenses	54,666	-	54,666	64,741
Total nonsalary operating expenses	2,100,859	-	2,100,859	2,044,761
Interest on indebtedness	72,764	-	72,764	82,814
Depreciation and amortization	303,345	-	303,345	294,291
<b>Total operating expenses</b>	<b>6,585,625</b>	<b>-</b>	<b>6,585,625</b>	<b>6,314,527</b>
<b>NET OPERATING ACTIVITIES</b>	<b>(147,423)</b>	<b>14,254</b>	<b>(133,169)</b>	<b>21,839</b>
<b>NONOPERATING ACTIVITIES, NET</b>				
Investment return in excess of spending distribution for current operations	305,197	332,669	637,866	247,949
Change in undistributed income from perpetual funds held by others	-	(37,422)	(37,422)	195,591
Gifts and contributions for capital and long-term investment	22,146	55,170	77,316	136,128
Other (loss) gain	(4,042)	-	(4,042)	14,774
Gain (loss) on defeasance of debt	4,386	-	4,386	(11,442)
Change in fair value of derivative instruments	(32,864)	-	(32,864)	(109,251)
Net periodic benefit cost other than service cost	(7,720)	-	(7,720)	(19,865)
Changes in pension and other postretirement obligations	17,715	-	17,715	(114,462)
Other nonoperating items, net	(2,176)	(1,240)	(3,416)	2,461
Net assets released from restrictions	5,000	(19,797)	(14,797)	(27,803)
<b>Total nonoperating activities, net</b>	<b>307,642</b>	<b>329,380</b>	<b>637,022</b>	<b>314,080</b>
<b>CHANGE IN NET ASSETS</b>	<b>160,219</b>	<b>343,634</b>	<b>503,853</b>	<b>335,919</b>
Less change in net assets related to noncontrolling interests	(2,910)	-	(2,910)	(5,965)
<b>CHANGE IN NET ASSETS CONTROLLED BY EMORY</b>	<b>\$ 163,129</b>	<b>343,634</b>	<b>\$ 506,763</b>	<b>\$ 341,884</b>

See accompanying notes to consolidated financial statements.

# EMORY UNIVERSITY

## CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED AUGUST 31, 2019 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2019
<b>OPERATING REVENUE</b>			
Tuition and fees, net of scholarship allowance	\$ 452,423	-	\$ 452,423
Sales and services of auxiliary enterprises, net of scholarship allowance	74,666	-	74,666
Endowment spending distribution	197,908	-	197,908
Distribution from perpetual funds	37,077	-	37,077
Other investment income designated for current operations	77,927	-	77,927
Gifts and contributions for current use	47,123	26,344	73,467
Grants and contracts	495,839	-	495,839
Indirect cost recoveries	147,534	-	147,534
Net patient service revenue	4,206,383	-	4,206,383
Medical services	246,435	-	246,435
Independent operations	23,798	-	23,798
Other revenue	275,106	-	275,106
Net assets released from restrictions	45,387	(17,584)	27,803
<b>Total operating revenue</b>	<b>6,327,606</b>	<b>8,760</b>	<b>6,336,366</b>
<b>OPERATING EXPENSES</b>			
Salaries	3,188,145	-	3,188,145
Fringe benefits	684,039	-	684,039
Student financial aid	20,477	-	20,477
Nonsalary operating expenses:			
Professional fees and purchased services	572,991	-	572,991
Supplies and pharmaceuticals	1,039,738	-	1,039,738
Rent, utilities, and maintenance	367,291	-	367,291
Other operating expenses	64,741	-	64,741
Total nonsalary operating expenses	2,044,761	-	2,044,761
Interest on indebtedness	82,814	-	82,814
Depreciation and amortization	294,291	-	294,291
<b>Total operating expenses</b>	<b>6,314,527</b>	<b>-</b>	<b>6,314,527</b>
<b>NET OPERATING ACTIVITIES</b>	<b>13,079</b>	<b>8,760</b>	<b>21,839</b>
<b>NONOPERATING ACTIVITIES, NET</b>			
Investment return in excess of spending distribution for current operations	174,375	73,574	247,949
Change in undistributed income from perpetual funds held by others	-	195,591	195,591
Gifts and contributions for capital and long-term investment	17,737	118,391	136,128
Other gain	14,774	-	14,774
Loss on defeasance of debt	(11,442)	-	(11,442)
Change in fair value of derivative instruments	(109,251)	-	(109,251)
Net periodic benefit cost other than service cost	(19,865)	-	(19,865)
Changes in pension and other postretirement obligations	(114,462)	-	(114,462)
Other nonoperating items, net	(2,547)	5,008	2,461
Net assets released from restrictions	(3,378)	(24,425)	(27,803)
<b>Total nonoperating activities, net</b>	<b>(54,059)</b>	<b>368,139</b>	<b>314,080</b>
<b>CHANGE IN NET ASSETS</b>	<b>(40,980)</b>	<b>376,899</b>	<b>335,919</b>
Less change in net assets related to noncontrolling interests	(5,965)	-	(5,965)
<b>CHANGE IN NET ASSETS CONTROLLED BY EMORY</b>	<b>\$ (35,015)</b>	<b>376,899</b>	<b>\$ 341,884</b>

See accompanying notes to consolidated financial statements.

# EMORY UNIVERSITY

## CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2020 AND 2019 (Dollars in thousands)

	August 31, 2020	August 31, 2019
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Change in net assets	\$ 503,853	\$ 335,919
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Restricted contributions for endowments and capital projects	(74,923)	(136,128)
Net realized and unrealized gains on investments	(970,091)	(494,199)
Contribution from acquisition	-	(17,304)
Loss on disposal of property and equipment	4,095	2,684
Interests in perpetual funds held by others	37,422	(195,591)
(Gain) loss on defeasance of debt	(4,386)	11,442
Depreciation and amortization of intangible assets	298,987	293,611
Accretion/amortization of debt discounts/premiums and issuance costs	(5,591)	(3,028)
Amortization of right-of-use assets - financing	4,358	-
Amortization of right-of-use assets - operating	41,675	-
Actuarial adjustments for retiree pension and benefit plans	(9,995)	105,641
Change in fair value of derivative instruments	32,864	109,251
Change in operating assets, net of effects from acquisition:		
Accounts and other receivables, net	(167,428)	51,347
Contributions receivable for operations	9,181	(10,004)
Prepaid expenses, deferred charges, and other assets	(69,413)	155,725
Change in operating liabilities, net of effects from acquisition:		
Accounts payable, accrued liabilities, and interest payable	68,343	(25,456)
CARES Act accrued liabilities	575,762	-
Asset retirement obligations	3,519	13,100
Accrued liabilities for benefit obligations and professional liabilities	88,326	22,977
Lease obligations, net	(38,707)	-
Deferred revenue	(14,069)	(180,843)
<b>Net cash provided by operating activities</b>	<b>313,782</b>	<b>39,144</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Cash received from acquisition	-	95,407
Disbursements for loans to students	(2,899)	(2,868)
Repayment of loans from students	4,076	4,046
Proceeds from sales and maturities of investments	7,327,933	6,126,997
Purchases of investments	(6,857,730)	(5,724,954)
Purchases of property, plant, and equipment	(417,158)	(434,868)
Increase in funds held in trust for others	84,475	34,822
<b>Net cash provided by investing activities</b>	<b>\$ 138,697</b>	<b>\$ 98,582</b>

(Continued)



# EMORY UNIVERSITY

## CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2020 AND 2019 (Dollars in thousands)

	August 31, 2020	August 31, 2019
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Receipts from contributions for donor-restricted endowment funds and capital projects	\$ 148,882	\$ 147,888
Proceeds from bonds payable, including premiums	1,535,171	594,373
Principal repayments of bonds payable	(938,336)	(752,037)
Payments on finance lease obligations	(4,087)	-
Change in annuities payable	(610)	(417)
Debt issuance costs	(4,003)	-
Change in government advances for federal loan programs	2,856	(2,021)
Borrowings on line of credit	275,000	-
Repayments on line of credit	(275,000)	-
<b>Net cash provided by (used in) financing activities</b>	<b>739,873</b>	<b>(12,214)</b>
Net increase in cash, cash equivalents, and restricted cash	1,192,352	125,512
Cash, cash equivalents, and restricted cash at beginning of year	274,961	149,449
<b>Cash, cash equivalents, and restricted cash at end of year <sup>(1)</sup></b>	<b>\$ 1,467,313</b>	<b>\$ 274,961</b>
<b>Supplemental disclosures:</b>		
Cash paid for interest	\$ 67,868	\$ 100,965
Accrued liabilities for property, plant, and equipment purchases	12,759	19,228

<sup>(1)</sup> See note 2(a) of the accompanying notes for a reconciliation of the ending balance of cash, cash equivalents, and restricted cash as shown in this consolidated statement of cash flows.

See accompanying notes to consolidated financial statements.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,000 undergraduate students and 7,000 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare System (Emory Healthcare), Emory Medical Care Foundation, and Emory Innovations, LLC.

Emory Healthcare consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), DeKalb Medical Center, Inc. (DMC), Decatur Health Resources, Inc. (DHR), DeKalb Medical Center Foundation (DMCF), DeKalb Regional Health System Ventures, Inc. (Ventures), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), and Clifton Casualty Insurance Company, Ltd. (CCIC). EUH, EUHM, EJCH, ESJH, ERH, DMC, and DHR are sometimes referred to herein, collectively, as “the Hospitals.” On September 1, 2018, Emory Healthcare became the sole and controlling member of DeKalb Regional Health System (DRHS) and its affiliates upon acquisition of DRHS' assets and liabilities. DMC, DHR, DMCF, and Ventures are the affiliates that account for DRHS' operations, assets, and liabilities. DMC operates a 451-bed general acute care hospital with a freestanding surgery center in Decatur, Georgia and a 100-bed general acute care hospital in Hillandale, Georgia. DRHS has been integrated operationally, financially, and clinically into Emory Healthcare since September 1, 2018, and the results of DRHS' operations have been included in the consolidated financial statements since that date.

The consolidated financial statements include the University and all other entities in which Emory has significant financial interest and control. All significant interentity accounts and transactions have been eliminated in consolidation.

### (2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared on the accrual basis in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenue, gains, and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

*Net assets without donor restrictions* – Net assets that are not subject to donor-imposed stipulations

*Net assets with donor restrictions* – Net assets that are subject to donor-imposed stipulations that will or may be met either by actions of the University and/or the passage of time. These net assets include donor-restricted endowments, unconditional pledges, split-interest agreements, and interests in perpetual trusts held by others. Generally, the donors of these assets permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes.

Revenue is reported as increases in net assets without donor restrictions unless their use is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

The University considers the following items to be nonoperating activities: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return in excess of spending distribution for current operations, change in fair value of derivative instruments, pension- and postretirement-related changes and net periodic benefit cost other than service cost, and other activities, net.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (a) Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities generally 90 days or less that are not invested as part of the long-term investment assets. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes. Restricted cash consists of cash on hand that is restricted for a specific purpose under various capital financing arrangements or cash held for others and, therefore, not available to Emory for immediate or general business use. Restricted cash appears separately from the cash and cash equivalents on the University's consolidated statements of financial position.

The following table is a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying consolidated statements of financial position that sum to the total of the same such amounts shown in the accompanying consolidated statements of cash flows as of August 31 (in thousands):

		2020	2019
Cash and cash equivalents	\$	1,368,050	\$ 229,414
Restricted cash included in investments		13,362	17,567
Restricted cash included in prepaid expenses, deferred charges, and other assets		85,901	27,980
<b>Total cash, cash equivalents, and restricted cash</b>	<b>\$</b>	<b>1,467,313</b>	<b>\$ 274,961</b>

Fiscal year 2020 cash, cash equivalents, and restricted cash is favorably impacted primarily by strategic realignment of operating investments to increase liquidity as well as CARES Act funding received.

### (b) Contributions Receivable, Net

Contributions to be received after one year, net of an allowance for uncollectible amounts are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is provided based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

### (c) Loans Receivable, Net

Emory-funded loans to students are carried at estimated net realizable value. Loans receivable from students under certain government loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to federal direct loans (which are not reported in the consolidated financial statements), loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing, and Health Professions Student Loan Programs.

### (d) Other Receivables, Net

Other receivables are recorded at net realizable value and include receivables under grants and contracts, medical services provided to other organizations, and losses recoverable from reinsurers.

### (e) Investments

Investments are reported at fair value. Investments in securities and listed funds are valued using quoted prices in active markets if available; otherwise, if the market is inactive, fair value is determined by the University in accordance with its valuation policy.

Investments in alternative investment fund structures are valued using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based and (b) the University does not currently have plans to sell the investment for an amount different from NAV. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office and are believed to present reasonable estimates of fair value at August 31, 2020 and 2019.

Investments are exposed to several risks, which may include (but are not limited to) interest rate, liquidity, currency, market, and credit risks. The University attempts to manage these risks through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions, though it is at least reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

Investment transactions are accounted for on the trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on the accrual basis. Investment return, including realized and unrealized gains and losses, is recognized when earned and reported in the consolidated

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

statements of activities net of external and direct internal investment expenses. Investment return, if restricted, is reported in the consolidated statements of activities as increases or decreases in net assets with donor restrictions until amounts have been appropriated and the donor-imposed or statutory time restrictions have been satisfied.

### **(f) Fair Value Measurements**

Fair value measurements reflected in the consolidated financial statements represent the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants at the measurement date. GAAP provides a hierarchy that prioritizes the inputs to fair value measurements based on the extent to which inputs to valuation techniques are observable in the marketplace. The hierarchy assigns a higher priority to observable inputs that reflect verifiable information obtained from independent sources and a lower priority to unobservable inputs that would reflect the University's assumptions about how market participants would value an asset or liability based on the best information available. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured and reported at fair value are classified and disclosed within one of the following categories:

*Level 1* – Valuations for assets and liabilities traded in active exchange markets as of the reporting date; valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities

*Level 2* – Valuations are determined through direct or indirect observations other than quoted market prices. The type of investments in Level 2 also includes certain positions in which the University is a unit of account holder within a fund or account that holds underlying assets that are traded in active exchange markets with readily available pricing.

*Level 3* – Valuations for assets and liabilities that are unobservable and derived from other valuation methodologies, including discounted cash flow models and similar techniques, and not based on market exchange, dealer, or broker-traded transactions; Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

In the event changes in the inputs used in the fair value measurement of an asset or liability result in a transfer of the fair value measurement to a different categorization, such transfers

between fair value categories are recognized at the end of the reporting period.

### **(g) Split-Interest Agreements**

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenue is recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

### **(h) Interests in Perpetual Funds Held by Others**

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' net assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in beneficial interest in perpetual funds and as contribution revenue at the date such funds are established. The largest fund of this type primarily holds shares of common stock of The Coca-Cola Company. The carrying value of Emory's interest in such perpetual funds is adjusted annually for changes in fair value.

### **(i) Property and Equipment, Net**

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$114.9 million and \$112.2 million, such as art, museum assets, and rare books, are included in property and equipment, net as of August 31, 2020 and 2019, respectively, but are not depreciated.

Property and equipment are reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss shall be recognized only if the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

eventual disposition of the asset. There were no asset impairments for fiscal years 2020 or 2019.

### **(j) Net Tuition and Fees**

Tuition and fees revenue is derived from degree programs and continuing education programs. Most undergraduate students receive institutional financial aid based upon academic promise and demonstrated financial need. Graduate students often receive tuition support in connection with research assistant, teaching assistant, and fellowship appointments. Student financial aid provided by the University for tuition and fees is reflected as a reduction of tuition and fees revenue from published rates.

### **(k) Health Insurance Plan**

The University is self-insured for employee and student health insurance costs, with losses insured in excess of a maximum amount on both a per claim and annual aggregate claim amount. The self-insurance liability is based on claims filed and an estimate of claims incurred but not yet reported. Self-insurance claims are reported as net of insurance premiums collected from employees and students.

### **(l) Gifts and Contributions Revenue**

Contributions, including unconditional promises to give, are recognized as revenue in the period received. Unconditional promises to give, with payments due in future periods, are recorded as increases in net assets with donor restrictions at the estimated present value of future cash flows, net of an allowance for uncollectible pledges. Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift.

Donor-restricted contributions are reported as revenue with donor restrictions, which increases this net asset class. If the donor stipulation is met in the year of the gift, the contribution is reflected in net assets without donor restrictions. Restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional; that is, when the barriers on which they depend are met.

### **(m) Grants and Contracts Revenue and Indirect Cost Recoveries**

Funding from the federal government, corporations, or private foundations (sponsors) is recorded as grants and contracts revenue when it is for a specified activity with a defined budget, period of performance, and scope of work undertaken by the University. The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement and is generally in

direct support of the University's mission. Sponsored program revenue and program income are earned when the University has substantially met its obligations and when the contractual performance measures have been completed. Revenue is recognized when services are rendered, milestones are met, or qualifying expenses are incurred as specified in the terms and conditions of the agreements, not necessarily when payments are received. Unearned revenue results when cash is received from sponsors in advance of revenue being earned. Unearned revenue is recorded as a liability (deferred revenue) until it is earned. Amounts recorded in grants and contracts receivable are for services rendered or expenditures incurred in advance of the receipt of funds.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grants and contracts agreements.

### **(n) Net Patient Service Revenue**

Net patient service revenue is reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations. Emory Healthcare's estimates in this area may differ from actual experience, and those differences may be material.

The Hospitals reserve for third-party payor cost report audits and anticipated settlements through initial audit and final settlement of the cost reports. The Hospitals maintain estimates of third-party settlements for the Hospitals' routine exposures in this area in recognition of the complexity of relevant reimbursement regulations and the volatility of related settlement processes.

### **(o) Sales and Services of Auxiliary Enterprises and Independent Operations**

An auxiliary enterprise is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises include residential halls, a bookstore, and parking operations. Fee charges are directly related to the costs of services provided.

Independent operations are activities that are solely owned and/or controlled by the University but are unrelated or independent of its mission. Independent operations include an externally



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

managed conference center, hotel, and a fitness center. Fee charges are based on market rates for the services provided.

### **(p) Leases**

The University determines whether an arrangement is a lease (operating or finance) at inception by evaluating whether the contract conveys the right to use an identified asset and whether Emory obtains substantially all of the economic benefits from and has the right to control the asset. Right-of-use (ROU) assets represent the University's right to use an underlying asset for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the lease commencement date based on present value of the lease payments over the lease term discounted using the interest rate implicit in the lease agreement or Emory's relevant incremental borrowing rate. The University's current discount rates range from 0.47% to 4.52% depending on the term of the arrangement.

### **(q) Income Taxes**

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code of 1986, as amended (the Code) and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University is, however, subject to federal and state income tax on unrelated business income.

In December 2017, the Tax Cuts and Job Acts (the Act) was approved by the U.S. Congress. Among other things, the Act imposes an excise tax on net investment income for certain organizations and establishes new rules for calculating unrelated business income. Emory has adopted the relevant positions of the Act based on reasonable estimates under the currently available regulatory guidance on the Act and there was no material impact on the consolidated financial statements.

The University regularly evaluates its tax positions and as of August 31, 2020 and 2019, there were no material uncertain tax positions.

### **(r) Derivative Instruments**

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments in order to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in investments. Changes in the fair value of investment-related derivative instruments are included in

investment return in excess of spending distribution for current operations on the consolidated statements of activities. The University utilizes interest swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these swap agreements are recognized as nonoperating activities in the consolidated statements of activities.

### **(s) Pension and Postretirement Benefit Plans**

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in net assets without donor restrictions.

### **(t) COVID-19 Pandemic**

In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. The COVID-19 pandemic has resulted in financial loss, stress, and hardship for many. The U.S. Congress passed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help individuals and businesses affected by the pandemic and economic downturn. Government orders suspending elective surgical procedures have had an adverse effect on the operations of healthcare providers, including Emory Healthcare, primarily due to reduction in overall patient volumes.

Under the provision of the CARES Act, Emory Healthcare received approximately \$219.2 million in provider relief funds (PRF) from the Department of Health and Human Services (HHS) for both general and targeted distributions. Such funding is accounted for as a conditional contribution and is recognized in revenue once the applicable terms and condition have been met. According to the HHS guidance released September 19, 2020, the measurement date to determine the amount of funding to be recognized in revenue is December 31, 2020. Accordingly, the amounts are recorded as refundable advances in CARES Act accrued liabilities in the accompanying 2020 consolidated statement of financial position. As of the measurement date, Emory will evaluate revenue recognition for all or a portion of the \$219.2 million currently recorded as an accrued liability. The University, on behalf of one of its physician practice plans, received \$0.9 million in PRF, which was recognized as revenue in fiscal year 2020.

Emory Healthcare also received approximately \$285.2 million in advance payments from the Centers for Medicare and Medicaid

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

Services (CMS) to provide necessary funds when there is a disruption in claims submissions and processing or in circumstances such as national emergency or natural disasters in order to accelerate cash flow to impacted healthcare providers. These advances are reflected in CARES Act accrued liabilities in the accompanying 2020 consolidated statement of financial position.

In August 2020, the University received \$4.0 million from the Department of Education pursuant to the institution's Certification and Agreement for Emergency Financial Aid Grants to Students that is included in CARES Act accrued liabilities in the accompanying 2020 consolidated statement of financial position. In alignment with the Department of Education guidance, Emory distributed the relief funds to Title IV aid-eligible students in September 2020. Emory received the institutional portion of the relief funds in September 2020, and elected also to provide these funds to students.

The CARES Act allows employers to defer deposits and payments of the employer's share of Social Security taxes incurred between March 27, 2020 and December 31, 2020. Emory has deferred payment of \$67.4 million of employer taxes that are included in CARES Act accrued liabilities in the accompanying 2020 consolidated statement of financial position. Fifty percent of the deferred tax amount must be paid by December 31, 2021, with the remainder by December 31, 2022.

Commencing March 13, 2020, undergraduate and graduate course education was conducted virtually, and most students vacated the campus. The University granted refunds and additional aid to students totaling \$16.9 million in fiscal year 2020 for housing, dining, parking, and other services not provided after March 13, 2020. Students continued to meet their academic requirements for the remainder of the 2019–20 academic year. While some faculty and staff are working on-campus to ensure continuity of essential operations, most faculty and staff have transitioned to remote work.

Emory established a \$5.0 million EmoryTogether Fund to support undergraduate, graduate, and professional students of various income levels and backgrounds who incurred financial hardships as a result of COVID-19 pandemic.

The University's pandemic response plan has multiple facets and continues to evolve as the pandemic unfolds. Management initiated steps to ensure operational and functional flexibility in order to offset the increased expenditures due to COVID-19 pandemic, including the following:

- Temporarily paused existing routine capital projects and reduced routine budgeted capital expenditures for 2021; and
- Enhanced certain cost cutting measures.

The continued spread of COVID-19 and its impact on social interaction, travel, economies, and financial markets may adversely affect the University's operations and financial condition.

### (u) New Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*. The University adopted ASU No. 2016-02, as amended, using the optional transition method, effective September 1, 2019. The adoption of this ASU resulted in the initial recognition of operating lease ROU assets and liabilities of approximately \$238.9 million on the accompanying 2020 consolidated statement of financial position and the reclassification of approximately \$18.2 million of assets and liabilities that were previously presented on the consolidated statements of financial position as capital leases and under Topic 842 as finance lease ROU assets and liabilities. As permitted by ASU No. 2016-02, for a short-term lease with a term of 12 months or less without a purchase option that the University is likely to exercise, Emory has elected not to recognize lease assets and liabilities.

In November 2016, the FASB issued ASU No. 2016-18, *Statement of Cash Flows (Topic 230) — Restricted Cash*, to add or clarify classification and presentation of restricted cash in the statement of cash flows. This update requires the amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This ASU is effective for the fiscal year ended August 31, 2020. The University adopted ASU No. 2016-18 in fiscal year 2020, retrospectively to fiscal year 2019.

In March 2017, the FASB issued ASU No. 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Benefit Cost (Topic 715)*, which requires the University to present the service cost component of net benefit cost within operating expenses and all other components of net benefit cost, such as interest, gains or losses, and amortization of other actuarially determined amounts, in nonoperating activities. The University adopted ASU No. 2017-07 in fiscal year 2020 with retrospective changes to the August 31, 2019 financial statements.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

In August 2018, the FASB issued ASU No. 2018-13, *Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)*. ASU No. 2018-13 eliminates, modifies, and adds certain disclosures on fair value measurements. ASU No. 2018-13 is effective for fiscal periods beginning after December 15, 2019. Emory is evaluating the effect of adoption on its consolidated financial statements beginning in FY 2021.

### (v) Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires that management make estimates and assumptions affecting the reported amounts of assets, liabilities, revenue, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for price concessions for medical services, reserves for employee and student healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

### (w) Conflict of Interest Policies

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members.

When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

### (3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	2020	2019
UNCONDITIONAL PROMISES EXPECTED TO BE COLLECTED IN:		
Less than one year	\$ 122,430	\$ 164,414
One year to five years	42,804	35,094
Over five years	4,787	3,973
Gross contributions receivable	170,021	203,481
Less:		
Allowance for uncollectible amounts	(4,861)	(5,497)
Discount to present value	(4,731)	(4,192)
<b>Contributions receivable, net</b>	<b>\$ 160,429</b>	<b>\$ 193,792</b>

At August 31, 2020 and 2019, the five largest outstanding donor pledge balances represented 74% and 73%, respectively, of Emory's gross contributions receivable. Contributions receivable are discounted at rates ranging from 3.87% to 4.25%.

As of August 31, 2020, the University had received bequest intentions and conditional promises of approximately \$56.7 million. These intentions to give are not recognized as assets or revenue and, if received, will generally be restricted for purposes stipulated by the donor.

### (4) Patient Accounts Receivable and Credit Concentrations

Emory Healthcare grants credit to patients, substantially all of whom reside in the service areas. Emory Healthcare generally does not require collateral or other security in extending credit to patients; however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health insurance programs, plans, or policies (e.g., Medicare, Medicaid, managed care, capitated, and other preferred provider arrangements and commercial insurance policies).



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The composition of net receivables from patients and third-party payors for the years ended August 31 is as follows:

	2020	2019
Managed care and other third-party payors	55%	56%
Medicare	31	31
Medicaid	8	7
Patients	6	6
	100%	100%

### (5) Revenue from Contracts with Customers

#### (a) Contracts with Customers

The University recognizes revenue, when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the University expects to receive in exchange for those goods or services.

#### (b) Contract Balances

Accounts receivable are recorded only when the University's right to consideration is unconditional (i.e., the contract is noncancelable – generally after the expiration of a student withdrawal period).

Deferred revenue relates to payments received in advance of performance under contracts with customers. Emory invoices customers (i.e., students) for education and residential services and customers transfer consideration before the University has transferred promised goods or services to its customers. At each reporting date, Emory records all prepayment amounts associated with educational services that have not yet been delivered as deferred revenue.

The University records accounts receivable and related contract liabilities for noncancelable contracts with customers when there is a right to consideration.

#### (c) Significant Judgments

Emory applies the portfolio approach to educational and residential services (room and board) and to patient services due to the large volume of similar contracts and similar customer classes. Using the portfolio approach streamlines Emory's processes for collectibility assessment and refund estimation.

The University determined that the effect of applying this guidance to the portfolio does not differ materially from applying the guidance to the individual contracts within the portfolio. Emory considers education and residential service as separate and distinct performance obligations. Since students receive instruction and housing concurrently during the academic term, they simultaneously receive and use all the benefits that Emory provides in the performance of the contracts. Therefore, the performance obligations associated with academic programs are satisfied over time and revenue recognized as the related services are performed.

Tuition and fees are recognized in the fiscal year in which the academic programs and residential services are provided. Revenue is reflected in the consolidated statements of activities for the portion that is completed by the end of the fiscal year. The remaining performance obligation that will be completed in the following fiscal year remains a liability on the consolidated statements of financial position.

Emory provides institutionally funded grants and scholarships to students, who either demonstrate financial need or qualify academically, as a form of price reduction up to and equal to amounts owed by students to the University. Institutional resources provided in excess of amounts owed by the students to Emory are recorded as scholarship expenses. Students receive Title IV financial aid, state funds, and employer reimbursements. Emory accounts for the payment as a third-party payment on behalf of an identified customer to an existing exchange transaction, and therefore, the grant or loan amount does not reduce the transaction price.

Auxiliary enterprises revenue includes revenue from residential services, parking operations, bookstore, conference services offered by the University, ticket sales for events, and other miscellaneous activities, which furnish goods or services to students, faculty, staff, and, in some cases, to the general public. Within auxiliary enterprises, Emory considers parking service agreements to be distinct performance obligations that are billed to students in advance and payments due prior to the start of each academic term. Prepayments are reflected on the consolidated statements of financial position as deferred revenue and recognized as revenue ratably over the period during which the parking services are rendered. Sales of goods within auxiliary enterprises generally occur as a point of sale transaction, and the revenue is recognized as the sale occurs. Any discounts are factored into the selling price at the point of sale.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

Emory considers revenue from clinical trial agreements to be exchange transactions where revenue is recognized as services are performed, billed, and the University has contractual right to consideration. Revenue related to clinical trial agreements included in grants and contracts revenue in the consolidated statements of activities for the years ended August 31, 2020 and 2019 totaled \$54.6 million and \$49.8 million, respectively.

The University recognizes revenue from nonrefundable, up-front fees allocated to a license at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the University recognizes revenue when the related sales occur.

The University has contractual agreements with Grady Memorial Hospital where practicing interns and medical residents of the Emory School of Medicine receive clinical training and faculty provide teaching, medical care, and hospitalization services. The School of Medicine is reimbursed for expenses incurred for interns and medical residents based on the costs for labor and reimbursed for the faculty teaching, administrative, and clinical services based on the number of interns and residents trained and time spent performing clinical and administrative services. Medical services revenue is recognized as services are performed and the customer receives and uses the benefits of the services.

The University also has affiliation and administrative services agreements with Children's Healthcare of Atlanta and the Emory + Children's Pediatric Institute, where it provides various administrative services. Revenue is recorded as other revenue in the consolidated statements of activities as the University satisfies the performance obligation over time. The customer simultaneously receives and consumes the benefits as the University performs.

### (d) Disaggregation of Student Revenue

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2020 (in thousands):

	<b>Tuition and Fees</b>	<b>Auxiliary Enterprises <sup>(1)</sup></b>	<b>Total</b>
Undergraduate programs	\$ 439,894	38,450	478,344
Graduate and professional programs	317,229	910	318,139
<b>Total at published rates</b>	<b>757,123</b>	<b>39,360</b>	<b>796,483</b>
Less institutional aid for undergraduate programs	(162,077)	(5,755)	(167,832)
Less institutional aid for graduate and professional programs	(157,328)	(181)	(157,509)
<b>Tuition and fees and auxiliary enterprises, net of institutional aid</b>	<b>437,718</b>	<b>33,424</b>	<b>471,142</b>
Other academic programs	17,359	3,010	20,369
<b>Total tuition and fees and auxiliary enterprises</b>	<b>\$ 455,077</b>	<b>36,434</b>	<b>491,511</b>

- (1) The University granted refunds for housing and parking services not provided to students in fiscal year 2020 due to the COVID-19 pandemic.

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2019 (in thousands):

	<b>Tuition and Fees</b>	<b>Auxiliary Enterprises</b>	<b>Total</b>
Undergraduate programs	\$ 421,061	46,015	467,076
Graduate and professional programs	314,700	1,365	316,065
<b>Total at published rates</b>	<b>735,761</b>	<b>47,380</b>	<b>783,141</b>
Less institutional aid for undergraduate programs	(152,366)	(4,538)	(156,904)
Less institutional aid for graduate and professional programs	(152,695)	(254)	(152,949)
<b>Tuition and fees and auxiliary enterprises, net of institutional aid</b>	<b>430,700</b>	<b>42,588</b>	<b>473,288</b>
Other academic programs	21,723	669	22,392
<b>Total tuition and fees and auxiliary enterprises</b>	<b>\$ 452,423</b>	<b>43,257</b>	<b>495,680</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (6) Grants and Contracts

The University receives grants and contracts revenue from federal, state, corporate, and private sources. If resource providers do not receive commensurate benefit (only indirect benefit because the research findings serve the general public) in exchange and the results are maintained and can be used by the University, such grants and contracts are considered contributions.

Most Emory nonexchange, sponsored research agreements are conditional contributions as the agreements include both a right of return or release of assets and a barrier that Emory must overcome to be entitled to the consideration. These agreements become unconditional as barriers are satisfied. The University recognizes revenue associated with these sponsored agreements as qualifying allowable expenses are incurred or a measurable performance-related barrier is achieved in accordance with the terms and conditions of the agreements. Conditional contributions are recognized as deferred revenue if assets are transferred in advance or not recognized at all until the conditions have been substantially met or explicitly waived by the sponsoring entity, at which point the contributions are recognized as unconditional. Conditional agreements with sponsor-imposed restrictions that expire simultaneously with the satisfaction of the specified conditions are reported as net assets without donor restrictions.

The following table presents Emory's sources of grants and contracts revenue (including indirect cost recoveries) for the year ended August 31 (in thousands):

	2020		2019	
	Grants	Contracts with Customers	Grants	Contracts with Customers
Federal government	\$ 500,823	1,021	\$ 479,084	2,292
Other government	1,770	207	13,051	229
Corporate	16,248	50,162	12,170	44,528
Private institutions	93,884	3,209	89,272	2,747
<b>Total</b>	<b>\$ 612,725</b>	<b>54,599</b>	<b>\$ 593,577</b>	<b>49,796</b>

As of August 31, 2020 and 2019, Emory had unexpended grant awards of \$739.2 million and \$627.6 million, respectively, for which revenue will be recognized when conditions have been met or performance obligations have been satisfied.

### (7) Net Patient Services Revenue

Emory Healthcare has agreements with government and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Emory Healthcare believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in Emory Healthcare's hospitals receiving inpatient, outpatient, or emergency services. Emory Healthcare measures the performance obligation from admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when goods are provided to Emory Healthcare's patients and customers in a retail setting (e.g., pharmaceuticals), and Emory Healthcare does not believe it is required to provide additional goods or services related to that sale.

Emory Healthcare determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Emory Healthcare policy, and implicit price concessions provided to patients. Emory Healthcare determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. Emory Healthcare cannot pursue collections for the contractual or discount amounts; therefore, such amounts are not reported as revenue.

Emory Healthcare provides care to patients regardless of their ability to pay. Emory Healthcare has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles).

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Emory Healthcare expects to collect based on its collection history with those patients considering business and economic conditions, trends in healthcare coverage, and other collection indicators. Periodically, management assesses the adequacy of the allowance for implicit price concessions based upon historical write-off experience by payor category and adjusts the reserve as appropriate.

Patient service revenue, net of contractual adjustments, implicit price concessions and other discounts recognized from major payor sources for the years ended August 31 is as follows (in thousands):

	2020	2019
Medicare	\$ 1,213,659	\$ 1,322,185
Medicaid	180,758	233,463
Other third-party payors	2,728,112	2,613,609
Patients	68,508	37,126
<b>Net patient service revenue</b>	<b>\$ 4,191,037</b>	<b>\$ 4,206,383</b>

The composition of net patient service revenue based on the Emory Healthcare lines of business for the years ended August 31 is as follows (in thousands):

	2020	2019
Services lines:		
Hospital – inpatient	\$ 1,876,358	\$ 1,781,251
Hospital – outpatient	1,407,373	1,421,988
Physician services	907,306	1,003,144
<b>Net patient service revenue</b>	<b>\$ 4,191,037</b>	<b>\$ 4,206,383</b>

### (8) Charity Care and Community Benefits

Emory Healthcare provides care to patients who meet certain criteria under their charity care policies without charge or at amounts less than their established rates and such amounts are not included in net patient service revenue.

Records are maintained to identify and monitor the level of charity care provided. These records include the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies.

The cost of charity care provided totaled approximately \$130.3 million and \$151.5 million for the years ended August 31, 2020 and 2019, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

### (9) Liquidity and Availability

Emory regularly monitors liquidity required to meet its operating needs and other contractual commitments, while also maximizing the investment of its available funds.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, the University considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures.

In addition to financial assets available to meet general expenditures over the next 12 months, the University operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by donor-restricted resources.

As of August 31, 2020 and 2019, the following financial assets could readily be made available within one year of the statements of financial position date to meet cash needs for general expenditures (in thousands):

	2020
<b>TOTAL ASSETS</b>	<b>\$ 17,172,361</b>
Less:	
Land, building, and equipment, net	(3,629,700)
Interest in perpetual trusts held by others	(1,670,377)
Donor-restricted and board-designated endowment funds	(5,889,384)
Other investments	(2,884,965)
Prepaid expenses, deferred charges, and other assets	(446,925)
Operating lease right-of-use assets	(212,499)
Contributions receivable, net	(160,429)
Loans receivable, net	(20,783)
Add:	
Endowment payout in following year	203,790
Contributions receivable due within one year for operations	122,430
<b>Financial assets available to meet cash needs for general expenditures within one year</b>	<b>\$ 2,583,519</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

	<b>2019</b>
<b>TOTAL ASSETS</b>	<b>\$ 15,024,872</b>
Less:	
Land, building, and equipment, net	(3,502,052)
Interest in perpetual trusts held by others	(1,757,576)
Donor-restricted and board-designated endowment funds	(5,399,522)
Other investments	(2,174,895)
Prepaid expenses, deferred charges, and other assets	(319,591)
Contributions receivable, net	(193,792)
Loans receivable, net	(21,960)
Add:	
Endowment payout in following year	203,334
Contributions receivable due within one year for operations	164,414
<b>Financial assets available to meet cash needs for general expenditures within one year</b>	<b>\$ 2,023,232</b>

The University has \$2,583.5 million of financial assets as of August 31, 2020 to meet cash needs for general expenditures, consisting of cash of \$1,368.1 million, accounts receivable of \$885.5 million, contributions receivable, less than one year of \$122.4 million, payout on with and without donor-restricted endowment funds of \$203.8 million, and other operating investments of \$3.7 million.

As described further in note 16, to supplement working capital and other commitments, the University also has lines of credit.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (10) Investments

The following table summarizes investments as of August 31 (in thousands):

	2020	2019
Short-term investments and cash equivalents <sup>(a)</sup>	\$ 384,127	\$ 181,658
Public equity <sup>(b)</sup>	3,663,833	3,079,796
Absolute return/fixed income <sup>(c) (g)</sup>	1,852,781	2,491,602
Private equity/venture capital <sup>(d)</sup>	2,196,033	1,786,917
Real assets <sup>(e)</sup>	650,838	731,062
Derivative instruments <sup>(f)</sup>	2,890	8,846
<b>Total investments at fair value</b>	<b>8,750,502</b>	<b>8,279,881</b>
Joint ventures (equity method)	27,586	2,524
<b>Total investments</b>	<b>\$ 8,778,088</b>	<b>\$ 8,282,405</b>

- (a) Includes short-term U.S. and non-U.S. Treasury securities with maturities of less than one year, as well as funds that invest in these types of investments
- (b) Includes domestic and international stocks, as well as interests in funds that invest in both long only and long/short equity-based strategies; certain investments in funds may be subject to restrictions that limit the University's ability to withdraw capital until (i) certain "lock-up period" has expired or (ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, fund investments in this category may be subject to restrictions limiting the amount the University is able to withdraw as of a given redemption date.
- (c) Includes directly held actively traded global fixed-income securities (such as government bonds and corporate bonds) or commingled funds holding such securities of \$0.9 billion and \$1.38 billion and investments in multistrategy or credit funds as well as opportunistic absolute return funds intended to enhance diversification and reduce correlation to public equity of \$1.0 billion and \$1.11 billion as of August 31, 2020 and 2019, respectively; certain fund investments included in this category may hold marketable securities and be subject to redemption terms governed by the respective fund agreement or may contain illiquid investments and, therefore, offer no liquidity over the fund life. Such funds holding illiquid investments are expected to yield liquidating distributions over the next 6 years.
- (d) Includes illiquid investments in private and public companies, both domestically and internationally; the majority of these investments are held through funds and also include buyout, venture capital, high yield, and subordinated debt strategies. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 11 years.
- (e) Includes investments in oil and gas, commodities, timber, and real estate, the majority of which are held through commingled funds; the nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 12 years.
- (f) Includes investments in equity options, swaps, and forwards value at fair value of each underlying investments
- (g) Amounts presented net of \$7.2 million and \$244.0 million of net pending trade payables related to unsettled forward purchases and sales of such securities as of August 31, 2020 and 2019, respectively



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

As of August 31, 2020, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

		Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Absolute return	\$	358,518	90-360 days or not eligible	90-306 days
Private equity/venture capital		800,945	not eligible	not eligible
Public equity		—	30-360 days	10-180 days
Real assets		408,170	not eligible	not eligible
	\$	1,567,633		

Unfunded commitments are expected to be called by funds within five years of fund inception.

### (11) Endowment Net Assets

The University's endowed assets (the Endowment) consists of 2,108 individual funds established for a variety of purposes, including with donor restriction endowment funds and without donor restrictions funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

### (a) Interpretation of Relevant Law

The Board of Trustees of the University has approved the University's adoption of the State of Georgia Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as donor-restricted historical value net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is classified as restricted appreciation until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University, and the investment policies of the University.

The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, funds held in trust for others, and miscellaneous investments. As of August 31, 2020, approximately 67.1% of the investments described in note 10 are classified as endowed net assets.

Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2020			2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds						
Appreciation	\$ —	3,167,571	3,167,571	\$ —	2,845,925	2,845,925
Historical value	—	988,755	988,755	—	950,730	950,730
<b>Total donor restricted</b>	<b>—</b>	<b>4,156,326</b>	<b>4,156,326</b>	<b>—</b>	<b>3,796,655</b>	<b>3,796,655</b>
Funds functioning as endowments or board-designated	1,733,058	—	1,733,058	1,602,867	—	1,602,867
<b>Total endowment net assets</b>	<b>\$ 1,733,058</b>	<b>4,156,326</b>	<b>5,889,384</b>	<b>\$ 1,602,867</b>	<b>3,796,655</b>	<b>5,399,522</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The following table represents endowment net asset composition by purpose as of August 31 (in thousands):

	2020			2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Student financial aid	\$ 168,002	852,068	1,020,070	\$ 150,500	755,011	905,511
Academic, research, and program support	933,303	3,062,131	3,995,434	868,568	2,830,894	3,699,462
Capital projects, real estate, and infrastructure	631,753	242,127	873,880	583,799	210,750	794,549
<b>Total endowment net assets</b>	<b>\$ 1,733,058</b>	<b>4,156,326</b>	<b>5,889,384</b>	<b>\$ 1,602,867</b>	<b>3,796,655</b>	<b>5,399,522</b>

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Balance as of August 31, 2018	\$ 1,556,384	3,685,935	5,242,319
Investment return:			
Investment income	9,805	23,261	33,066
Net realized and unrealized gains on investments	94,099	240,376	334,475
Total investment return	103,904	263,637	367,541
Cash contributions	9,369	26,375	35,744
Additions of funds for endowments	—	406	406
Transfers of institutional funds for endowments without donor restrictions	11,426	—	11,426
Withdrawal of board-designated funds for strategic initiatives	(7,686)	—	(7,686)
Appropriations for expenditure	(64,093)	(162,946)	(227,039)
Appropriations for capital purposes	(6,437)	(16,752)	(23,189)
<b>Balance as of August 31, 2019</b>	<b>\$ 1,602,867</b>	<b>3,796,655</b>	<b>5,399,522</b>
Investment return:			
Investment income	5,896	13,974	19,870
Net realized and unrealized gains on investments	196,339	488,317	684,656
Total investment return	202,235	502,291	704,526
Cash contributions	4,527	38,636	43,163
New board-designated endowment funds	—	—	—
Additions of funds for endowments	—	4,792	4,792
Transfers of institutional funds for endowments without donor restrictions	3,719	—	3,719
Withdrawal of board-designated funds for strategic initiatives	(9,080)	—	(9,080)
Appropriations for expenditure	(64,604)	(168,834)	(233,438)
Appropriations for capital purposes	(6,606)	(17,214)	(23,820)
<b>Balance as of August 31, 2020</b>	<b>\$ 1,733,058</b>	<b>4,156,326</b>	<b>5,889,384</b>

### (b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. No significant deficiencies of this nature are reported in net assets with donor restrictions.

### (c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment and seek to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested within risk tolerances of the University to



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

provide an expected total return in excess of spending and inflation over the long term.

### (d) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, real assets, and derivative instruments to achieve its long-term return objectives within a prudent risk framework. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

### (e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs. The distribution of endowment investment return in 2020 and 2019 was based on 4.75% of the average fair value of the endowment over the previous 12 months ended on August 31. The University considers the expected return on its endowment, including the effect of inflation in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

### (12) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2020 (in thousands):

	Total Fair Value	Investments Measured at NAV <sup>(2)</sup>	Fair Value Hierarchy		
			Level 1	Level 2	Level 3
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ 384,127	—	229,026	155,101	—
Public equity	3,663,834	3,398,975	259,516	5,340	3
Absolute return/fixed income	1,852,780	963,452	151,780	737,548	—
Private equity/venture capital	2,196,034	2,174,383	—	—	21,651
Real assets	650,837	648,682	31	1,674	450
Derivative instruments	2,890	—	—	2,890	—
Total investments at fair value	8,750,502	7,185,492	640,353	902,553	22,104
Interests in perpetual funds held by others <sup>(1)</sup>	1,670,377	—	—	—	1,670,377
<b>Total assets at fair value</b>	<b>10,420,879</b>	<b>7,185,492</b>	<b>640,353</b>	<b>902,553</b>	<b>1,692,481</b>
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	(270,976)	—	—	(270,976)	—
Funds held in trust for others <sup>(3)</sup>	(911,138)	—	—	(911,138)	—
<b>Total liabilities at fair value</b>	<b>\$ (1,182,114)</b>	<b>—</b>	<b>—</b>	<b>(1,182,114)</b>	

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2019 (in thousands):

	Total Fair Value	Investments Measured at NAV <sup>(2)</sup>	Fair Value Hierarchy		
			Level 1	Level 2	Level 3
Short-term investments and cash equivalents	\$ 181,658	–	181,548	110	–
Public equity	3,079,796	2,732,350	275,789	71,654	3
Absolute return/fixed income	2,491,602	1,112,463	193,331	1,185,808	–
Private equity/venture capital	1,786,917	1,771,318	–	54	15,545
Real assets	731,062	727,567	205	1,674	1,616
Derivative instruments	8,846	–	191	8,655	–
Total investments at fair value	8,279,881	6,343,698	651,064	1,267,955	17,164
Interests in perpetual funds held by others <sup>(1)</sup>	1,757,576	–	–	–	1,757,576
<b>Total assets at fair value</b>	<b>10,037,457</b>	<b>6,343,698</b>	<b>651,064</b>	<b>1,267,955</b>	<b>1,774,740</b>
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	(238,112)	–	–	(238,112)	–
Funds held in trust for others <sup>(3)</sup>	(826,663)	–	–	(826,663)	–
<b>Total liabilities at fair value</b>	<b>\$ (1,064,775)</b>	<b>–</b>	<b>–</b>	<b>(1,064,775)</b>	<b>–</b>

(1) Primarily invested in The Coca-Cola Company

(2) Certain investments that are measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated statements of financial position.

(3) Emory uses net asset value of units held as an estimate for fair value.

The following tables summarize the University's Level 3 reconciliation for the years ended August 31, 2020 and 2019 (in thousands):

	Balance as of August 31, 2019	Net Gains (Losses)	Purchases	Sales	Transfer out	Balance as of August 31, 2020
Public equity	\$ 3	–	–	–	–	\$ 3
Absolute return/fixed income	–	–	–	–	–	–
Private equity/venture capital	15,545	6,085	59	(38)	–	21,651
Real assets	1,616	(694)	–	(472)	–	450
<b>Total investments</b>	<b>17,164</b>	<b>5,391</b>	<b>59</b>	<b>(510)</b>	<b>–</b>	<b>22,104</b>
Interests in perpetual funds held by others	1,757,576	(37,422)	35,000	–	(84,777)	1,670,377
<b>Total assets</b>	<b>\$ 1,774,740</b>	<b>(32,031)</b>	<b>35,059</b>	<b>(510)</b>	<b>(84,777)</b>	<b>\$ 1,692,481</b>

	Balance as of August 31, 2018	Net Gains (Losses)	Purchases	Sales	Transfer out	Balance as of August 31, 2019
Public equity	\$ 706	(205)	–	(7)	(491)	\$ 3
Absolute return/fixed income	726	(726)	–	–	–	–
Private equity/venture capital	20,632	8,508	452	(14,047)	–	15,545
Real assets	5,659	(4,022)	–	(21)	–	1,616
<b>Total investments</b>	<b>27,723</b>	<b>3,555</b>	<b>452</b>	<b>(14,075)</b>	<b>(491)</b>	<b>17,164</b>
Interests in perpetual funds held by others	1,311,406	195,591	255,380	–	(4,801)	1,757,576
<b>Total assets</b>	<b>\$ 1,339,129</b>	<b>199,146</b>	<b>255,832</b>	<b>(14,075)</b>	<b>(5,292)</b>	<b>\$ 1,774,740</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (13) Derivative Instruments and Hedging Activities

#### (a) Investments

Investment strategies employed by Emory and investment managers retained by Emory may incorporate futures, options, swaps, and other derivative instruments to adjust elements of investment exposures to various securities, markets, and

currencies without taking a position in the underlying assets. These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations, and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks.

Emory's investment-related derivative exposures, categorized by primary underlying risk, as of and for the years ended August 31 are as follows (in thousands):

2020	Notional Amount <sup>(1)</sup>	Asset Fair Value	Liability Fair Value	Total Earnings <sup>(2)</sup>
Interest-rate contracts	\$ —	—	—	2,974
Foreign exchange contracts	27	14	(14)	1,690
Equity contracts <sup>(3)</sup>	133,704	14,288	(11,398)	(19,418)
Credit contracts	—	—	—	(74)
<b>Total <sup>(4)</sup></b>	<b>\$ 133,731</b>	<b>14,302</b>	<b>(11,412)</b>	<b>(14,828)</b>

2019	Notional Amount <sup>(1)</sup>	Asset Fair Value	Liability Fair Value	Total Earnings <sup>(2)</sup>
Interest-rate contracts	\$ 759,465	305	(7,427)	(8,563)
Foreign exchange contracts	1,352,696	662	(956)	4,007
Equity contracts <sup>(3)</sup>	220,797	31,347	(14,954)	14,133
Credit contracts	28,962	364	(495)	10
<b>Total <sup>(4)</sup></b>	<b>\$ 2,361,920</b>	<b>32,678</b>	<b>(23,832)</b>	<b>9,587</b>

- (1) The notional amount is representative of the absolute value of the open contracts as of August 31, 2020 and 2019, except as otherwise discussed below in (3).
- (2) Gains (losses) on derivative instruments incurred during the fiscal year are included in the consolidated statements of activities in investment return in excess of spending distribution for current operations in nonoperating activities.
- (3) The notional value for options is presented on a net delta-adjusted basis.
- (4) Derivatives are held primarily with two counterparties. No cash collateral is pledged or held as of August 31, 2020 and \$6.0 million as of August 31, 2019.

#### (b) Debt

As a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by any potential basis risk with variable rate debt. Certain of the University's derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivative instruments in net liability positions. At August 31,

2020, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2020, Emory had eight interest rate swap agreements expiring on various dates ranging from September 1, 2035 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.238% to 3.607% in exchange for variable rate payments from the counterparties based on a percentage of the three-month LIBOR.

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$12.3 million and \$10.6 million during 2020 and 2019, respectively. The fair value of each exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

The aggregate fair value of all derivative instruments with credit risk-related contingent features that are in a liability position was \$271.0 million and \$238.1 million, collateralized by \$85.9 million and \$28.0 million of cash on August 31, 2020 and 2019, respectively. Collateral postings are reported in prepaid expenses, deferred charges, and other assets in the consolidated statements of financial position.

The following table summarizes the debt-related derivative instruments as of August 31 (in thousands):

Interest Rate Swaps			2020		2019	
Inception	Maturity	Notional Amount <sup>(2)</sup>	Liability Fair Value	Unrealized Loss	Liability Fair Value	Unrealized (Loss) Gain
August 4, 2005	September 1, 2035	\$ 125,000	(44,378)	(5,951)	\$ (38,427)	(18,110)
August 25, 2005	September 1, 2035	40,000	(15,030)	(2,066)	(12,964)	(6,106)
April 19, 2007 <sup>(1)</sup>	November 15, 2028	—	—	—	—	991
December 1, 2007	September 1, 2035	75,000	(31,227)	(3,726)	(27,501)	(12,049)
May 1, 2008	September 1, 2038	75,000	(37,097)	(3,587)	(33,510)	(14,327)
December 1, 2008	December 1, 2042	100,000	(52,107)	(7,376)	(44,731)	(22,137)
December 1, 2009	September 1, 2035	75,000	(31,585)	(3,097)	(28,488)	(12,193)
June 23, 2015	September 1, 2035	125,000	(44,522)	(5,281)	(39,241)	(18,924)
June 23, 2015	September 1, 2035	40,000	(15,030)	(1,780)	(13,250)	(6,396)
<b>Total</b>		<b>\$ 655,000</b>	<b>(270,976)</b>	<b>(32,864)</b>	<b>\$ (238,112)</b>	<b>(109,251)</b>

(1) Interest rate swap terminated on April 11, 2019

(2) The notional amount is the predetermined dollar amount on which the exchanged interest payments are based.

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and, therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisers, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed. The swaps are exchanged with five counterparties.

### (14) Property and Equipment, Net

Property and equipment, net as of August 31 is summarized as follows (in thousands):

	2020	2019
Land and improvements	\$ 241,771	\$ 241,771
Buildings and improvements	3,963,022	3,888,388
Equipment	2,824,581	2,677,517
Finance lease ROU assets (Note 15)	20,820	—
Library and museum assets	483,366	460,960
Construction in progress	300,607	171,332
	<b>7,834,167</b>	<b>7,439,968</b>
Less: accumulated depreciation	(4,200,109)	(3,937,916)
Less: accumulated amortization of finance leases	(4,358)	—
<b>Total property, plant, and equipment, net</b>	<b>\$ 3,629,700</b>	<b>\$ 3,502,052</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The University has identified asset retirement obligations predominantly from commitments to remove asbestos and lead paint in the University's facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.00% and discount rate of 4.74%. The liability for asset retirement obligations at August 31, 2020 and 2019 is \$82.6 million and \$79.1 million, respectively.

### (15) Leases

The University has operating and finance leases for office buildings, research and development facilities, hospital and educational buildings, and certain equipment. Leases have remaining lease terms of 1 year to 25 years, some of which include purchase options or options to extend the leases.

Operating leases are included in operating lease right-of-use assets and operating lease liabilities in the 2020 consolidated statement of financial position. Finance leases are included in property, plant, and equipment, net and finance lease liabilities in the 2020 consolidated statement of financial position. Operating lease ROU assets include any lease payments made and exclude lease incentives. Renewal options are excluded from the calculation of lease liabilities unless it is reasonably assured that the renewal option will be exercised. Costs associated with operating lease ROU assets are recognized on a straight-line basis within operating expenses over the term of the lease.

Finance lease ROU assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest-method over the lease term. Variable lease costs, such as common area maintenance, property taxes, and insurance are expensed as incurred.

Emory has lease agreements with lease and nonlease components. The University elected a practical expedient, primarily for its copier leases, whereby nonlease components are not separated from the lease component. This results in all of the lease and non-lease components being combined, and accounted for, as a single lease component. In electing the practical expedient both the lease and nonlease components are included in the measurement of the ROU assets and lease liabilities.

The components of lease expense for the year ended August 31, are as follows (in thousands):

	<b>2020</b>
Finance lease cost	\$ 7,881
Amortization of right-of-use assets	4,358
Interest on lease liabilities	3,523
Operating lease cost	41,977
Short-term lease cost	15,963
<b>Total lease expense</b>	<b>\$ 65,821</b>

The University has entered into a lease for space to serve as an expanded point of entry for imaging and surgical cases for Emory Healthcare, referred to as the Musculoskeletal Outpatient Center (MSK Center) at its Executive Park property, which has not yet commenced as of August 31, 2020. The underlying asset is currently under construction, and although the University is involved in the design and construction, the University does not control the building during construction, and is thus not deemed to be the owner during construction. Construction of the building is anticipated to be substantially complete by September 1, 2021, at which time the University will obtain the right of use of the asset and the lease will commence.

Aggregate future payments under noncancelable operating and finance leases as of August 31, 2020 are as follows (in thousands):

	<b>Operating Leases</b>	<b>Finance Leases</b>
2021	\$ 43,131	\$ 1,480
2022	38,428	1,349
2023	32,039	1,197
2024	28,411	1,100
2025	22,168	1,057
Thereafter	70,046	21,099
Total lease payments	234,223	27,282
Less: amounts representing interest	(19,869)	(9,436)
<b>Total obligation</b>	<b>\$ 214,354</b>	<b>\$ 17,846</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

Supplemental cash flow information related to leases for the year ended August 31 is as follows (in thousands):

	<b>2020</b>
Other information	
Cash paid for amounts included in the measurement of lease liabilities	
Operating cash flows from operating leases	\$ 41,811
Operating cash flows from finance leases	3,523
Financing cash flows from finance leases	4,087
Right-of-use assets obtained in exchange for lease obligations	
Operating leases	15,253
Finance leases	311
Weighted-average remaining lease term -- finance lease	24 years
Weighted-average remaining lease term -- operating lease	8 years
Weighted-average discount rate -- finance lease	3.82%
Weighted-average discount rate -- operating lease	2.00%

Given the transition adoption method elected by the University, future aggregate minimum payments under noncancelable operating and capital leases for the years ended August 31, under ASC Topic 840 are as follows (in thousands):

	<b>Operating Leases</b>	<b>Capital Leases</b>
2020	\$ 41,957	\$ 2,179
2021	33,224	2,081
2022	29,760	1,924
2023	23,033	1,750
2024	18,775	1,636
Thereafter	46,795	29,070
<b>Total lease payments</b>	<b>\$ 193,544</b>	<b>\$ 38,640</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (16) Bonds and Notes Payable

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following as of August 31 (dollars in thousands):

	Average Interest Rate	Final Maturity	Outstanding Principal	
			2020	2019
Tax-exempt, fixed-rate revenue bonds:				
2020 Series B	4.63%	September 1, 2041	\$ 486,470	\$ —
2019 Series A	4.96	September 1, 2039	218,115	218,115
2019 Series B	5.00	September 1, 2048	39,725	39,725
2016 Series A	4.62	October 1, 2046	130,030	130,030
2016 Series B	4.22	October 1, 2043	201,280	204,385
2013 Series A	5.00	October 1, 2043	180,605	182,205
2011 Series A <sup>(1)</sup>	5.00	September 1, 2041	—	121,500
Total tax-exempt, fixed-rate revenue bonds			1,256,225	895,960
Tax-exempt, variable-rate revenue bonds:				
2013 Series B <sup>(2)</sup>	1.37	October 1, 2039	135,100	135,100
2013 Series C <sup>(1)</sup>	1.39	October 1, 2039	—	57,865
2005 Series B <sup>(1)</sup>	1.10	September 1, 2035	—	250,000
2005 Series C <sup>(1)</sup>	1.16	September 1, 2036	—	124,150
Total tax-exempt, variable-rate revenue bonds			135,100	567,115
Taxable, fixed-rate revenue bonds:				
2020 Series A	2.41	September 1, 2050	943,750	—
1994 Series C	8.00	October 1, 2024	3,545	4,100
1991 Series	8.85	April 1, 2022	85	133
Total taxable, fixed-rate revenue bonds			947,380	4,233
Taxable, variable-rate revenue bonds:				
1999 Series B <sup>(1)</sup>	1.54	November 1, 2029	—	8,105
1995 Series B <sup>(1)</sup>	1.57	November 1, 2025	—	1,750
1994 Series B <sup>(1)</sup>	2.57	October 1, 2024	—	6,375
Total taxable, variable-rate revenue bonds			—	16,230
Commercial Paper:				
2010 Program 1 - Tax-exempt <sup>(1)</sup>	1.66	August 1, 2050	—	164,422
2008 Program 1 - Taxable <sup>(1)</sup>	2.13	April 1, 2047	—	203,247
Total Commercial Paper			—	367,669
Unamortized bond premiums			233,401	136,687
Bond issuance costs			(9,191)	(7,834)
Total bonds and notes payable			\$ 2,562,915	\$ 1,980,060

- (1) Various bonds were refunded with proceeds from the University's issuance of 2020 Series A and 2020 Series B bonds.
- (2) 2013 Series B bonds are floating rate notes and the interest rate is based on a spread to The Securities Industry and Financial Markets Association Index (SIFMA).



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The University incurred interest expense of \$72.2 million and \$83.5 million in 2020 and 2019, respectively, net of capitalized interest of \$1.5 million and \$0.0 million in 2020 and 2019, respectively.

As of August 31, 2020, the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

	2020
PAYABLE IN FISCAL YEAR:	
2021	\$ 16,769
2022	11,536
2023	11,345
2024	11,450
2025	19,305
Thereafter	2,268,300
	2,338,705
Unamortized net premium	233,401
Unamortized net bond issuance costs	(9,191)
	<b>\$ 2,562,915</b>

During 2020, the University refunded its 1994 Series B bonds, 1995 Series B bonds, 1999 Series B bonds, 2011 Series A bonds, and a portion of the 2005 Series B bonds and 2008 taxable Commercial Paper program totaling \$332.6 million with proceeds from the University's issuance of 2020 Series A bonds. Additionally, the University funded \$600.0 million for general corporate purposes with proceeds from the University's issuance of the 2020 Series A bonds. The University also refunded its 2005 Series C bonds, 2013 Series C bonds, 2010 tax-exempt Commercial Paper program, and a portion of the 2005 Series B bonds and 2008 taxable Commercial Paper program totaling \$603.2 million with proceeds from the 2020 Series B bonds. The University recognized a net accounting gain of \$4.4 million in conjunction with issuance of the 2020 Series A and 2020 Series B bonds, which is included in nonoperating activities, net in the accompanying 2020 consolidated statement of activities.

On August 18, 2010, the University established a \$400.0 million tax-exempt Commercial Paper program and issued the final

program order of \$164.4 million in September 2018. During 2020, the outstanding commercial paper was refunded as part of the 2020 Series B bonds issuance. The University cannot issue additional commercial paper under the 2010 tax-exempt Commercial Paper program.

In 2008, the University established a \$100.0 million taxable Commercial Paper program. The taxable Commercial Paper program was increased to \$150.0 million in 2014 and to \$350.0 million in 2019. As of August 31, 2020 and 2019, the University has an outstanding balance of \$0.0 million and \$203.2 million, respectively, under this program.

The University has a standby credit facility to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. Currently, it has one diversified facility totaling \$175.0 million that is committed for this sole purpose and cannot be used for operating needs of the University. There were no draws against this line of credit in 2020 or 2019.

Emory Healthcare entered into an affiliation agreement with one of its payors effective June 11, 2018, which was renewed in June 2020. This affiliation agreement includes, among other provisions, a \$100.0 million line of credit to Emory University, which can be utilized for any purpose that advances the charitable mission of Emory Healthcare. The affiliation agreement and related line of credit expire on September 1, 2021. There is no outstanding balance on this line of credit as of August 31, 2020 or 2019. The University has an additional \$725.0 million of lines credit with three commercial banks for which there is also no outstanding balance as of August 31, 2020. The three lines of credit mature in March and April 2021.

The University has two letters of credit with a commercial bank totaling \$1.3 million. There were no outstanding balances as of August 31, 2020 or 2019. The letter of credit agreements have varying expiration dates through fiscal year 2021.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

### (17) Net Assets

The following is a summary of net assets as of August 31 (in thousands):

	2020			2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
University funds	\$ 1,235,116	–	1,235,116	\$ 1,112,978	–	1,112,978
EHC funds	222,282	–	222,282	369,882	–	369,882
Endowment funds	1,733,058	4,156,326	5,889,384	1,602,867	3,796,655	5,399,522
Investment in plant	1,269,046	–	1,269,046	1,213,556	–	1,213,556
Interest in perpetual funds held by others	–	1,670,377	1,670,377	–	1,757,576	1,757,576
Contributions receivable, net	–	160,429	160,429	–	193,792	193,792
Annuity and other split-interest agreements	–	8,810	8,810	–	14,065	14,065
Capital projects and other donor purposes	–	162,433	162,433	–	52,653	52,653
	<b>\$ 4,459,502</b>	<b>6,158,375</b>	<b>10,617,877</b>	<b>\$ 4,299,283</b>	<b>5,814,741</b>	<b>10,114,024</b>

### (18) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions made by Emory Healthcare and its employees. The benefits are vested only to the extent of the annuities purchased. TEC sponsors The Emory Clinic, Inc. Retirement Savings Plan (the Retirement Plan), covering all its employees, except those considered leased employees or those covered under collective bargaining agreements, as defined. The Retirement Plan provides for employees to make salary reduction contributions and for TEC to make discretionary contributions for employees who have attained the age of 21 and are employees at the date the contribution is made. The Retirement Plan provides for contributions at an annual determined percentage of compensation and employees cliff vest in employer contributions after three years of service. Retirement expense totaled \$154.9 million and \$154.8 million during 2020 and 2019, respectively, and is included in fringe benefits expense in the accompanying consolidated statements of activities.

The University sponsors the Code Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the time of termination of

employment from the University. As of August 31, 2020 and 2019, respectively, the University held other assets of \$170.5 million and \$142.0 million under the Retirement Plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$170.5 million and \$142.0 million as of August 31, 2020 and 2019, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

### (19) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

The Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan's investment objectives.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan's target asset allocation.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by Saint Joseph's Health System SJHS (the SJHS Pension Plan). The plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

In connection with the acquisition of DRHS, Emory Healthcare assumed sponsorship of DRHS' trustee noncontributory, defined-benefit pension plan on September 1, 2018. Prior to the acquisition, the DRHS Pension Plan had been permanently frozen effective December 31, 2008 as a result of DRHS' Board of Directors approving such action.

Given the curtailment of the plans, the accumulated benefit obligations at August 31, 2020 and 2019 are the same as the projected benefit obligations.

The changes in the projected benefit obligations as of and for the years ended August 31 are as follows (in thousands):

	2020			2019		
	Emory Healthcare	SJHS	DRHS	Emory Healthcare	SJHS	DRHS
Projected benefit obligation, beginning of year	\$ 341,188	176,513	64,408	\$ 320,034	149,118	161,598
Interest cost	11,106	5,335	628	12,582	6,250	5,695
Actuarial (gain) loss	23,551	5,338	(3,228)	63,650	27,051	23,282
Plan combinations	61,547	—	(61,547)	—	—	—
Plan settlements	—	—	—	(45,951)	—	(117,884)
Benefits paid	(7,282)	(6,461)	(261)	(9,127)	(5,906)	(8,283)
<b>Projected benefit obligation, end of year</b>	<b>\$ 430,110</b>	<b>180,725</b>	<b>—</b>	<b>\$ 341,188</b>	<b>176,513</b>	<b>64,408</b>

As a result of the acquisition of DRHS, the funded status of the DRHS Pension Plan was remeasured as of September 1, 2018, and unamortized prior service costs and experience gains and losses were eliminated.

On December 31, 2019, the DRHS pension plan was merged into the Emory Healthcare Plan. Liabilities and assets were re-measured as of the date of the merger. The result was a liability transfer of \$61.5 million, an asset transfer of \$60.0 million, and a transfer of unrecognized net loss of \$6.0 million for the plan combination.

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2020			2019		
	Emory Healthcare	SJHS	DRHS	Emory Healthcare	SJHS	DRHS
Fair Value of plan assets, beginning of year	\$ 228,046	127,001	62,160	\$ 251,372	121,388	165,400
Actual return on plan assets	36,490	17,134	(1,924)	16,226	5,153	17,810
Employer contributions	2,500	6,414	—	10,516	6,366	—
Plan combinations	59,975	—	(59,975)	—	—	—
Plan settlements	—	—	—	(40,941)	—	(112,767)
Benefits paid	(7,282)	(6,461)	(261)	(9,127)	(5,906)	(8,283)
<b>Fair value of plan assets, end of year</b>	<b>\$ 319,729</b>	<b>144,088</b>	<b>—</b>	<b>\$ 228,046</b>	<b>127,001</b>	<b>62,160</b>
<b>Funded status - accrued pension cost recognized in the consolidated statements of financial position</b>	<b>\$ (110,381)</b>	<b>(36,637)</b>	<b>—</b>	<b>\$ (113,142)</b>	<b>(49,512)</b>	<b>(2,248)</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The components of net periodic pension cost for the years ended August 31 are as follows (in thousands):

	2020			2019		
	Emory Healthcare	SJHS	DRHS	Emory Healthcare	SJHS	DRHS
Interest cost	\$ 11,106	5,335	628	\$ 12,582	6,250	5,695
Expected return on assets	(12,065)	(8,567)	(621)	(17,077)	(8,200)	(7,035)
Amortization of prior service cost	—	(438)	—	—	(438)	—
Settlement loss recognized	—	—	—	15,549	—	5,731
Amortization of net loss	—	—	91	—	—	4
Recognized actuarial loss	2,832	2,654	—	1,947	1,679	—
<b>Net periodic pension cost</b>	<b>\$ 1,873</b>	<b>(1,016)</b>	<b>98</b>	<b>\$ 13,001</b>	<b>(709)</b>	<b>4,395</b>

Net periodic pension costs are recognized as employees render the services necessary to earn the pension and postretirement benefits. Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position as of August 31 are as follows:

	2020			2019		
	Emory Healthcare	SJHS	DRHS	Emory Healthcare	SJHS	DRHS
Discount rate	2.78%	2.71%	—%	3.11%	3.08%	3.14%
Expected long-term rate of return on plan assets	4.65	6.75	—	6.80	6.75	4.81

Weighted average assumptions used to determine net periodic pension cost for the years ended August 31 are as follows:

	2020			2019		
	Emory Healthcare	SJHS	DRHS	Emory Healthcare	SJHS	DRHS
Discount rate	3.11%	3.08%	3.14%	4.31%	4.28%	4.24%
Expected long-term rate of return on plan assets	4.65	6.75	3.50	6.80	6.75	4.81

The following tables summarize the plan assets, which are recorded at fair value as of August 31 as follows (in thousands):

	2020				2019			
	Emory Healthcare	SJHS	DRHS	Total	Fair Value Hierarchy		Total Fair Value	Target <sup>(1)</sup> Allocation
					Level 1	Level 2		
INVESTMENTS:								
Short-term investments and cash equivalents	\$ 528	6,392	—	6,920	(378)	7,298	6,920	—%
Commingled funds – equity	209,979	72,528	—	282,507	28,583	253,924	282,507	60
Commingled funds – fixed income	109,222	49,294	—	158,516	—	158,516	158,516	30
Managed funds	—	15,874	—	15,874	—	15,874	15,874	10
<b>Total investments</b>	<b>\$ 319,729</b>	<b>144,088</b>	<b>—</b>	<b>463,817</b>	<b>28,205</b>	<b>435,612</b>	<b>463,817</b>	<b>100%</b>

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

					2019				
	Emory Healthcare	SJHS	DRHS	Total	Fair Value Hierarchy		Total Fair Value	Target (1) Allocation	
					Level 1	Level 2			
INVESTMENTS:									
Short-term investments and cash equivalents	\$	302	4,460	4,570	9,332	5,871	3,461	9,332	—%
Commingled funds – equity		154,068	58,278	–	212,346	25,940	186,406	212,346	60
Commingled funds – fixed income		73,676	46,315	57,590	177,581	1,949	175,632	177,581	30
Managed funds		–	17,948	–	17,948	–	17,948	17,948	10
<b>Total investments</b>	<b>\$</b>	<b>228,046</b>	<b>127,001</b>	<b>62,160</b>	<b>417,207</b>	<b>33,760</b>	<b>383,447</b>	<b>417,207</b>	<b>100%</b>

(1) While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

### Cash Flows

Emory Healthcare expects to contribute \$11.8 million to the Emory Healthcare Pension Plan, and \$7.4 million to the SJHS Pension Plan during fiscal year 2021.

### Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$10.4 million to \$16.3 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump-sum settlements, are expected to range from \$7.0 million to \$8.3 million for the next five years.

### Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

### (20) Postretirement Healthcare and Life Insurance Benefits

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

		2020			2019	
		Emory University	Emory Healthcare	Total	Total	Total
APBO, beginning of year	\$	128,681	72,054	200,735	\$	160,648
Service cost		1,926	684	2,610		2,112
Interest cost		3,635	1,998	5,633		6,456
Actuarial losses (gains)		6,391	(129)	6,262		37,039
Benefits paid		(3,898)	(1,763)	(5,661)		(5,520)
<b>APBO, end of year</b>	<b>\$</b>	<b>136,735</b>	<b>72,844</b>	<b>209,579</b>	<b>\$</b>	<b>200,735</b>

Discount rate to determine APBO as of August 31, 2020 and 2019 was 2.80% and 3.12%, respectively.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2020			2019	
	Emory University	Emory Healthcare	Total	Total	
Fair value of plan assets, beginning of year	\$ 73,080	17,450	90,530	\$ 93,040	
Actual return on plan assets	7,605	1,411	9,016	(459)	
Benefits paid from plan assets	—	(1,763)	(1,763)	(2,051)	
<b>Fair value of plan assets, end of year</b>	<b>\$ 80,685</b>	<b>17,098</b>	<b>97,783</b>	<b>\$ 90,530</b>	
<b>Funded status</b> – accrued postretirement benefit cost recognized in the consolidated statements of financial position	<b>\$ (56,050)</b>	<b>(55,746)</b>	<b>(111,796)</b>	<b>\$ (110,205)</b>	

The components of net periodic postretirement benefit cost for the years ended August 31 are as follows (in thousands):

	2020			2019	
	Emory University	Emory Healthcare	Total	Total	
Service cost of benefits earned	\$ 1,926	684	2,610	\$ 2,112	
Interest cost on APBO	3,635	1,998	5,633	6,456	
Expected return on plan assets	(5,116)	(1,134)	(6,250)	(7,223)	
Recognized net actuarial loss	3,642	3,740	7,382	3,945	
<b>Net periodic postretirement benefit cost</b>	<b>\$ 4,087</b>	<b>5,288</b>	<b>9,375</b>	<b>\$ 5,290</b>	

Discount rate and expected return on plan assets used to determine net periodic postretirement benefit cost for the years ended August 31, 2020 and 2019 was 3.12% and 4.32%, respectively, and 7.00% and 8.00%, respectively.

The amounts accumulated in net assets without donor restrictions follow as of August 31 (in thousands):

	2020			2019	
	Emory University	Emory Healthcare	Total	Total	
Net unrecognized actuarial loss	\$ 67,806	29,503	97,309	\$ 101,207	
Prior service cost	(86)	—	(86)	(98)	
<b>Total</b>	<b>\$ 67,720</b>	<b>29,503</b>	<b>97,223</b>	<b>\$ 101,109</b>	

In fiscal year 2021, net unrecognized actuarial losses of \$3.6 million for Emory University and \$3.7 million for Emory Healthcare are expected to be amortized from net assets without donor restrictions into net periodic postretirement benefit cost.

### Plan Assets

The Investment Committee of Emory University's Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans.

The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

The following table summarizes the VEBA Trust assets for the University and Emory Healthcare as of August 31 (in thousands):

2020						
	Total Fair Value	Fair Value Hierarchy		NAV	Target Allocation	Total Asset Allocation
		Level 1	Level 2			
Fixed income	\$ 20,924	13,998	6,926	—	25%	21%
Public equity	76,861	17,750	44,352	14,759	75	79
Short-term investment and cash equivalent	(2)	(2)	—	—	—	—
<b>Total investments</b>	<b>\$ 97,783</b>	<b>31,746</b>	<b>51,278</b>	<b>14,759</b>	<b>100%</b>	<b>100%</b>

  

2019						
	Total Fair Value	Fair Value Hierarchy		NAV	Target Allocation	Total Asset Allocation
		Level 1	Level 2			
Fixed income	\$ 23,614	13,119	10,495	—	25%	26%
Public equity	66,952	17,292	35,777	13,883	75	74
Short-term investment and cash equivalent	(36)	(36)	—	—	—	—
<b>Total investments</b>	<b>\$ 90,530</b>	<b>30,375</b>	<b>46,272</b>	<b>13,883</b>	<b>100%</b>	<b>100%</b>

### Cash Flows

Emory University and Emory Healthcare expect to contribute \$4.2 million and \$2.5 million, respectively, to the postretirement benefit plan during fiscal year 2021.

### Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$4.2 million to \$5.3 million for Emory University and from \$2.5 million to \$3.2 million for Emory Healthcare for the next five years.

### (21) Functional Expenses

The consolidated statements of activities present expenses by

natural classification. The University also summarizes expenses by functional classification, in accordance with its mission. The University's primary program services are instruction, research, public service, and the delivery of healthcare and medical services. Expenses for academic support, institutional support, and independent operations/auxiliary enterprises are generally incurred in support of these primary program activities, with academic support being related to student financial aid. Capital and plant expenditures, costs for operation and maintenance of plant, interest on indebtedness, and depreciation and amortization are allocated using a variety of cost allocation techniques, such as square footage and time and effort.

The consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands, net of the cost allocations and recharges referenced above):

2020								
	Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$ 310,588	250,500	90,830	161,045	55,504	2,398,787	99,878	3,367,132
Fringe benefits	74,597	62,373	22,334	20,294	14,054	499,813	20,758	714,223
Student financial aid	—	—	27,302	—	—	—	—	27,302
Nonsalary operating expenses	55,590	198,984	56,377	4,898	42,579	1,715,070	27,361	2,100,859
Interest on indebtedness	7,046	11,216	4,479	2,261	1,771	27,072	18,919	72,764
Depreciation and amortization	29,537	49,476	17,832	25,563	8,130	155,687	17,120	303,345
<b>Total expenses</b>	<b>\$ 477,358</b>	<b>572,549</b>	<b>219,154</b>	<b>214,061</b>	<b>122,038</b>	<b>4,796,429</b>	<b>184,036</b>	<b>6,585,625</b>

\* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$4.6 billion. Healthcare administrative costs are \$445.8 million, included therein.

# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

2019

	Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$ 289,428	231,901	83,253	150,487	56,359	2,280,392	96,325	3,188,145
Fringe benefits	74,962	57,474	20,662	28,216	14,593	468,562	19,570	684,039
Student financial aid	—	—	20,477	—	—	—	—	20,477
Nonsalary operating expenses	49,216	189,874	62,063	19,586	47,855	1,676,151	15	2,044,761
Interest on indebtedness	8,127	12,936	5,166	2,608	2,044	29,738	22,195	82,814
Depreciation and amortization	28,572	47,885	17,249	24,726	7,864	151,080	16,915	294,291
<b>Total expenses</b>	<b>\$ 450,305</b>	<b>540,070</b>	<b>208,870</b>	<b>225,623</b>	<b>128,715</b>	<b>4,605,923</b>	<b>155,020</b>	<b>6,314,527</b>

\* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$4.3 billion. Healthcare administrative costs are \$396.7 million, included therein.

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study and debt financing records. Total amounts allocated in 2020 and 2019 were \$175.8 million and \$175.6 million, respectively. Fundraising costs were approximately \$40.0 million and \$43.0 million in 2020 and 2019, respectively.

### (22) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare's wholly owned offshore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2020 and 2019, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$262.1 million (discounted 2.5%) and \$203.8 million (discounted at 2.5%), respectively.

Emory has purchased layered excess and umbrella insurance and reinsurance coverage beyond the amounts retained by CCIC, through various carriers, for a total of \$105.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range of potential outcomes complicate the estimation. The

University's management believes adequate provision has been made for the related risk.

### (23) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The Board of Trustees of CCI comprises 16 to 28 members, including its founders, and others as elected half by the University, including the University's president, and half by the Carter Center class trustees. The University's Board of Trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws. Funds held in trust for others include \$866.1 million and \$780.2 million, representing CCI's investment in the University's long-term investment portfolio as of August 31, 2020 and 2019, respectively.

Emory University and Children's Healthcare of Atlanta, Inc. (Children's), a Georgia nonprofit corporation, established the Emory + Children's Pediatric Institute (the Institute) effective September 1, 2018 under a Master Affiliation Agreement (the affiliation agreement). Under the terms of the affiliation agreement, approximately 350 Emory University School of Medicine Department of Pediatrics faculty physicians and PhD researchers transferred to the Institute and became employees thereof. The affiliation agreement restructured previous arrangements between the parties for pediatric teaching, research, and related clinical services. The ownership of the Institute is 50% Emory University and 50% Children's, with equal representation on the governing board. The funding obligations of each party are specified by the affiliation agreement, and each party funds its mission-related expenses. The University reports research and teaching expenses provided by these 350 faculty members in salaries, fringe benefits, professional fees and



# EMORY UNIVERSITY

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2020 AND 2019

purchased services, and other operating expenses in the consolidated statements of activities.

### **(24) Commitments and Contingencies**

Emory University and Emory Healthcare are in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2020 totaled \$280.6 million and \$377.0 million, respectively.

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures which may be disallowed by the granting agencies, cannot be determined at this time, although management expects they will not have a material effect on the University's consolidated financial statements.

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel review.

In addition, the University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the consolidated statements of financial position or operating results of the University. The University also has a comprehensive program of primary and excess insurance. Management of the University believes any current pending lawsuit subjecting the University to liability would not have a materially adverse effect on the University's consolidated statements of financial position.

Emory Healthcare and SJHS have a JOC under the name of Emory/Saint Joseph's, Inc. to further the respective missions of Emory Healthcare and CHE Trinity Health. Under the JOC Contribution Agreement, Emory Healthcare maintains a 51% controlling ownership interest in the JOC. SJHS has a noncontrolling membership interest in the JOC of 49%. Effective August 31, 2014, CHE Trinity Health has a put right, as defined in the JOC Contribution Agreement, that may be exercised at any time with written notice to Emory Healthcare. Upon the occurrence of such event, Emory Healthcare may be required to purchase from SJHS its noncontrolling interest in the JOC.

As part of the terms of the Definitive Agreement to acquire DRHS, Emory Healthcare committed \$239.0 million on capital projects to benefit DRHS and its affiliates over a 7-year period, beginning September 1, 2018. Such period may be extended under certain circumstances to a period of no more than 10 years.

### **(25) Subsequent Events**

Emory has evaluated subsequent events after the consolidated statements of financial position date of August 31, 2019 through December 18, 2020, the date the consolidated financial statements were available to be issued, and noted that there are no other items to disclose.



## **SUPPLEMENTARY INFORMATION**

**EMORY UNIVERSITY** (EXCLUDING EMORY HEALTHCARE)  
**STATEMENTS OF FINANCIAL POSITION - SUPPLEMENTARY INFORMATION**  
**SCHEDULE 1**

AUGUST 31, 2020 AND 2019 (Dollars in thousands)

	August 31, 2020	August 31, 2019
<b>ASSETS:</b>		
Cash and cash equivalents	\$ 640,687	\$ 43,908
Student accounts receivable, net	81,136	21,875
Loans receivable, net	20,783	21,960
Contributions receivable, net	160,429	193,792
Other receivables, net	180,104	139,947
Prepaid expenses, deferred charges, and other assets	201,745	129,567
Investments	8,338,921	7,694,406
Interests in perpetual funds held by others	1,670,377	1,757,576
Operating lease right-of-use assets	27,556	-
Property and equipment, net	2,067,448	2,039,401
Due from affiliates	704,491	683,888
<b>Total assets</b>	<b>\$ 14,093,677</b>	<b>\$ 12,726,320</b>
<b>LIABILITIES AND NET ASSETS:</b>		
Accounts payable and accrued liabilities	\$ 208,501	\$ 190,817
CARES Act accrued liabilities	33,085	-
Deferred revenue	242,931	286,381
Interest payable	28,735	14,892
Liability for derivative instruments	270,976	238,112
Bonds and notes payable	2,562,915	1,980,060
Accrued liabilities for benefit obligations and professional liabilities	181,175	160,002
Operating lease liabilities	29,298	-
Finance lease liabilities	17,846	-
Funds held in trust for others	911,138	826,663
Annuities payable	14,677	15,287
Government advances for federal loan programs	19,494	16,638
Asset retirement obligation	57,436	54,986
<b>Total liabilities</b>	<b>4,578,207</b>	<b>3,783,838</b>
Net assets without donor restrictions	3,392,244	3,162,389
Net assets with donor restrictions	6,123,226	5,780,093
<b>Total net assets</b>	<b>9,515,470</b>	<b>8,942,482</b>
<b>TOTAL LIABILITIES AND NET ASSETS</b>	<b>\$ 14,093,677</b>	<b>\$ 12,726,320</b>

See accompanying independent auditors' report.

**EMORY UNIVERSITY** (EXCLUDING EMORY HEALTHCARE)  
**STATEMENTS OF ACTIVITIES - SUPPLEMENTARY INFORMATION**  
**SCHEDULE 2**

YEARS ENDED AUGUST 31, 2020 AND 2019 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2020	Total August 31, 2019
<b>OPERATING REVENUE</b>				
Tuition and fees, net of scholarship allowance	\$ 455,077	-	\$ 455,077	\$ 452,423
Sales and services of auxiliary enterprises, net of scholarship allowance	62,363	-	62,363	74,666
Endowment spending distribution	204,034	-	204,034	197,908
Distribution from perpetual funds	38,797	-	38,797	37,077
Other investment income designated for current operations	54,870	3	54,873	67,117
Gifts and contributions for current use	64,825	30,120	94,945	69,676
Grants and contracts	513,925	-	513,925	495,839
Indirect cost recoveries	153,399	-	153,399	147,534
Medical services	254,179	-	254,179	246,435
Independent operations	13,001	-	13,001	23,798
Other revenue	130,773	-	130,773	92,565
Net assets released from restrictions	23,761	(15,919)	7,842	19,425
<b>Total operating revenue</b>	<b>1,969,004</b>	<b>14,204</b>	<b>1,983,208</b>	<b>1,924,463</b>
Operating support from Emory Healthcare	95,274	-	95,274	98,089
<b>Total operating revenue and other support</b>	<b>2,064,278</b>	<b>14,204</b>	<b>2,078,482</b>	<b>2,022,552</b>
<b>OPERATING EXPENSES</b>				
Salaries	1,198,919	-	1,198,919	1,124,106
Fringe benefits	263,303	-	263,303	270,609
Student financial aid	27,302	-	27,302	20,477
Nonsalary operating expenses:				
Professional fees and purchased services	171,939	-	171,939	189,127
Supplies and pharmaceuticals	74,251	-	74,251	75,789
Rent, utilities, and maintenance	115,218	-	115,218	124,683
Other operating expenses	3,667	-	3,667	4,985
Total nonsalary operating expenses	365,075	-	365,075	394,584
Interest on indebtedness	46,060	-	46,060	53,500
Depreciation and amortization	153,058	-	153,058	148,435
<b>Total operating expenses</b>	<b>2,053,717</b>	<b>-</b>	<b>2,053,717</b>	<b>2,011,711</b>
<b>NET OPERATING ACTIVITIES</b>	<b>10,561</b>	<b>14,204</b>	<b>24,765</b>	<b>10,841</b>
<b>NONOPERATING ACTIVITIES, NET</b>				
Investment return in excess of spending distribution for current operations	277,322	330,858	608,180	218,994
Change in undistributed income from perpetual funds held by others	-	(37,422)	(37,422)	195,591
Gifts and contributions for capital and long-term investment	19,752	55,172	74,924	130,975
Other losses	(4,245)	-	(4,245)	(2,842)
Gain on defeasance of debt	4,386	-	4,386	4,277
Change in fair value of derivative instruments	(32,864)	-	(32,864)	(110,242)
Net periodic benefit cost other than service cost	(2,161)	-	(2,161)	(323)
Changes in pension and other postretirement obligations	3,638	-	3,638	(24,164)
Other nonoperating items, net	(51,534)	(6,837)	(58,371)	(1,230)
Net assets released from restrictions	5,000	(12,842)	(7,842)	(19,425)
<b>Total nonoperating activities, net</b>	<b>219,294</b>	<b>328,929</b>	<b>548,223</b>	<b>391,611</b>
<b>CHANGE IN NET ASSETS</b>	<b>229,855</b>	<b>343,133</b>	<b>572,988</b>	<b>402,452</b>
<b>BEGINNING NET ASSETS</b>	<b>3,162,389</b>	<b>5,780,093</b>	<b>8,942,482</b>	<b>8,540,030</b>
<b>ENDING NET ASSETS</b>	<b>\$ 3,392,244</b>	<b>6,123,226</b>	<b>\$ 9,515,470</b>	<b>\$ 8,942,482</b>

See accompanying independent auditors' report.

**EMORY UNIVERSITY** (EXCLUDING EMORY HEALTHCARE)  
**STATEMENT OF CASH FLOWS - SUPPLEMENTARY INFORMATION**  
**SCHEDULE 3**

YEAR ENDED AUGUST 31, 2020 (Dollars in thousands)

**August 31, 2020**

**CASH FLOWS FROM OPERATING ACTIVITIES:**

Change in net assets	\$ 572,988
Adjustments to reconcile change in net assets to net cash used in operating activities:	
Receipts from restricted contributions for long-term investments and capital projects	(74,923)
Net realized and unrealized gains on investments	(942,194)
Loss on disposal of property and equipment	4,245
Interests in perpetual funds held by others	37,422
Gain on defeasance of debt	(4,386)
Depreciation and amortization of intangible assets	148,700
Accretion/amortization of debt discounts/premiums and issuance costs	(5,591)
Amortization of right-of-use assets - financing	4,358
Amortization of right-of-use assets - operating	6,150
Actuarial adjustments for retiree pension and benefit plans	4,347
Change in fair value of derivative instruments	32,864
Change in operating assets:	
Accounts and other receivables, net	(109,633)
Contributions receivable for operations	9,181
Prepaid expenses, deferred charges, and other assets	(14,257)
Due to/from affiliates	(20,604)
Change in operating liabilities:	
Accounts payable, accrued liabilities, and interest payable	31,526
CARES Act accrued liabilities	33,085
Asset retirement obligation	2,450
Accrued liabilities for benefit obligations and professional liabilities	16,827
Lease obligations, net	(3,295)
Deferred revenue	(33,235)

<b>Net cash used in operating activities</b>	<b>(303,975)</b>
--	------------------

**CASH FLOWS FROM INVESTING ACTIVITIES:**

Disbursements of loans to students	(2,899)
Repayment of loans from students	4,076
Proceeds from sales and maturities of investments	7,100,225
Purchases of investments	(6,802,545)
Purchases of property, plant, and equipment	(164,530)
Increase in funds held in trust for others	84,475

<b>Net cash provided by investing activities</b>	<b>\$ 218,802</b>
--	-------------------

(Continued)

**EMORY UNIVERSITY** (EXCLUDING EMORY HEALTHCARE)  
**STATEMENT OF CASH FLOWS - SUPPLEMENTARY INFORMATION**  
**SCHEDULE 3**

YEAR ENDED AUGUST 31, 2020 (Dollars in thousands)

**August 31, 2020**

**CASH FLOWS FROM FINANCING ACTIVITIES:**

Receipts from contributions for donor-restricted endowment funds and capital projects	\$	148,882
Proceeds from bonds payable		1,535,171
Principal repayments of bonds payable		(938,336)
Payments on finance lease obligations		(4,087)
Debt issuance costs		(4,003)
Change in annuities payable		(610)
Change in government advances for federal loan programs		2,856
Borrowings on line of credit		275,000
Repayments on line of credit		(275,000)
<b>Net cash provided by financing activities</b>		<b>739,873</b>
Net increase in cash, cash equivalents, and restricted cash		654,700
Cash, cash equivalents, and restricted cash at beginning of year		71,888
<b>Cash, cash equivalents, and restricted cash at end of year</b>	<b>\$</b>	<b>726,588</b>

See accompanying independent auditors' report.



KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

**Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards***

The Board of Trustees  
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statement of financial position as of August 31, 2020, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 18, 2020. Our report contains an emphasis of matters paragraph referring to the University's adoption, in fiscal year 2020, of Accounting Standards Update (ASU) No. 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*, and ASU No. 2016-02, *Leases (Topic 842)*, as amended.

**Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

**Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia  
December 18, 2020



**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF  
FEDERAL AWARDS**

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Research and Development Cluster:				
U.S. Department of Agriculture:				
Agriculture Research – Basic and Applied Research:				
Pass-through CRDF Global	DAA9-19-65373-1	10.001	\$ —	6,025
Total CFDA No. 10.001			—	6,025
Sustainable Agriculture Research and Education:				
Pass-through University of Georgia	20163864025382	10.215	—	6,128
Total CFDA No. 10.215			—	6,128
Agriculture and Food Research Initiative (AFRI)	2018-67011-28030	10.310	—	29,596
Agriculture and Food Research Initiative (AFRI)	2019-67013-29371	10.310	—	41,234
Agriculture and Food Research Initiative (AFRI)	20196701729642	10.310	—	100,177
Pass-through University of Georgia	20206701931157	10.310	—	16,086
Total CFDA No. 10.310			—	187,093
Crop Protection and Pest Management Competitive Grants Program				
Pass-through North Carolina State University	20187000828884	10.329	—	10,403
Total CFDA No. 10.329			—	10,403
U.S. Department of Agriculture Total			—	209,649
U.S. Department of Commerce:				
Sea Grant Support				
Pass-through Georgia Southern University	NA180AR4170084	11.417	—	16,844
Total CFDA No. 11.417			—	16,844
Fisheries Development and Utilization Research and Development Grants and Cooperative Agreements				
Total CFDA No. 11.427	NA15NMF4270347	11.427	—	375
U.S. Department of Commerce Total			—	375
U.S. Department of Commerce Total			—	17,219
U.S. Department of Defense:				
Basic and Applied Scientific Research				
Pass-through Brown University	N00014-16-1-2276	12.300	486	926
Pass-through Brown University	N00014-16-1-2355	12.300	—	59,834
Total CFDA No. 12.300			486	60,760
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA1-15-C-0075	12.351	1,125,809	2,067,574
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA-1-16-1-0029	12.351	—	2,408
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA11810029	12.351	261,288	353,507
Total CFDA No. 12.351			1,387,097	2,423,489
Military Medical Research and Development	W81XWH-15-1-0132	12.420	—	(163)
Military Medical Research and Development	W81XWH-15-1-0154	12.420	69,109	150,745
Military Medical Research and Development	W81XWH-15-1-0545	12.420	—	13,573
Military Medical Research and Development	W81XWH-16-1-0535	12.420	—	114,981
Military Medical Research and Development	W81XWH-16-1-0584	12.420	33,642	74,672
Military Medical Research and Development	W81XWH-17-1-0104	12.420	—	29,652
Military Medical Research and Development	W81XWH-17-1-0186	12.420	—	127,729
Military Medical Research and Development	W81XWH1710187	12.420	—	124,557
Military Medical Research and Development	W81XWH-17-1-0271	12.420	—	284,549
Military Medical Research and Development	W81XWH-17-1-0438	12.420	—	252,984
Military Medical Research and Development	W81XWH-17-1-0439	12.420	—	273,695
Military Medical Research and Development	W81XWH-17-1-0459	12.420	—	114,206
Military Medical Research and Development	W81XWH1810373	12.420	100,470	209,855
Military Medical Research and Development	W81XWH1810526	12.420	2,149	159,258
Military Medical Research and Development	W81XWH-18-1-0619	12.420	49,949	76,556
Military Medical Research and Development	W81XWH1810700	12.420	—	338,997
Military Medical Research and Development	W81XWH-18-KCRP-CA	12.420	—	56,629
Military Medical Research and Development	W81XWH1910068	12.420	—	195,511
Military Medical Research and Development	W81XWH-19-1-0069	12.420	—	200,928
Military Medical Research and Development	W81XWH1910498	12.420	84,735	423,030
Military Medical Research and Development	W81XWH1910567	12.420	—	110,925
Military Medical Research and Development	W81XWH1910776	12.420	—	377,538
Military Medical Research and Development	W81XWH1910840	12.420	—	105,367
Military Medical Research and Development	W81XWH2010052	12.420	—	1,861
Military Medical Research and Development	W81XWH2010446	12.420	—	25,245
Military Medical Research and Development	W81XWH-17-1-0634	12.420	178,402	324,321
Military Medical Research and Development	W81XWH-17-C-0229	12.420	—	374,983
Pass-through Fdtn for Atlanta Veterans Educ and Res	W81XWH-08-02-0062	12.420	—	175
Pass-through Georgia Institute of Technology	W81XWH-18-1-0669	12.420	—	94,012
Pass-through University of California San Francisco	W81XWH-14-2-0176	12.420	—	2,254
Pass-through University of Miami	W81XWH-16-1-0756	12.420	—	1,456
Pass-through University of Rochester	W81XWH-17-1-0168	12.420	—	1,430
Pass-through University of Texas San Antonio	W81XWH13220063	12.420	—	22,295
Pass-through Wayne State University	W81XWH-19-1-0794	12.420	—	91,778
Total CFDA No. 12.420			518,456	4,755,584
Basic Scientific Research	W911NF-13-1-0182	12.431	—	(50)
Basic Scientific Research	W911NF-17-1-0382	12.431	—	87,090
Basic Scientific Research	W911NF-17-1-0427	12.431	166,492	116,013
Pass-through Arizona State University	W911NF1910231	12.431	—	72,673
Pass-through University of California Los Angeles	W911NF-14-1-0378	12.431	—	121,334
Pass-through Virginia Tech	W911NF1520107	12.431	—	49,283
Total CFDA No. 12.431			166,492	446,343
Basic, Applied, and Advanced Research in Science and Engineering	FA9550-13-1-0002	12.630	—	64
Pass-through University of Washington	W911NF1910291	12.630	—	30,713
Total CFDA No. 12.630			—	30,777

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Uniformed Services University Medical Research Projects				
Pass-through Duke University	HT9404-13-0032	12.750	\$ —	335,923
Pass-through Henry M Jackson Foundation	HT9404-13-1-0030	12.750	—	1,151
Pass-through Henry M Jackson Foundation	HU0001-14-2-0052	12.750	1,250	(5,762)
Pass-through Henry M Jackson Foundation	HU0001-15-20001	12.750	—	787,398
Pass-through Henry M Jackson Foundation	HU00012020018	12.750	—	571,200
Total CFDA No. 12.750			1,250	1,689,910
Air Force Defense Research Sciences Program	FA9550-17-1-0006	12.800	—	75,655
Air Force Defense Research Sciences Program	FA9550-18-1-0189	12.800	—	159,909
Air Force Defense Research Sciences Program	FA9550-18-1-0414	12.800	—	81
Air Force Defense Research Sciences Program	FA9550-18-1-0420	12.800	1,730,616	1,974,101
Pass-through Georgia State University	FA95501510373	12.800	—	374
Pass-through State University of New York Buffalo	FA8650-18-2-5402	12.800	—	9,243
Pass-through University of Southern California	34438627	12.800	—	47
Pass-through Yale University	FA9550-17-0198	12.800	—	114,957
Total CFDA No. 12.800			1,730,616	2,334,367
Language Grant Program	H98230-19-1-0116	12.900	—	44,071
Total CFDA No. 12.900			—	44,071
Research and Technology Development	N66001-16-2-4054	12.910	11,871	17,082
Pass-through Duke University	W911NF1920111	12.910	—	56,737
Pass-through Georgia Institute of Technology	HR001117C0124	12.910	—	12,613
Pass-through Georgia Institute of Technology	HR0011-19-2-0008	12.910	—	1,597,767
Pass-through Georgia Institute of Technology	HRO01I-18-2-0019	12.910	—	32,774
Pass-through Johns Hopkins University	2019-190516000005	12.910	—	52,001
Pass-through University of Western Ontario	D18AC0035	12.910	—	25,207
Total CFDA No. 12.910			11,871	1,794,181
Contract	HR0011940590	12.RD	203,292	492,986
Contract	W911NF-16-C-0008	12.RD	685,128	695,494
Contract	W81XWH	12.RD	—	131,276
Contract	W81XWH-16-0108	12.RD	—	16,371
Contract	W81XWH-16-1-0721	12.RD	—	45,872
Contract	W81XWH1810505	12.RD	—	322,559
Contract	W81XWH1910353	12.RD	—	209,090
Contract	W81XWH1910420	12.RD	—	244,171
Pass-through Geneva Foundation	W81XWH-17-C-0029	12.RD	—	418,656
Pass-through Georgia Institute of Technology	W81XWH-16-1-0518	12.RD	—	38
Pass-through Mclean Hospital	W81XWH18P0128	12.RD	—	558
Pass-through North Carolina State University	W911NF	12.RD	—	217,984
Pass-through University of Michigan	DTNH2215D00017/693JJ918F000234	12.RD	—	18,281
Pass-through University of Michigan	W911QX17D0006	12.RD	—	163,046
Pass-through University of Pittsburgh	W81XWH-16-D-0024 - W81XWH18F0426	12.RD	—	47,517
Pass-through University of Southern California	PO# 57169635	12.RD	—	(98)
Pass-through Weill Cornell Medical College	15060932	12.RD	—	(166)
Total CFDA No. 12.RD			888,420	3,023,635
U.S. Department of Defense Total			4,704,688	16,603,117
U.S. Department of Justice:				
National Institute of Justice Research, Evaluation, and Development Project Grants				
Pass-through George Mason University	2019-R2-CX-0005	16.560	—	7,173
Total CFDA No. 16.560			—	7,173
Rural Domestic Violence, Dating Violence, Sexual Assault, and Stalking Assistance Program				
Pass-through Childrens Healthcare of Atlanta	2017-WR-AX-0005	16.589	—	22,504
Total CFDA No. 16.589			—	22,504
U.S. Department of Justice Total			—	29,677
U.S. Department of State:				
Academic Exchange Programs – Humphrey Fellowship Program				
Pass-through Institute of International Education	3223-Emory_7.1.1.16	19.010	—	60
Pass-through Institute of International Education	CAGD-18-CA-1027	19.010	—	(4,343)
Pass-through Institute of International Education	SECAGD19CA0047	19.010	—	37,530
Total CFDA No. 19.010			—	33,247
U.S. Department of State Total			—	33,247
U.S. Department of Transportation:				
Contract	DTNH2217D00068	20.RD	—	94,614
Contract	DTNH2217F00160	20.RD	79,501	606,516
Total CFDA No. 20.RD			79,501	701,130
U.S. Department of Transportation Total			79,501	701,130
National Aeronautics and Space Administration:				
Science	80NSSC18M0053	43.001	—	53,626
Science	80NSSC19K0191	43.001	164,675	312,928
Science	80NSSC20K0309	43.001	—	129,583
Science	NNX16AQ28G 000004	43.001	30,191	138,645
Science	NNX17AE72G	43.001	—	48,987
Pass-through California Institute of Technology	1588347	43.001	—	105,327
Pass-through Center for the Advancement of Science In Space	NNH11CD70A	43.001	—	833
Pass-through Massachusetts Institute of Technology	NNX16AN15G	43.001	—	2,744
Pass-through University of Georgia	80NSSC20K0360	43.001	—	43,036
Pass-through University of Iowa	NNXAF09G	43.001	—	3,988
Total CFDA No. 43.001			194,866	839,697

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Aeronautics				
Pass-through California Institute of Technology	NMO710860	43.002	\$ —	37,271
Total CFDA No. 43.002			—	37,271
Exploration	80NSSC188K1116	43.003	—	717,369
Total CFDA No. 43.003			—	717,369
National Aeronautics and Space Administration Total			194,866	1,594,337
National Endowment for the Humanities:				
Promotion of the Humanities – Division of Preservation and Access	PW-264219-19	45.149	—	34,117
Total CFDA No. 45.149			—	34,117
Promotion of the Humanities Research	RQ-260871-18	45.161	—	86,500
Promotion of the Humanities Research	RZ – 230579-15	45.161	—	78,923
Total CFDA No. 45.161			—	165,423
Promotion of the Humanities-Office of Digital Humanities				
Pass-through Georgia Institute of Technology	HAA-261266-18	45.169	—	5,512
Total CFDA No. 45.169			—	5,512
National Leadership Grants	LG-94-17-0269-17	45.312	—	41,446
Total CFDA No. 45.312			—	41,446
National Endowment for the Humanities Total			—	246,498
National Science Foundation:				
Engineering Grants	1512826	47.041	—	25,474
Engineering Grants	1706891	47.041	—	(609)
Engineering Grants	1741691	47.041	606,820	792,855
Engineering Grants	1762211	47.041	—	118,831
Engineering Grants	1804198	47.041	—	160,243
Engineering Grants	1807568	47.041	—	133,862
Engineering Grants	1818476	47.041	—	100,265
Engineering Grants	1822606	47.041	24,445	100,558
Engineering Grants	184186	47.041	—	115,417
Engineering Grants	1926387	47.041	—	87,187
Engineering Grants	2032273	47.041	—	42,544
Pass-through Georgia Institute of Technology	1749677	47.041	—	1,710
Pass-through Georgia Institute of Technology	EEC-1648035	47.041	—	19,299
Pass-through Indiana University	1928481	47.041	—	73,060
Total CFDA No. 47.041			631,265	1,770,696
Mathematical and Physical Sciences	1455086	47.049	—	51,082
Mathematical and Physical Sciences	1504449	47.049	—	46
Mathematical and Physical Sciences	1506405	47.049	—	(749)
Mathematical and Physical Sciences	1555048	47.049	—	73,116
Mathematical and Physical Sciences	1557960	47.049	—	(11,636)
Mathematical and Physical Sciences	1609763	47.049	—	9,439
Mathematical and Physical Sciences	1611102	47.049	—	310
Mathematical and Physical Sciences	1654485	47.049	—	64,813
Mathematical and Physical Sciences	1700982	47.049	2,149,444	3,441,754
Mathematical and Physical Sciences	1709132	47.049	—	34
Mathematical and Physical Sciences	1709182	47.049	—	101,305
Mathematical and Physical Sciences	1710225	47.049	—	156
Mathematical and Physical Sciences	1719578	47.049	—	42,252
Mathematical and Physical Sciences	1726536	47.049	—	(162)
Mathematical and Physical Sciences	1751636	47.049	—	78,814
Mathematical and Physical Sciences	1755698	47.049	—	(2,112)
Mathematical and Physical Sciences	1764385	47.049	—	59,929
Mathematical and Physical Sciences	1801951	47.049	—	97,104
Mathematical and Physical Sciences	1807865	47.049	—	123,483
Mathematical and Physical Sciences	1808288	47.049	—	84,810
Mathematical and Physical Sciences	1808509	47.049	—	16,254
Mathematical and Physical Sciences	1808771	47.049	—	107,460
Mathematical and Physical Sciences	1809566	47.049	—	28,919
Mathematical and Physical Sciences	1818781	47.049	—	19,927
Mathematical and Physical Sciences	1819042	47.049	—	60,488
Mathematical and Physical Sciences	1822262	47.049	—	109,076
Mathematical and Physical Sciences	1849959	47.049	—	161
Mathematical and Physical Sciences	1900532	47.049	—	113,496
Mathematical and Physical Sciences	1900555	47.049	—	125,812
Mathematical and Physical Sciences	1904885	47.049	—	116,841
Mathematical and Physical Sciences	1905782	47.049	—	184,434
Mathematical and Physical Sciences	1905809	47.049	—	80,721
Mathematical and Physical Sciences	1905947	47.049	—	140,480
Mathematical and Physical Sciences	1945200	47.049	—	52,405
Mathematical and Physical Sciences	2003692	47.049	—	17,062
Mathematical and Physical Sciences	2003962	47.049	—	56,518
Mathematical and Physical Sciences	2003987	47.049	—	6,561
Mathematical and Physical Sciences	2004080	47.049	—	13,921
Mathematical and Physical Sciences	2004126	47.049	—	4,756
Mathematical and Physical Sciences	2004846	47.049	—	13,810
Mathematical and Physical Sciences	2012686	47.049	—	13,631
Mathematical and Physical Sciences	CHE 1205646	47.049	—	5,465
Mathematical and Physical Sciences	CHE 1213904	47.049	—	(38)
Mathematical and Physical Sciences	CHE 1352040	47.049	—	4,792
Pass-through Georgia Institute of Technology	1806833	47.049	—	79,324
Total CFDA No. 47.049			2,149,444	5,586,064

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Computer and Information Science and Engineering	1553579	47.070	\$ —	144,544
Computer and Information Science and Engineering	1618932	47.070	—	193,130
Computer and Information Science and Engineering	1636933	47.070	105,122	141,535
Computer and Information Science and Engineering	1722906	47.070	—	30,113
Computer and Information Science and Engineering	1755958	47.070	—	73,533
Computer and Information Science and Engineering	1822378	47.070	7,015	118,148
Computer and Information Science and Engineering	1835364	47.070	28,113	147,133
Computer and Information Science and Engineering	1838200	47.070	—	205,781
Computer and Information Science and Engineering	1907711	47.070	—	81,971
Computer and Information Science and Engineering	2027783	47.070	—	2,183
Pass-through Georgia Institute of Technology	1915504	47.070	—	41,221
Pass-through University of Arizona	HS-1838745	47.070	—	9,038
Pass-through Virginia Tech	1547580	47.070	—	47,649
Total CFDA No. 47.070			140,250	1,235,979
Biological Sciences	1557724	47.074	—	87,404
Biological Sciences	1624104	47.074	—	68,652
Biological Sciences	1655163	47.074	—	224
Biological Sciences	1656247	47.074	33,571	170,489
Biological Sciences	1726544	47.074	—	616
Biological Sciences	1750553	47.074	—	151,941
Biological Sciences	1754431	47.074	—	139,080
Biological Sciences	1754595	47.074	—	129,188
Biological Sciences	1755002	47.074	—	53,437
Biological Sciences	1755418	47.074	—	77,335
Biological Sciences	1827160	47.074	—	61,108
Biological Sciences	1834487	47.074	—	52,821
Biological Sciences	1844803	47.074	846	115,413
Biological Sciences	1919953	47.074	—	17,462
Biological Sciences	1920190	47.074	—	448,875
Biological Sciences	1922720	47.074	—	60,583
Biological Sciences	1927411	47.074	—	20,001
Biological Sciences	1931697	47.074	—	407,179
Biological Sciences	1943415	47.074	—	81,080
Biological Sciences	2032084	47.074	—	14,201
Biological Sciences	2032610	47.074	—	5,008
Biological Sciences	DBI 1346549	47.074	—	21,765
Biological Sciences	IOS 1354998	47.074	4,054	36
Biological Sciences	MCB 1350829	47.074	—	579
Biological Sciences	MCB 1359575	47.074	—	4,382
Pass-through University of California Riverside	S-001187	47.074	—	52,800
Pass-through University of Washington Seattle	1748843	47.074	—	107,163
Total CFDA No. 47.074			38,471	2,348,822
Social, Behavioral, and Economic Sciences	1533260	47.075	131,350	170,912
Social, Behavioral, and Economic Sciences	1560458	47.075	—	16,621
Social, Behavioral, and Economic Sciences	1632477	47.075	—	186,476
Social, Behavioral, and Economic Sciences	1748293	47.075	—	171,544
Social, Behavioral, and Economic Sciences	1756853	47.075	—	8,897
Social, Behavioral, and Economic Sciences	1822677	47.075	—	461,086
Social, Behavioral, and Economic Sciences	1824062	47.075	—	22,660
Social, Behavioral, and Economic Sciences	1830816	47.075	—	1,816
Social, Behavioral, and Economic Sciences	1851501	47.075	—	24,769
Social, Behavioral, and Economic Sciences	1853185	47.075	—	28,128
Social, Behavioral, and Economic Sciences	1904396	47.075	—	1,740
Social, Behavioral, and Economic Sciences	1918367	47.075	—	3,150
Social, Behavioral, and Economic Sciences	1920081	47.075	—	2,599
Social, Behavioral, and Economic Sciences	1926075	47.075	—	173,448
Social, Behavioral, and Economic Sciences	1945046	47.075	—	11,382
Social, Behavioral, and Economic Sciences	1946767	47.075	—	20,115
Social, Behavioral, and Economic Sciences	1946768	47.075	—	126,744
Social, Behavioral, and Economic Sciences	1947845	47.075	—	3,326
Social, Behavioral, and Economic Sciences	1952874	47.075	—	55,038
Social, Behavioral, and Economic Sciences	1952882	47.075	—	50,713
Social, Behavioral, and Economic Sciences	2017425	47.075	—	46,965
Social, Behavioral, and Economic Sciences	BCS 1354088	47.075	—	(300)
Pass-through University of California San Diego	1919372	47.075	—	2,107
Pass-through University of Michigan	1756746	47.075	—	6,891
Total CFDA No. 47.075			131,350	1,596,827
Education and Human Resources	1444932	47.076	—	364,057
Education and Human Resources	1821533	47.076	—	150,030
Education and Human Resources	1937971	47.076	—	953,775
Education and Human Resources	2010333	47.076	—	30,948
Pass-through Georgia Institute of Technology	1545287	47.076	—	19,100
Pass-through Georgia Institute of Technology	2013 FACES	47.076	—	326
Pass-through Georgia State University	1631563	47.076	—	(36,783)
Pass-through Harvard University	1631563	47.076	—	126,107
Total CFDA No. 47.076			—	1,607,560
Polar Programs	1949637	47.078	—	1,040
Total CFDA No. 47.078			—	1,040
International Science and Engineering (OISE)	1827201	47.079	—	28,054
Pass-through CRDF Global	9531011	47.079	—	15,651
Pass-through CRDF Global	OISE-20-66527-1	47.079	—	466
Total CFDA No. 47.079			—	44,171
Trans-NSF Recovery Act Research Support	DMS-0903039	47.082	—	417
Total CFDA No. 47.082			—	417

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Contract				
Pass-through Council of Graduate Schools	CC-92480	47.RD	\$ —	33,693
Total CFDA No. 47.RD			—	33,693
National Science Foundation Total			3,090,780	14,225,269
U.S. Environmental Protection Agency:				
Science to Achieve Results (STAR) Research Program	83586901	66.509	8,313	9,751
Science to Achieve Results (STAR) Research Program	83615301 Mod. 2	66.509	—	232,447
Pass-through Carleton University	4962-RFA17-2/18-4	66.509	—	15,674
Pass-through Rutgers University	PO519729 8195 Mod 3	66.509	—	426
Total CFDA No. 66.509			8,313	258,298
U.S. Environmental Protection Agency Total			8,313	258,298
U.S. Department of Energy:				
Office of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	42,090
Office of Science Financial Assistance Program	DE-FG02-01ER15153-0016	81.049	—	169,173
Office of Science Financial Assistance Program	DE-FG02-07ER15906	81.049	—	424,859
Office of Science Financial Assistance Program	DE-FG02-07ER15906/ 9	81.049	—	1,509
Office of Science Financial Assistance Program	DE-SC0008798	81.049	—	190,012
Office of Science Financial Assistance Program	DE-SC0016004 MOD 0002	81.049	—	127,733
Office of Science Financial Assistance Program	DE-SC0018976	81.049	—	142,736
Office of Science Financial Assistance Program	DE-SC0019362	81.049	—	69,377
Office of Science Financial Assistance Program	DE-SC0019374	81.049	605,387	764,448
Office of Science Financial Assistance Program	DE-SC0020101	81.049	—	100,860
Total CFDA No. 81.049			605,387	2,032,797
U.S. Department of Energy Total			605,387	2,032,797
U.S. Department of Education:				
Education Research, Development, and Dissemination	R305A160240-18	84.305	58,254	162,086
Total CFDA No. 84.305			58,254	162,086
Research in Special Education				
Pass-through Florida State University	R324A180193	84.324	246,054	330,308
Total CFDA No. 84.324			246,054	330,308
Contract	P022A190032	84.RD	—	27,600
Contract	PO22A180025	84.RD	—	39,335
Total CFDA No. 84.RD			—	66,935
U.S. Department of Education Total			304,308	559,329
U.S. Department of Health and Human Services:				
Global AIDS	NU14GH001237	93.067	1,549,021	2,476,536
Global AIDS	NU2GGH001815	93.067	176,387	211,110
Total CFDA No. 93.067			1,725,408	2,687,646
Chronic Diseases: Research, Control, and Prevention				
Pass-through American College of Rheumatology	6 NU58DP006138-02-02	93.068	—	39,293
Pass-through Lupus Foundation of America	NU58DP006139	93.068	—	27,481
Total CFDA No. 93.068			—	66,774
Birth Defects and Developmental Disabilities – Prevention and Surveillance				
Pass-through University of Iowa	NU50DD000057	93.073	—	383,333
Pass-through University of Iowa	U01DD001223	93.073	—	8,897
Total CFDA No. 93.073			—	392,230
Blood Disorder Program: Prevention, Surveillance, and Research				
Pass-through Georgia State University	NU58DD000003	93.080	—	16,362
Pass-through Hemophilia of Georgia	NU27DD001155	93.080	—	37,040
Total CFDA No. 93.080			—	53,402
Prevention of Disease, Disability, and Death by Infectious Diseases				
Pass-through Johns Hopkins University	U01CK000554	93.084	—	20,421
Pass-through State University of New York Albany	NU38PS004650	93.084	—	202,524
Pass-through University of Illinois at Chicago	U01CK000557	93.084	—	120,640
Pass-through University of Maryland, Baltimore	U01CK000556	93.084	—	36,801
Pass-through University of Utah	U01CK000555	93.084	—	122,135
Pass-through Yale University	U01CK000572	93.084	—	95,792
Total CFDA No. 93.084			—	598,313
Food and Drug Administration Research				
Food and Drug Administration Research	R01FD004814	93.103	49,737	68,457
Food and Drug Administration Research	R01FD005746	93.103	200,770	271,074
Food and Drug Administration Research	U01FD006884	93.103	—	65,415
Pass-through Duke University	R01FD003539	93.103	—	58,606
Pass-through Georgia Institute of Technology	P50FD004193	93.103	—	13,061
Pass-through University of Georgia	RR211-393/4940576	93.103	—	(300)
Pass-through University of Pittsburgh	1U01FD00687801	93.103	—	15,825
Total CFDA No. 93.103			250,507	492,138
Maternal and Child Health Federal Consolidated Programs	5T76MC28446-04	93.110	93,357	277,725
Maternal and Child Health Federal Consolidated Programs	6 T03MC07651-12-03	93.110	—	21,312
Maternal and Child Health Federal Consolidated Programs	T76MC28446	93.110	—	22,236
Pass-through Organization of Teratology Information Specialists	UG4MC27861	93.110	—	53,178
Total CFDA No. 93.110			93,357	374,451
Environmental Health	3R01ES023839-04S1	93.113	—	(3,311)
Environmental Health	5 R21 ES022795-02REV	93.113	—	(1,018)
Environmental Health	5K99ES027869-02	93.113	—	13,868
Environmental Health	5P30ES019776-03REVIS	93.113	—	(294)
Environmental Health	5R01ES025145-05	93.113	190,761	344,094
Environmental Health	5R21ES028226-02	93.113	—	645
Environmental Health	D43ES030927	93.113	46,800	69,875

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Environmental Health	F30ES029018	93.113	\$ —	49,869
Environmental Health	F31ES030980	93.113	—	44,441
Environmental Health	F32ES031827	93.113	—	29,918
Environmental Health	P30ES019776	93.113	269,323	1,929,509
Environmental Health	P50ES026071	93.113	—	186,174
Environmental Health	R00ES026648	93.113	—	238,016
Environmental Health	R01ES023485	93.113	—	126,178
Environmental Health	R01ES025775	93.113	33,873	646,558
Environmental Health	R01ES026082	93.113	340,714	665,770
Environmental Health	R01ES027859	93.113	—	553,427
Environmental Health	R01ES027892	93.113	269,626	716,433
Environmental Health	R01ES028346	93.113	181,657	349,923
Environmental Health	R01ES029165	93.113	155,651	267,413
Environmental Health	R01ES029212	93.113	366,911	687,904
Environmental Health	R21ES028903	93.113	23,381	153,658
Environmental Health	R21ES031824	93.113	—	18,954
Environmental Health	R24ES028507	93.113	276,190	324,316
Environmental Health	R24ES028528	93.113	6,959	349,582
Environmental Health	R24ES029490	93.113	—	339,245
Environmental Health	T32ES012870	93.113	—	431,242
Environmental Health	R01ES029995	93.113	—	17,716
Pass-through Colorado State University	R21ES029252	93.113	—	16,834
Pass-through Georgia State University	R01ES024332	93.113	—	8,820
Pass-through Harvard School of Public Health	R01ES030414	93.113	—	67,581
Pass-through Johns Hopkins University	R21ES029328	93.113	—	102,563
Pass-through Mount Sinai School of Medicine	U54ES030246	93.113	—	12,850
Pass-through University of Alabama Birmingham	R21ES030175	93.113	—	155,561
Pass-through University of California Los Angeles	R01ES029528	93.113	—	28,110
Pass-through University of Nevada	R01ES029944	93.113	—	73,021
Pass-through University of Southern California	R21ES029681	93.113	—	13,012
Total CFDA No. 93.113			2,161,846	9,028,357
Preventive Medicine and Public Health Residency Training Program, Integrative Medicine Program, and National Center for Integrative Primary Healthcare	5 D33HP31663--02--00	93.117	—	522,729
Total CFDA No. 93.117			—	522,729
Oral Diseases and Disorders Research	R00DE025060	93.121	12,255	211,820
Oral Diseases and Disorders Research	R00DE026810	93.121	—	2,087
Oral Diseases and Disorders Research	R01DE025837	93.121	30,071	378,343
Oral Diseases and Disorders Research	R01DE026333	93.121	12,416	1,016,122
Oral Diseases and Disorders Research	R01DE026941	93.121	250,490	638,930
Oral Diseases and Disorders Research	R01DE028342	93.121	27,193	194,562
Oral Diseases and Disorders Research	R01DE028905	93.121	—	163,824
Oral Diseases and Disorders Research	R03DE027103	93.121	—	94,565
Oral Diseases and Disorders Research	R21DE029698	93.121	—	35,618
Oral Diseases and Disorders Research	R56DE026762	93.121	—	30,640
Oral Diseases and Disorders Research	R01DE027983	93.121	—	67,507
Pass-through Massachusetts General Hospital	1 R01 DE027362-01A1	93.121	—	57,717
Pass-through University of Iowa	R01DE028146	93.121	—	43,492
Pass-through University of North Carolina Chapel Hill	R01DE016148	93.121	—	20,014
Pass-through University of Pittsburgh			—	—
Total CFDA No. 93.121			332,425	2,955,241
Nurse Anesthetist Traineeships	19A22HP31815	93.124	—	8,459
Total CFDA No. 93.124			—	8,459
Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006377	93.135	9,196	923,481
Pass-through Morehouse School of Medicine	U48DP005042	93.135	—	8,534
Total CFDA No. 93.135			9,196	932,015
Injury Prevention and Control Research and State and Community Based Programs	R01CE003104	93.136	—	280,228
Injury Prevention and Control Research and State and Community Based Programs	R49CE003072	93.136	—	475,988
Injury Prevention and Control Research and State and Community Based Programs	U01CE002939	93.136	129,210	522,564
Total CFDA No. 93.136			129,210	1,278,780
NIEHS Hazardous Waste Worker Health and Safety Training	UH4ES027093	93.142	51,455	166,519
Total CFDA No. 93.142			51,455	166,519
Health Program for Toxic Substances and Disease Registry			—	—
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	—	157,104
Total CFDA No. 93.161			—	157,104
Human Genome Research			—	—
Pass-through University of Chicago	RM1HG008935	93.172	—	240,047
Pass-through University of Iowa	R01HG008348	93.172	—	(94)
Pass-through University of Maryland, Baltimore	R21HG010412	93.172	—	10,020
Total CFDA No. 93.172			—	249,973
Research Related to Deafness and Communication Disorders	5R01DC008343-10	93.173	—	(381)
Research Related to Deafness and Communication Disorders	7R03DC015305-04	93.173	—	98,577
Research Related to Deafness and Communication Disorders	R01DC008343	93.173	—	420,995
Research Related to Deafness and Communication Disorders	R01DC014496	93.173	—	429,063
Research Related to Deafness and Communication Disorders	R21DC017272	93.173	—	135,650
Pass-through University of Memphis	R01DC015108	93.173	13,271	125,673
Total CFDA No. 93.173			13,271	1,209,577
Nursing Workforce Diversity	5D19HP269730303	93.178	—	661
Total CFDA No. 93.178			—	661
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001117	93.185	169,508	347,991
Pass-through Yale University	U011PO1110	93.185	—	58,582
Total CFDA No. 93.185			169,508	406,573



**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Telehealth Programs:				
Pass-through University of Arizona	G22RH30360	93.211	\$ —	53,634
Pass-through University of Arizona	GA5RH37465	93.211	—	26,512
Total CFDA No. 93.211			—	80,146
Research and Training in Complementary and Alternative Medicine	K01AT010488	93.213	—	40,009
Research and Training in Complementary and Alternative Medicine	K23AT009713	93.213	—	126,632
Research and Training in Complementary and Alternative Medicine	K24AT009893	93.213	—	182,557
Research and Training in Complementary and Alternative Medicine	R21AT010774	93.213	71,804	180,650
Research and Training in Complementary and Alternative Medicine	R61AT010457	93.213	16,387	323,830
Pass-through University of Illinois	R01AT009169	93.213	—	9,558
Pass-through Veterans Medical Research Foundation	U01AT010332	93.213	—	38,007
Total CFDA No. 93.213			88,191	901,243
Research on Healthcare Costs, Quality and Outcomes	1R01HS026081	93.226	161,301	477,702
Research on Healthcare Costs, Quality and Outcomes	1R03HS026578-01	93.226	—	(1,404)
Research on Healthcare Costs, Quality and Outcomes	5R01HS024530-03	93.226	—	31,790
Research on Healthcare Costs, Quality and Outcomes	5R18HS024499-03	93.226	67,959	97,099
Research on Healthcare Costs, Quality and Outcomes	K08HS025240	93.226	—	132,649
Research on Healthcare Costs, Quality and Outcomes	R01HS026232	93.226	6,100	266,126
Research on Healthcare Costs, Quality and Outcomes	R13HS026453	93.226	18,103	18,103
Research on Healthcare Costs, Quality and Outcomes	R13HS027064	93.226	—	8,757
Research on Healthcare Costs, Quality and Outcomes	R18HS026877	93.226	45,236	319,066
Pass-through Cincinnati Childrens Hospital	R01HS024390	93.226	35,126	43,605
Pass-through Clemson University	R01HS025981	93.226	—	119,027
Pass-through Northwestern University	R01HS024712	93.226	—	192,171
Pass-through University of Iowa	R0HS026724	93.226	—	29,940
Pass-through University of Kentucky	R01HS025148	93.226	—	28,667
Total CFDA No. 93.226			333,825	1,763,298
National Center on Sleep Disorders Research	K01HL138211	93.233	—	150,381
Total CFDA No. 93.233			—	150,381
Mental Health Research Grants	5R01MH056120-12	93.242	—	30
Mental Health Research Grants	5R01MH102690-04	93.242	—	3,495
Mental Health Research Grants	F30MH117878	93.242	—	49,396
Mental Health Research Grants	1F31MH114509-01A1	93.242	—	45,162
Mental Health Research Grants	1K23MH114037-01A1 REVISED	93.242	—	186,082
Mental Health Research Grants	1R21MH118092-01REVISED	93.242	55,089	189,313
Mental Health Research Grants	1R56MH116994-01	93.242	—	193,888
Mental Health Research Grants	3R01MH111682-03S1	93.242	—	(3,195)
Mental Health Research Grants	4R01MH101477-05	93.242	—	104
Mental Health Research Grants	5F30MH108276-03	93.242	—	49,393
Mental Health Research Grants	5F31MH111224-03	93.242	—	14,656
Mental Health Research Grants	5K01MH107320-04	93.242	—	55,157
Mental Health Research Grants	5R01MH073719-09 REVISED	93.242	25,464	381,134
Mental Health Research Grants	5R01MH099211-05 REVISED	93.242	—	(72)
Mental Health Research Grants	5R01MH100318-05	93.242	—	202,457
Mental Health Research Grants	5R01MH100390-05	93.242	13,668	9,977
Mental Health Research Grants	5R01MH100467-05 REVISED	93.242	—	(588)
Mental Health Research Grants	5R01MH104534-05	93.242	—	141,288
Mental Health Research Grants	5R01MH104632-05	93.242	—	288,890
Mental Health Research Grants	5R01MH105561-04	93.242	24,829	114,907
Mental Health Research Grants	5R01MH107305-05	93.242	—	372,392
Mental Health Research Grants	5R21MH108025-02	93.242	—	553
Mental Health Research Grants	5R21MH108873-02 REVISED	93.242	33,542	33,542
Mental Health Research Grants	5R21MH108928-03 REVISED	93.242	—	14,148
Mental Health Research Grants	5R21MH112449-02 REVISED	93.242	8,675	46,384
Mental Health Research Grants	5R25MH101079-05	93.242	—	127,341
Mental Health Research Grants	5R56MH111459-02	93.242	15,192	299,474
Mental Health Research Grants	5U01MH081988	93.242	—	245,224
Mental Health Research Grants	F30MH117873	93.242	—	47,718
Mental Health Research Grants	F31MH114624	93.242	—	42,173
Mental Health Research Grants	F31MH116622	93.242	—	42,626
Mental Health Research Grants	F31MH119745	93.242	—	44,535
Mental Health Research Grants	F32 MH115692	93.242	—	52,372
Mental Health Research Grants	F32MH119750	93.242	—	22,275
Mental Health Research Grants	F32MH124273	93.242	—	5,660
Mental Health Research Grants	K01MH108741	93.242	—	186,662
Mental Health Research Grants	K01MH121653	93.242	—	24,581
Mental Health Research Grants	K23MH123816	93.242	—	9,914
Mental Health Research Grants	P50MH100023	93.242	535,717	2,569,149
Mental Health Research Grants	P50MH100029	93.242	899,596	2,261,705
Mental Health Research Grants	R01MH069852	93.242	—	196,726
Mental Health Research Grants	R01MH072908	93.242	—	280,668
Mental Health Research Grants	R01MH082833	93.242	106,573	286,491
Mental Health Research Grants	R01MH107033	93.242	—	295,630
Mental Health Research Grants	R01MH108605	93.242	—	323,296
Mental Health Research Grants	R01MH108826	93.242	208,905	368,338
Mental Health Research Grants	R01MH109026	93.242	—	232,334
Mental Health Research Grants	R01MH109637	93.242	—	350,588
Mental Health Research Grants	R01MH1110701	93.242	15,610	589,777
Mental Health Research Grants	R01MH111416	93.242	26,472	443,471
Mental Health Research Grants	R01MH112076	93.242	—	371,286
Mental Health Research Grants	R01MH112788	93.242	—	561,860
Mental Health Research Grants	R01MH114692	93.242	564,662	1,151,576
Mental Health Research Grants	R01MH115174	93.242	6,894	509,057
Mental Health Research Grants	R01MH115831	93.242	—	324,177
Mental Health Research Grants	R01MH116695	93.242	—	530,409
Mental Health Research Grants	R01MH117009	93.242	20,232	539,311
Mental Health Research Grants	R01MH117103	93.242	—	343,168
Mental Health Research Grants	R01MH117122	93.242	27,539	393,363
Mental Health Research Grants	R01MH117315	93.242	—	522,388

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	R01MH118285	93.242	\$ 33,025	380,268
Mental Health Research Grants	R01MH118534	93.242	4,697	343,464
Mental Health Research Grants	R01MH118771	93.242	—	449,513
Mental Health Research Grants	R01MH118982	93.242	27,090	333,287
Mental Health Research Grants	R01MH119251	93.242	—	24,769
Mental Health Research Grants	R01MH120133	93.242	—	532,694
Mental Health Research Grants	R01MH120262	93.242	—	5,618
Mental Health Research Grants	R01MH120299	93.242	3,217	243,172
Mental Health Research Grants	R01MH121363	93.242	35,913	295,489
Mental Health Research Grants	R01MH121962	93.242	—	90,120
Mental Health Research Grants	R01MH122341	93.242	—	78,555
Mental Health Research Grants	R21MH114151	93.242	—	213,464
Mental Health Research Grants	R21MH117338	93.242	—	264,241
Mental Health Research Grants	R21MH117512	93.242	—	238,706
Mental Health Research Grants	R21MH119455	93.242	—	176,631
Mental Health Research Grants	R21MH121164	93.242	5,850	65,624
Mental Health Research Grants	R21MH121891	93.242	—	52,361
Mental Health Research Grants	R34MH116805	93.242	16,863	111,353
Mental Health Research Grants	R34MH119007	93.242	14,914	279,774
Mental Health Research Grants	R34MH124638	93.242	—	19,372
Mental Health Research Grants	R56MH1119903	93.242	—	448,856
Mental Health Research Grants	RF1MH1119622	93.242	—	57,636
Mental Health Research Grants	U01MH116441	93.242	561,755	780,586
Pass-through Boston Children's Hospital	R01MH0725	93.242	—	57,686
Pass-through Boston University	R01MH109507	93.242	—	33,578
Pass-through Boston University	R01MH110453	93.242	—	29,983
Pass-through Butler Hospital	R01MH101107	93.242	—	25,209
Pass-through Child Mind Institute	R24MH114806	93.242	—	16,211
Pass-through Columbia University	R01MH101307	93.242	—	42,803
Pass-through Columbia University	R01MH104606	93.242	—	42,530
Pass-through Creighton University	R01MH116003	93.242	—	51,504
Pass-through Duke University	R01MH108348	93.242	—	51,101
Pass-through Duke University	R01MH111671	93.242	—	64,736
Pass-through Florida State University	R01MH104423	93.242	—	59,400
Pass-through Georgia Institute of Technology	R01MH103517	93.242	—	80,374
Pass-through Georgia State University	R01MH110212	93.242	—	319,504
Pass-through Georgia State University	R25MH095735	93.242	—	(1,056)
Pass-through Johns Hopkins University	R01MH110358	93.242	—	492,353
Pass-through Massachusetts General Hospital	R34MH122362	93.242	—	6,056
Pass-through Mclean Hospital	R01MH117292	93.242	—	282,588
Pass-through Public Health Foundation Enterprises	R01MH109320	93.242	—	160,159
Pass-through Regents of the University of California	R25MH067127	93.242	—	5,669
Pass-through State University of New York	R01MH104964	93.242	—	61,789
Pass-through University of Alabama Birmingham	R01MH104114	93.242	—	7,184
Pass-through University of California Los Angeles	R01MH100027	93.242	—	107,616
Pass-through University of California Los Angeles	R01MH118514	93.242	—	188,813
Pass-through University of California Los Angeles	R01MH118973	93.242	—	33,289
Pass-through University of Cape Town	U01MH115484	93.242	—	71,638
Pass-through University of Georgia	R01MH116039	93.242	—	2,848
Pass-through University of Illinois at Chicago	R01MH116721	93.242	—	118,498
Pass-through University of Illinois at Chicago	R01MH114847	93.242	—	46,966
Pass-through University of Iowa	R01MH104363	93.242	—	226
Pass-through University of Maryland, Baltimore	R01MH121102	93.242	—	125,881
Pass-through University of North Carolina	U01MH110925	93.242	—	(1,163)
Pass-through University of North Carolina Chapel Hill	5RU01MH110925-04	93.242	—	159,983
Pass-through University of Pittsburgh	U01MH111658	93.242	—	90,770
Pass-through University of Rochester	R01MH045573	93.242	—	4,050
Pass-through University of Washington	R01MH121424	93.242	—	17,857
Pass-through Wayne State University	R01MH111682	93.242	—	80,484
Total CFDA No. 93.242			3,291,983	25,406,486
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM081774	93.243	202,413	1,124,518
Pass-through American Psychiatric Association	H79SM080818	93.243	—	131,492
Total CFDA No. 93.243			202,413	1,256,010
Advanced Nursing Education Grant Program	T14HP33112	93.247	39,427	479,997
Total CFDA No. 93.247			39,427	479,997
Public Health Training Centers Grant Program	UB6HP27875	93.249	(1,068)	32,462
Total CFDA No. 93.249			(1,068)	32,462
Occupational Safety and Health Program	5R01OH010745-03	93.262	—	32,608
Occupational Safety and Health Program	R01OH011782	93.262	—	386,949
Pass-through University of Florida	U54OH011230	93.262	28,807	52,182
Total CFDA No. 93.262			28,807	471,739
Alcohol Research Programs	1R21AA027345-01	93.273	—	181,314
Alcohol Research Programs	5R01AA023826-03 REVISED	93.273	—	120,895
Alcohol Research Programs	5R01AA025882-02 REVISED	93.273	—	(2,339)
Alcohol Research Programs	K08AA024512	93.273	—	136,521
Alcohol Research Programs	R01AA022601	93.273	—	68,013
Alcohol Research Programs	R01AA025854	93.273	—	316,725
Alcohol Research Programs	R01AA025857	93.273	—	266,035
Alcohol Research Programs	R01AA026086	93.273	—	424,170
Alcohol Research Programs	R01AA027020	93.273	—	405,179
Alcohol Research Programs	R01AA027396	93.273	—	354,844
Alcohol Research Programs	R03AA027335	93.273	—	66,747
Alcohol Research Programs	R21AA025723	93.273	43,635	190,016
Alcohol Research Programs	U01AA026108	93.273	125,599	276,271
Alcohol Research Programs	R01AA025882	93.273	—	24,401
Pass-through New York University	PO# S9000068/AMND#4	93.273	—	11,248
Pass-through University of California San Diego	R01AA026579	93.273	—	26,723
Pass-through University of California San Diego	U01AA014835	93.273	—	36,813

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through University of Colorado	R24AA019661	93.273	\$ —	10,368
Pass-through University of Georgia	R01AA026623	93.273	—	25,617
Pass-through Wayne State University	R01AA025905	93.273	—	32,884
Total CFDA No. 93.273			169,234	2,972,445
Drug Abuse and Addiction Research Programs	5T32DA015040-10 REV	93.279	—	10,567
Drug Abuse and Addiction Research Programs	34DA050340	93.279	—	221,022
Drug Abuse and Addiction Research Programs	5R01DA035101-05 REVISED	93.279	—	22,716
Drug Abuse and Addiction Research Programs	5R01DA037568-05 REVISED	93.279	54,513	200,038
Drug Abuse and Addiction Research Programs	5R01DA038196-05	93.279	—	131,544
Drug Abuse and Addiction Research Programs	5R01DA038453-05	93.279	182,240	376,708
Drug Abuse and Addiction Research Programs	5R01DA038588-04	93.279	—	101,384
Drug Abuse and Addiction Research Programs	5R21DA042727-02 REVISED	93.279	4,616	14,228
Drug Abuse and Addiction Research Programs	DP1DA042103	93.279	48,121	340,091
Drug Abuse and Addiction Research Programs	F31DA044726	93.279	—	49,926
Drug Abuse and Addiction Research Programs	F31DA051184	93.279	—	5,885
Drug Abuse and Addiction Research Programs	K01DA051696	93.279	—	11,074
Drug Abuse and Addiction Research Programs	R01DA042742	93.279	69,451	324,050
Drug Abuse and Addiction Research Programs	R01DA044297	93.279	—	490,043
Drug Abuse and Addiction Research Programs	R01DA045612	93.279	173,345	968,397
Drug Abuse and Addiction Research Programs	R01DA046197	93.279	181,763	695,016
Drug Abuse and Addiction Research Programs	R01DA046619	93.279	—	302,358
Drug Abuse and Addiction Research Programs	R21DA046738	93.279	40,937	160,728
Drug Abuse and Addiction Research Programs	T32DA050552	93.279	—	255
Drug Abuse and Addiction Research Programs	U01DA036233	93.279	26,833	31,775
Drug Abuse and Addiction Research Programs	UG3DA048502	93.279	—	3,142
Drug Abuse and Addiction Research Programs	UG3DA050234	93.279	7,193	259,532
Pass-through Boston Medical Center	R01DA037768	93.279	—	3,984
Pass-through Case Western Reserve University	R01DA042712	93.279	—	100,434
Pass-through Case Western Reserve University	R01DA043263	93.279	—	114,222
Pass-through Magee-Womens Research Institute and Foundation	R25DA043880	93.279	—	21,475
Pass-through Mclean Hospital	UG1DA015831	93.279	—	88,311
Pass-through Miriam Hospital	R01DA044504	93.279	—	63,514
Pass-through Miriam Hospital	R25DA037190	93.279	—	864
Pass-through Northwestern University	P30DA027828	93.279	—	13,532
Pass-through Northwestern University	R01DA042711	93.279	—	6,832
Pass-through Ohio State University	R21DA045236	93.279	—	19,262
Pass-through Pennsylvania State University	R01DA047396	93.279	—	38,413
Pass-through University of Kentucky	UG30A044798	93.279	—	20,771
Pass-through University of Kentucky	UG3DA044798	93.279	3,534	(13,368)
Pass-through University of Kentucky	UH3DA044798	93.279	—	206,444
Pass-through University of Kentucky	UM1DA049406	93.279	—	15,288
Pass-through University of Miami	UG1DA013720	93.279	—	61,939
Pass-through University of Michigan	R01-DA-041032	93.279	—	9,822
Pass-through Yale University	UG1DA015831	93.279	—	54,067
Total CFDA No. 93.279			792,546	5,546,285
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	5U01DP005119-05-00	93.283	—	32,816
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	U01DP006488	93.283	—	786,307
Pass-through Fdtn for Atlanta Veterans Educ and Res	40500-036-18182551	93.283	—	(864)
Pass-through Fdtn for Atlanta Veterans Educ and Res	40500-036-20192856	93.283	—	1,369,156
Pass-through Georgia Dept of Public Health	40500-036-15110270	93.283	—	640,356
Pass-through Georgia Dept of Public Health	40500-036-16161891	93.283	—	490
Pass-through Georgia State University	200-2017-93187	93.283	—	41,128
Total CFDA No. 93.283			—	2,869,389
COVID-19 - Discovery and Applied Research for Technological Innovations to Improve Human Health	U54EB027690	93.286	3,027,816	4,505,337
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB020008-04	93.286	90,702	122,766
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB022872-03	93.286	—	83
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB016662-02	93.286	—	(421)
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB022828-02	93.286	—	2,424
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB027147	93.286	—	291,038
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB027774	93.286	—	9,900
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB028350	93.286	27,797	323,606
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB029320	93.286	—	6,902
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB025646	93.286	21,813	156,322
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB026591	93.286	—	301,992
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB028519	93.286	30,386	192,554
Discovery and Applied Research for Technological Innovations to Improve Human Health	U01EB028145	93.286	452,564	829,834
Discovery and Applied Research for Technological Innovations to Improve Human Health	U54EB027690	93.286	762,273	1,131,308
Pass-through Duke University	R01EB028324	93.286	—	77,621
Pass-through Georgia Institute of Technology	R01E029331	93.286	—	10,819
Pass-through Georgia Institute of Technology	R01EB020050	93.286	—	29,740
Pass-through Georgia Institute of Technology	T32EB021962	93.286	—	45,079
Pass-through Georgia Institute of Technology	T32EB025816	93.286	—	90,850
Pass-through Univ of Massachusetts Medical School	U54HL143541	93.286	—	6,949
Pass-through University of South Florida	R01EB020601	93.286	—	172,068
Total CFDA No. 93.286			4,413,351	8,306,771
Minority Health and Health Disparities Research	5R01MD010290-05	93.307	13,739	425,798
Minority Health and Health Disparities Research	5U01MD010611	93.307	91,075	510,305
Minority Health and Health Disparities Research	F31MD0114051	93.307	—	19,049
Minority Health and Health Disparities Research	KMD015088A	93.307	—	26,102
Minority Health and Health Disparities Research	R01MD009064	93.307	—	5,659
Minority Health and Health Disparities Research	R01MD009746	93.307	13,313	648,728
Minority Health and Health Disparities Research	R01MD010241	93.307	11,314	189,338
Minority Health and Health Disparities Research	R01MD010455	93.307	—	409,017
Minority Health and Health Disparities Research	R01MD011682	93.307	35,024	374,989
Minority Health and Health Disparities Research	R01MD0113320	93.307	213,506	381,265
Minority Health and Health Disparities Research	R03MD0113509	93.307	—	42,784
Minority Health and Health Disparities Research	R21MD011590	93.307	131,005	193,951
Minority Health and Health Disparities Research	5R01MD008966-05 REVISED	93.307	—	117,659
Pass-through Morehouse School of Medicine	U54MD007602	93.307	—	204,233

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through New York University	19A0S1008337	93.307	\$ —	177,742
Pass-through Nova Southeastern University	R01MD010368	93.307	—	269,792
Pass-through University of Minnesota	R01MD013801	93.307	—	76,476
Pass-through University of Pennsylvania	R01MD013558	93.307	—	84,089
Pass-through University of Pennsylvania	U01MD011274	93.307	—	535,953
Pass-through University of Southern California	R01MD011698	93.307	—	325,916
Pass-through University of Utah	R21MD014281	93.307	—	8,105
Pass-through Yale University	U54MD010711	93.307	—	17,538
Total CFDA No. 93.307			508,976	5,044,488
Trans-NIH Research Support	U01CA235493	93.310	53,602	181,767
Trans-NIH Research Support	U01CA242109	93.310	123,462	470,708
Trans-NIH Research Support	5DP5OD019892	93.310	—	352,111
Trans-NIH Research Support	5U24DK112341	93.310	692,102	1,252,771
Trans-NIH Research Support	1U2CES026560-01 REVISED	93.310	300,426	1,452,119
Trans-NIH Research Support	U2CES030163	93.310	—	883,957
Trans-NIH Research Support	5U01GM116254-03	93.310	54,806	80,943
Trans-NIH Research Support	5DP7OD018424-05	93.310	—	(644)
Trans-NIH Research Support	5K01OD023039-03	93.310	21,092	174,913
Trans-NIH Research Support	DP5OD019792-05	93.310	—	264,058
Trans-NIH Research Support	UH3OD023318	93.310	—	1,428,949
Pass-through Children's Hospital of Philadelphia	U2CHL138346	93.310	—	65,712
Pass-through Georgia Institute of Technology	UG3TR002855	93.310	—	45,779
Pass-through Research Foundation for Mental Hygiene	UH3OD023328	93.310	—	35,426
Pass-through State University of New York Buffalo	U01CA221244	93.310	—	26,749
Pass-through University of Miami	1OT2OD26551-01	93.310	—	3,235,245
Pass-through University of Miami	OT2OD025285	93.310	—	3,203
Pass-through University of Michigan	R01HD086676	93.310	—	38,680
Pass-through University of North Carolina	UH3OD023348	93.310	—	42,484
Pass-through Women & Infants Hospital of Rhode Island	UH3OD023347	93.310	—	83,325
Total CFDA No. 93.310			1,245,490	10,118,255
Rare Disorders: Research, Surveillance, Health Promotion, and Education				
Pass-through Research Foundation for Mental Hygiene	U01DD001189	93.315	—	11,739
Total CFDA No. 93.315			—	11,739
National Center for Advancing Translational Sciences	5R21TR001751-02	93.350	—	54,649
National Center for Advancing Translational Sciences	5U54TR001456-08 REVISED	93.350	10,202	945
National Center for Advancing Translational Sciences	KL2TR002381	93.350	227,405	1,185,030
National Center for Advancing Translational Sciences	TL1TR002382	93.350	52,294	612,887
National Center for Advancing Translational Sciences	UL1TR002378	93.350	4,258,880	9,136,083
Pass-through University of Pittsburgh	UL1TR001857	93.350	—	22,922
Total CFDA No. 93.350			4,548,781	11,012,516
Research Infrastructure Programs	5R24OD020174-04	93.351	231,322	463,941
Research Infrastructure Programs	P51OD011132	93.351	60,984	11,472,895
Research Infrastructure Programs	R24OD020349	93.351	97,217	557,238
Research Infrastructure Programs	R25GM129213	93.351	—	216,777
Research Infrastructure Programs	S10OD028673	93.351	—	317,090
Research Infrastructure Programs	SOD026799A	93.351	—	985,030
Research Infrastructure Programs	U42OD011023	93.351	—	1,871,669
Pass-through Jackson Laboratory	U54 OD020351	93.351	—	9,299
Pass-through University of Georgia	R01OD028223	93.351	—	69,196
Total CFDA No. 93.351			389,523	15,963,135
21st Century Cures Act -- Beau Biden Cancer Moonshot				
Pass-through Dana Farber Cancer Institute	U01CA243688	93.353	—	55,958
Pass-through Dana Farber Cancer Institute	U24CA233243	93.353	—	120,790
Total CFDA No. 93.353			—	176,748
COVID-19 - Nurse Education, Practice and Retention Grants	T1PHP39097	93.359	—	7,843
Nurse Education, Practice and Retention Grants	6 UD7HP250460301	93.359	—	(250)
Nurse Education, Practice and Retention Grants	UK1HP31697	93.359	26,331	735,085
Total CFDA No. 93.359			26,331	742,678
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	IDSEP190055	93.360	48,903	96,936
Total CFDA No. 93.360			48,903	96,936
Nursing Research	5K01NR014673-03	93.361	—	27
Nursing Research	5R00NR014587-05	93.361	899	(298)
Nursing Research	5R00NR014675-06 REVISED	93.361	—	6,170
Nursing Research	5R01NR014973-04 Revised	93.361	—	75,801
Nursing Research	F31NR018369	93.361	—	42,337
Nursing Research	K01NR016971	93.361	—	82,835
Nursing Research	K01NR016984	93.361	—	51,998
Nursing Research	K01NR017664	93.361	—	68,713
Nursing Research	K23NR018485	93.361	—	97,872
Nursing Research	K99NR017897	93.361	—	63,994
Nursing Research	P30NR018090	93.361	—	860,262
Nursing Research	R01NR014800	93.361	—	63,781
Nursing Research	R01NR015783	93.361	12,266	463,509
Nursing Research	R01NR017018	93.361	212,053	916,088
Nursing Research	R01NR017939	93.361	21,647	314,091
Nursing Research	R01NR018666	93.361	1,379	351,382
Nursing Research	R21NR018015	93.361	7,825	172,561
Nursing Research	T32NR012715	93.361	—	351,477
Pass-through Columbia University	R01NR013520	93.361	—	13,115
Pass-through New York University	R01NR013520	93.361	—	113,464
Pass-through Northwestern University	R01NR015444	93.361	—	26,404
Total CFDA No. 93.361			256,069	4,135,583
Cancer Cause and Prevention Research	5R01CA077337-14	93.393	—	(158)
Cancer Cause and Prevention Research	5R01CA179424-04	93.393	—	106

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cancer Cause and Prevention Research	F99CA234959	93.393	\$ —	38,447
Cancer Cause and Prevention Research	F99CA245789	93.393	—	44,594
Cancer Cause and Prevention Research	F99CA253576	93.393	—	2,860
Cancer Cause and Prevention Research	R00CA204601	93.393	—	222,217
Cancer Cause and Prevention Research	R01CA095318	93.393	—	217,511
Cancer Cause and Prevention Research	R01CA178999	93.393	—	410,392
Cancer Cause and Prevention Research	R01CA203719	93.393	—	309,483
Cancer Cause and Prevention Research	R01CA207260	93.393	—	36,783
Cancer Cause and Prevention Research	R01CA207467	93.393	191,906	488,799
Cancer Cause and Prevention Research	R01CA208758	93.393	—	130,768
Cancer Cause and Prevention Research	R01CA211574	93.393	—	59,435
Cancer Cause and Prevention Research	R01CA215155	93.393	—	(14,718)
Cancer Cause and Prevention Research	R01CA218155	93.393	42,155	437,130
Cancer Cause and Prevention Research	R01CA218389	93.393	109,519	554,818
Cancer Cause and Prevention Research	R01CA230268	93.393	—	269,819
Cancer Cause and Prevention Research	R01CA234538	93.393	13,528	457,027
Cancer Cause and Prevention Research	R01CA235721	93.393	14,031	278,123
Cancer Cause and Prevention Research	R01CA237318	93.393	—	35,612
Cancer Cause and Prevention Research	R01CA245063	93.393	—	18,152
Cancer Cause and Prevention Research	R01CA254403	93.393	—	21,746
Cancer Cause and Prevention Research	R21CA238356	93.393	2,287	69,597
Cancer Cause and Prevention Research	R37CA234419	93.393	110,297	306,835
Cancer Cause and Prevention Research	U01CA217875	93.393	32,125	926,877
Cancer Cause and Prevention Research	U01CA220401	93.393	31,444	36,902
Cancer Cause and Prevention Research	U01CA240581	93.393	—	66,376
Cancer Cause and Prevention Research	2U10EY013272-11A1	93.393	(3,341)	(4,213)
Cancer Cause and Prevention Research	3R01CA178999-03S1	93.393	—	(6,484)
Cancer Cause and Prevention Research	5U01CA154282-05	93.393	—	52
Cancer Cause and Prevention Research	7R01NS060830-05	93.393	—	50
Cancer Cause and Prevention Research	R01CA236871	93.393	—	475,297
Cancer Cause and Prevention Research	R21CA208161	93.393	22,853	64,276
Pass-through Duke University	R37CA233777	93.393	—	2,341
Pass-through George Washington University	R01CA215155	93.393	—	160,951
Pass-through Georgia State University	R01CA239120	93.393	—	1,667
Pass-through Mayo Clinic	U01CA195568	93.393	—	311,596
Pass-through Nrg Oncology Foundation, Inc.	0003-NRG-15	93.393	—	(2,563)
Pass-through Ohio State University	R01CA169363	93.393	—	13,077
Pass-through Stanford University	61795884-129906	93.393	—	62,058
Pass-through State University of New York Stony Brook	1UG3CA22502101	93.393	—	14,165
Pass-through University of Michigan	R01CA201198	93.393	—	29,742
Pass-through University of Southern California	U19CA214253	93.393	—	325,336
Pass-through University of Washington Saint Louis	R01CA235773	93.393	—	63,353
Pass-through Vanderbilt University Medical Center	R01CA230352	93.393	—	79,848
Pass-through Wayne State University	R01CA240607	93.393	—	36,022
Total CFDA No. 93.393			566,804	7,052,104
Cancer Detection and Diagnosis Research	5U01CA207821-03	93.394	—	3,870
Cancer Detection and Diagnosis Research	5U24CA194362-04 REVISED	93.394	302,614	537,794
Cancer Detection and Diagnosis Research	R01CA202846	93.394	53,264	751,742
Cancer Detection and Diagnosis Research	R01CA203388	93.394	70,161	329,365
Cancer Detection and Diagnosis Research	U01CA113913	93.394	99,014	716,642
Cancer Detection and Diagnosis Research	U01CA198913	93.394	16,598	485,925
Pass-through Dartmouth College	PO1CA190193	93.394	—	112,616
Pass-through Georgia Institute of Technology	R21223853	93.394	—	12,023
Pass-through Georgia State University	U01CA242936	93.394	—	16,998
Pass-through Massachusetts General Hospital	R01CA237133	93.394	—	16,412
Pass-through Radboud University	R01CA181171	93.394	—	33,614
Pass-through State University of New York Stony Brook	U24CA180924	93.394	—	(15,143)
Pass-through Univ of Arkansas for Medical Services	U24CA215109	93.394	—	536,490
Pass-through University of Michigan	U24CA086368	93.394	—	2,146
Pass-through University of Texas Dallas	R01CA204254	93.394	—	20,628
Total CFDA No. 93.394			541,651	3,561,122
Cancer Treatment Research	1R01CA223220-01A1	93.395	—	328,461
Cancer Treatment Research	5 R01 CA176001-05REVISED	93.395	—	1,955
Cancer Treatment Research	5R01CA186129-05	93.395	—	53,336
Cancer Treatment Research	5R01CA207768	93.395	—	430,963
Cancer Treatment Research	5R01CA214557-03	93.395	69,929	(9,862)
Cancer Treatment Research	5R21CA155511-02	93.395	—	119
Cancer Treatment Research	5U10CA180950-05 REVISED	93.395	(2,879)	(2,879)
Cancer Treatment Research	R01CA136534	93.395	—	283,612
Cancer Treatment Research	R01CA186918	93.395	—	236,423
Cancer Treatment Research	R01CA193828	93.395	—	346,204
Cancer Treatment Research	R01CA194027	93.395	—	480,209
Cancer Treatment Research	R01CA200905	93.395	—	324,928
Cancer Treatment Research	R01CA202763	93.395	204,621	615,689
Cancer Treatment Research	R01CA203928	93.395	—	358,133
Cancer Treatment Research	R01CA208253	93.395	189,540	361,308
Cancer Treatment Research	R01CA208328	93.395	239,009	474,836
Cancer Treatment Research	R01CA215718	93.395	—	340,725
Cancer Treatment Research	R01CA226992	93.395	—	581,568
Cancer Treatment Research	R01CA228406	93.395	—	294,157
Cancer Treatment Research	R01CA228414	93.395	134,807	456,943
Cancer Treatment Research	R01CA238471	93.395	—	477,125
Cancer Treatment Research	R01CA245386	93.395	—	15,723
Cancer Treatment Research	R21CA223300	93.395	—	127,061
Cancer Treatment Research	UG1CA233259	93.395	683,864	885,127
Cancer Treatment Research	R00CA222493	93.395	—	179,585
Cancer Treatment Research	UG1CA233247	93.395	—	724,736
Pass-through Childrens Healthcare of Atlanta	U01CA180886	93.395	—	15,058
Pass-through Childrens Healthcare of Atlanta	U10CA180886	93.395	—	97,166
Pass-through City of Hope	R01CA194742	93.395	—	36,533
Pass-through Duke University	R01CA175759	93.395	—	40
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820	93.395	—	104,736
Pass-through Fred Hutchinson Cancer Research Center	CITN 49	93.395	—	(1,284)

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Georgia Institute of Technology	R01CA207619	93.395	\$ —	80,774
Pass-through Georgia State University	R01CA180519	93.395	—	39,676
Pass-through Indiana University	R01CA235632	93.395	—	1,040
Pass-through Johns Hopkins University	UM1CA186691	93.395	—	20,513
Pass-through Massachusetts General Hospital	233380	93.395	—	20,151
Pass-through Medical College of Wisconsin	R01CA184796	93.395	—	3,705
Pass-through Medical College of Wisconsin	R01CA184798	93.395	—	6,302
Pass-through Nrg Oncology Foundation, Inc.	U10CA180868	93.395	—	154,054
Pass-through Ohio State University	R01CA201382	93.395	—	80,478
Pass-through St. Jude Childrens Research Hospital	UM1CA081457	93.395	15,818	75,747
Pass-through Stanford University	U01CA199241	93.395	—	122,927
Pass-through University of California Los Angeles	UM1CA121947	93.395	—	366,844
Pass-through University of Florida	R01CA200867	93.395	—	73,957
Pass-through University of Minnesota	5P01CA111412-13	93.395	—	16,315
Pass-through University of North Carolina Chapel Hill	R01CA249190	93.395	—	13,057
Pass-through University of Rochester	R01 CA214890	93.395	—	11,223
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA193609	93.395	—	41,174
Pass-through University of Utah	R01CA206522	93.395	—	287,096
Total CFDA No. 93.395			1,534,709	10,033,467
Cancer Biology Research	3R01CA163722-05S1REVISED	93.396	—	3,806
Cancer Biology Research	3R01CA201340-04S1	93.396	17,517	289,161
Cancer Biology Research	5R01CA140515-09	93.396	20,933	223,844
Cancer Biology Research	5R01CA171189-03	93.396	—	21
Cancer Biology Research	5R01CA183594-05 REVISED	93.396	1,465	19,427
Cancer Biology Research	7R35CA197603-03	93.396	—	1,318,588
Cancer Biology Research	P30CA138292	93.396	—	3,092,197
Cancer Biology Research	R00CA197804	93.396	—	288,330
Cancer Biology Research	R01CA174786	93.396	91,133	253,711
Cancer Biology Research	R01CA175316	93.396	—	448,594
Cancer Biology Research	R01CA192844	93.396	62,321	369,312
Cancer Biology Research	R01CA236369	93.396	—	358,219
Cancer Biology Research	R01CA250422	93.396	—	28,530
Cancer Biology Research	RCA232244A	93.396	17,812	126,558
Cancer Biology Research	R01CA174786	93.396	—	114,003
Pass-through Georgia Institute of Technology	U01CA214354	93.396	—	65,866
Pass-through Georgia State University	R33CA235319	93.396	—	23,245
Pass-through Roswell Park Cancer Institute	R01CA121044	93.396	—	28,256
Pass-through University of Alabama Birmingham	U01CA223976	93.396	—	41,994
Total CFDA No. 93.396			211,181	7,093,662
Cancer Centers Support Grants	5P20CA210298-02 REVISED	93.397	44,711	21,286
Cancer Centers Support Grants	P50CA217691	93.397	100,642	2,060,059
Pass-through Yale University	U54CA209992	93.397	—	64,981
Total CFDA No. 93.397			145,353	2,146,326
Cancer Research Manpower	4T32CA160040-04	93.398	—	73,132
Cancer Research Manpower	5F31CA221002-02	93.398	—	19,617
Cancer Research Manpower	5F31CA225049-02	93.398	—	34,533
Cancer Research Manpower	F30CA206291	93.398	—	48,115
Cancer Research Manpower	F30CA216939	93.398	—	42,704
Cancer Research Manpower	F30CA236231	93.398	—	41,050
Cancer Research Manpower	F30CA243250	93.398	—	34,090
Cancer Research Manpower	F31CA225119	93.398	—	41,125
Cancer Research Manpower	F31CA225124	93.398	—	47,548
Cancer Research Manpower	F31CA232531	93.398	—	14,398
Cancer Research Manpower	F31CA236493	93.398	—	43,297
Cancer Research Manpower	F31CA239563	93.398	—	15,884
Cancer Research Manpower	F31CA239566	93.398	—	40,297
Cancer Research Manpower	F31CA243220	93.398	—	45,711
Cancer Research Manpower	F31CA243472	93.398	—	17,994
Cancer Research Manpower	F31CA243502	93.398	—	32,489
Cancer Research Manpower	F31CA246889	93.398	—	6,586
Cancer Research Manpower	F31CA247415	93.398	—	19,750
Cancer Research Manpower	F31CA247564	93.398	—	29,273
Cancer Research Manpower	K07CA211956	93.398	—	164,741
Cancer Research Manpower	K08CA194162	93.398	—	190,841
Cancer Research Manpower	K08CA248962	93.398	—	41,945
Cancer Research Manpower	K12CA237806	93.398	—	77,766
Cancer Research Manpower	K24CA201524	93.398	—	171,675
Total CFDA No. 93.398			—	1,294,561
Cancer Control	UG1CA189867	93.399	—	165,321
Pass-through Nrg Oncology Foundation, Inc.			—	165,321
Total CFDA No. 93.399			—	165,321
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health				
Pass-through Natl Assoc of County & City Health Office	NU38OT000306	93.421	—	38,500
Total CFDA No. 93.421			—	38,500
Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke				
Pass-through Mississippi State Department of Health	NU58DP006546	93.426	—	7,420
Pass-through South Dakota Department of Health	NU58DP006526	93.426	—	222,408
Total CFDA No. 93.426			—	229,828
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke				
Pass-through Wisconsin Department of Health and Family	NU58DP006607	93.435	—	14,203
Total CFDA No. 93.435			—	14,203
Affordable Care Act (ACA) Public Health Training Centers Program	UB6HP31680	93.516	268,322	1,102,215
Total CFDA No. 93.516			268,322	1,102,215

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2020

Health Care Innovation Awards	19032G	93.610	\$	—	40,456
Pass-through Georgia Department of Community Health				—	40,456
Total CFDA No. 93.610				—	40,456
Children's Justice Grants to States				—	3,058
Pass-through Georgia Department of Human Services	42700-040-0000072848	93.643		—	3,058
Total CFDA No. 93.643				—	3,058
Child Welfare Services_State Grants				—	97,000
Pass-through Georgia Department of Human Services	42700-040-0000088042	93.645		—	97,000
Total CFDA No. 93.645				—	97,000
Trans-NIH Recovery Act Research Support	3K08NS04632205S1	93.701		—	(30)
Pass-through University of Washington	718841Z	93.701		—	195
Pass-through Wistar Institute	PO1AI082282	93.701		—	(745)
Total CFDA No. 93.701				—	(580)
Medical Assistance Program				—	170,866
Pass-through Georgia Department of Behavioral Health	4410-907000133937	93.778		—	170,866
Total CFDA No. 93.778				—	170,866
Health Careers Opportunity Program	1D18HP32120-01-00	93.822		27,186	535,735
Health Careers Opportunity Program	6 D18HP290340301	93.822		—	(162)
Total CFDA No. 93.822				27,186	535,573
Ebola Support: Transmission and Prevention Control, Public Health Preparedness, Vaccine Development	1U54CK000453-01-06	93.823		54,173	89,548
Total CFDA No. 93.823				54,173	89,548
COVID-19 - National Ebola Training and Education Center	U3REP150549	93.825		—	86,528
National Ebola Training and Education Center	U3REP150549	93.825		1,002,407	1,766,104
National Ebola Training and Education Center	U3REP170552	93.825		2,661,673	3,791,825
Total CFDA No. 93.825				3,664,080	5,644,457
Section 223 Demonstration Programs to Improve Community Mental Health Services	1R56HL131059-01 REVISED	93.829		30,453	42,430
Total CFDA No. 93.829				30,453	42,430
Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing				—	199,064
Pass-through University of Florida	R01NS112291	93.835		—	199,064
Total CFDA No. 93.835				—	199,064
Cardiovascular Diseases Research	1R01HL136915-01A1	93.837		—	488,702
Cardiovascular Diseases Research	1R56HL142762-01	93.837		—	1,102
Cardiovascular Diseases Research	4U54HL112309-05 REVISED	93.837		—	442
Cardiovascular Diseases Research	5F31HL137367-02	93.837		—	17,603
Cardiovascular Diseases Research	5K08HL124292-05	93.837		—	99,797
Cardiovascular Diseases Research	5K22HL126922-03	93.837		—	166,717
Cardiovascular Diseases Research	5P01HL095070-09	93.837		—	1,182,843
Cardiovascular Diseases Research	5R01HL109413-03	93.837		—	(310)
Cardiovascular Diseases Research	5R01HL127726-04	93.837		—	119,283
Cardiovascular Diseases Research	5R01HL127759-04	93.837		—	47,339
Cardiovascular Diseases Research	5R01HL129511-03	93.837		6,548	415,984
Cardiovascular Diseases Research	5R01HL130471-04	93.837		68,747	731,790
Cardiovascular Diseases Research	5R21HL118454-02	93.837		—	169
Cardiovascular Diseases Research	5R25HL131507-03	93.837		—	(396)
Cardiovascular Diseases Research	5U54HL112309-04	93.837		—	(1,136)
Cardiovascular Diseases Research	7R01HL117759-06	93.837		—	21,315
Cardiovascular Diseases Research	F31HL136184	93.837		—	950
Cardiovascular Diseases Research	F31HL136194	93.837		—	15,799
Cardiovascular Diseases Research	F31HL143900	93.837		—	32,796
Cardiovascular Diseases Research	F31HL145974	93.837		—	42,323
Cardiovascular Diseases Research	F31HL149272	93.837		—	13,774
Cardiovascular Diseases Research	F31HL149285	93.837		—	4,220
Cardiovascular Diseases Research	F32HL147547	93.837		—	51,731
Cardiovascular Diseases Research	F32HL151163	93.837		—	4,423
Cardiovascular Diseases Research	K01HL149479	93.837		—	85,639
Cardiovascular Diseases Research	K01HL149982	93.837		—	18,247
Cardiovascular Diseases Research	K08HL136873	93.837		—	164,458
Cardiovascular Diseases Research	K23HL122361	93.837		—	143,275
Cardiovascular Diseases Research	K23HL124287	93.837		—	150,431
Cardiovascular Diseases Research	K23HL127251	93.837		2,685	86,472
Cardiovascular Diseases Research	K23HL128795	93.837		—	166,638
Cardiovascular Diseases Research	K23HL143164	93.837		—	145,036
Cardiovascular Diseases Research	K23HL152903	93.837		—	20,898
Cardiovascular Diseases Research	K24HL148521	93.837		—	82,569
Cardiovascular Diseases Research	OT2HL152668	93.837		—	16,825
Cardiovascular Diseases Research	OT2HL152762	93.837		—	156,125
Cardiovascular Diseases Research	R00HL127295	93.837		—	195,710
Cardiovascular Diseases Research	R01HL109413	93.837		—	560,159
Cardiovascular Diseases Research	R01HL119291	93.837		—	228,696
Cardiovascular Diseases Research	R01HL119798	93.837		111,088	451,810
Cardiovascular Diseases Research	R01HL122392	93.837		172,500	527,295
Cardiovascular Diseases Research	R01HL125246-04	93.837		44,909	45,531
Cardiovascular Diseases Research	R01HL125442	93.837		340,513	600,079
Cardiovascular Diseases Research	R01HL125761	93.837		117,684	450,856
Cardiovascular Diseases Research	R01HL127236	93.837		86,845	205,186
Cardiovascular Diseases Research	R01HL130915	93.837		97,500	383,257
Cardiovascular Diseases Research	R01HL133667	93.837		—	410,483
Cardiovascular Diseases Research	R01HL135145	93.837		8,249	454,260
Cardiovascular Diseases Research	R01HL135183	93.837		—	454,270
Cardiovascular Diseases Research	R01HL136205	93.837		43,215	501,159
Cardiovascular Diseases Research	R01HL136345	93.837		—	430,821
Cardiovascular Diseases Research	R01HL137338	93.837		141,067	363,161
Cardiovascular Diseases Research	R01HL139757	93.837		—	403,355



**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	R01HL140223	93.837	\$ —	475,194
Cardiovascular Diseases Research	R01HL142762	93.837	—	353,378
Cardiovascular Diseases Research	R01HL143065	93.837	—	627,702
Cardiovascular Diseases Research	R01HL143348	93.837	72,688	638,331
Cardiovascular Diseases Research	R01HL143350	93.837	127,071	693,432
Cardiovascular Diseases Research	R01HL144741	93.837	200,151	688,203
Cardiovascular Diseases Research	R01HL145644	93.837	256,256	709,453
Cardiovascular Diseases Research	R01HL146147	93.837	375,755	765,879
Cardiovascular Diseases Research	R01HL150005	93.837	—	25,090
Cardiovascular Diseases Research	R01HL150562	93.837	—	194,174
Cardiovascular Diseases Research	R01HL150887	93.837	—	462,901
Cardiovascular Diseases Research	R03HL146874	93.837	19,600	59,023
Cardiovascular Diseases Research	R03HL146879	93.837	58,763	98,030
Cardiovascular Diseases Research	R21HL145486	93.837	—	109,483
Cardiovascular Diseases Research	R34HL122557	93.837	938	31,018
Cardiovascular Diseases Research	R61HL154116	93.837	—	34,627
Cardiovascular Diseases Research	T32HL007745	93.837	—	497,023
Cardiovascular Diseases Research	T32HL130025	93.837	—	620,148
Cardiovascular Diseases Research	U01HL128566	93.837	282,625	764,508
Cardiovascular Diseases Research	U54HL141981	93.837	83,885	1,418,235
Cardiovascular Diseases Research	UG1HL135682	93.837	287,438	396,416
Cardiovascular Diseases Research	U01HL146241	93.837	118,727	2,028,885
Pass-through Beth Israel Deaconess Medical Center	R01HL086741	93.837	—	16,036
Pass-through Boston University	R01HL139867	93.837	—	146,008
Pass-through Boston University	U01HL146382	93.837	—	69,156
Pass-through Children's Hospital of Philadelphia	P01HL139420	93.837	—	24,187
Pass-through Duke University	A031304	93.837	—	15,679
Pass-through Duke University	R01HL130443	93.837	—	25
Pass-through Georgia Institute of Technology	DP2HL142050	93.837	—	48,484
Pass-through Georgia Institute of Technology	R01HL124417	93.837	—	93,357
Pass-through Georgia Institute of Technology	R01HL140325	93.837	—	374,897
Pass-through Georgia Institute of Technology	R01HL144714	93.837	—	155,586
Pass-through Georgia State University	R01HL14205	93.837	—	53,266
Pass-through Henry M Jackson Foundation	R01HL130448	93.837	—	1,725
Pass-through Michigan Technological University	R15HL140596	93.837	—	11,359
Pass-through New England Research Institutes	U24HL135691	93.837	—	12,962
Pass-through New York University	R25HL105444	93.837	—	2,808
Pass-through Ohio State University	R01HL128857	93.837	—	5,139
Pass-through Oregon Health and Science University	1002919-EU AM2	93.837	—	38
Pass-through St Jude Childrens Research Hospital	R34HL 127162	93.837	806	3,482
Pass-through University of California Los Angeles	R01HL118650	93.837	—	91,033
Pass-through University of California San Francisco	R25HL126146	93.837	—	7,617
Pass-through University of Florida	UFDSP00010263	93.837	—	50
Pass-through University of Minnesota	R01HL126837	93.837	—	10,912
Pass-through University of Minnesota	R01HL131579	93.837	—	16,048
Pass-through University of Minnesota	R01HL136679	93.837	—	3,999
Pass-through University of Minnesota	R01HL141288	93.837	—	7,441
Pass-through University of Pittsburgh	R01HL128818	93.837	—	743
Pass-through University of Utah	R01HL150608	93.837	—	24,831
Pass-through University of Utah	U24HL135691	93.837	4,000	4,000
Pass-through University of Virginia	R01HL130918	93.837	45,584	166,306
Pass-through University of Virginia	R01HL137112	93.837	—	130,466
Pass-through Vanderbilt University	R01HL132338	93.837	—	46,070
Pass-through Wake Forest University	01HL130856	93.837	—	70,164
Pass-through Wake Forest University	01HL135853	93.837	—	138,111
Total CFDA No. 93.837			3,175,837	24,803,079
Lung Diseases Research	5F31HL136101-02REVISED	93.838	—	4,251
Lung Diseases Research	5R01HL122559-05	93.838	—	365,281
Lung Diseases Research	5R01HL125042-04	93.838	—	36
Lung Diseases Research	F31HL139109	93.838	—	43,078
Lung Diseases Research	F31HL139134	93.838	—	41,231
Lung Diseases Research	F31HL143863	93.838	—	44,251
Lung Diseases Research	F31HL149323	93.838	—	45,756
Lung Diseases Research	F32HL151133	93.838	—	13,536
Lung Diseases Research	K23HL151897	93.838	—	79,372
Lung Diseases Research	K99HL151965	93.838	—	37,552
Lung Diseases Research	R01HL113548	93.838	27,000	311,902
Lung Diseases Research	R01HL126603-04	93.838	—	(6,539)
Lung Diseases Research	R01HL133053	93.838	—	378,630
Lung Diseases Research	R01HL136414	93.838	384,891	662,488
Lung Diseases Research	R01HL138508	93.838	—	326,612
Lung Diseases Research	R01HL139876	93.838	221,569	768,122
Lung Diseases Research	R01HL142866	93.838	—	330,317
Lung Diseases Research	R01HL144478	93.838	—	339,870
Lung Diseases Research	R35HL145000	93.838	—	497,341
Lung Diseases Research	R35HL150803	93.838	—	265,190
Lung Diseases Research	T32HL116271	93.838	—	507,611
Lung Diseases Research	UM1HL134590	93.838	4,921,792	6,956,000
Pass-through Medical College of Georgia	R01HL138410	93.838	—	154,657
Pass-through University of Arizona	U01HL130045	93.838	—	43,318
Pass-through University of Georgia	R01HL136707	93.838	—	368,299
Total CFDA No. 93.838			5,555,252	12,578,162
Blood Diseases and Resources Research	5K23HL128942-03	93.839	—	136,789
Blood Diseases and Resources Research	5R01HL095479-08	93.839	50,511	41,889
Blood Diseases and Resources Research	5R01HL117061-06	93.839	—	21,150
Blood Diseases and Resources Research	5R01HL123984-04	93.839	—	58,571
Blood Diseases and Resources Research	5R01HL131414-03	93.839	—	549,341
Blood Diseases and Resources Research	5R21HL133584-02	93.839	—	3,323
Blood Diseases and Resources Research	5R21HL138062-02	93.839	—	(79)
Blood Diseases and Resources Research	5T32HL09769-15 REVISED	93.839	—	35,991
Blood Diseases and Resources Research	F31HL138934	93.839	—	47,183
Blood Diseases and Resources Research	F31HL149357	93.839	—	43,331
Blood Diseases and Resources Research	K01HL131333	93.839	—	110,597

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Blood Diseases and Resources Research	K08HL141635	93.839	\$ —	152,759
Blood Diseases and Resources Research	K23HL133457	93.839	32,603	150,984
Blood Diseases and Resources Research	K23HL136900	93.839	—	117,565
Blood Diseases and Resources Research	K23HL140142	93.839	—	130,937
Blood Diseases and Resources Research	K23HL146904	93.839	—	50,916
Blood Diseases and Resources Research	K25HL141636	93.839	—	193,390
Blood Diseases and Resources Research	K99HL150595	93.839	—	82,509
Blood Diseases and Resources Research	K99HL150626	93.839	—	91,428
Blood Diseases and Resources Research	P01HL086773	93.839	435,485	1,482,645
Blood Diseases and Resources Research	R01HL082808	93.839	5,088	275,593
Blood Diseases and Resources Research	R01HL129141	93.839	—	552,070
Blood Diseases and Resources Research	R01HL130995	93.839	—	475,520
Blood Diseases and Resources Research	R01HL135575	93.839	—	410,916
Blood Diseases and Resources Research	R01HL137128	93.839	165,332	530,104
Blood Diseases and Resources Research	R01HL138423	93.839	—	624,776
Blood Diseases and Resources Research	R01HL138656	93.839	33,767	471,695
Blood Diseases and Resources Research	R01HL140589	93.839	338,325	655,080
Blood Diseases and Resources Research	R01HL141335	93.839	—	518,069
Blood Diseases and Resources Research	R01HL143794	93.839	296,594	737,175
Blood Diseases and Resources Research	R01HL146668	93.839	—	52,683
Blood Diseases and Resources Research	R01HL152074	93.839	—	153,920
Blood Diseases and Resources Research	R01HL152131	93.839	—	65,295
Blood Diseases and Resources Research	R01HL154034	93.839	—	7,011
Blood Diseases and Resources Research	R21HL146299	93.839	34,640	161,056
Blood Diseases and Resources Research	R56HL147867	93.839	—	183,038
Blood Diseases and Resources Research	T32HL069769	93.839	—	33,290
Blood Diseases and Resources Research	T32HL139443	93.839	—	101,911
Blood Diseases and Resources Research	U01HL117721	93.839	66,700	68,919
Blood Diseases and Resources Research	U01HL139483	93.839	—	562,550
Pass-through Augusta University Research Institute Inc	R25HL106365	93.839	—	2,367
Pass-through Boston Children's Hospital	P01HL046925	93.839	—	366,344
Pass-through Medical College of Wisconsin	U01HL143477	93.839	—	2,696
Pass-through University of Alabama Birmingham	R01HL133896	93.839	6,491	15,181
Pass-through University of Florida	UG1HL069301	93.839	—	70,089
Pass-through University of Pittsburgh	UG3HL143192	93.839	—	38,561
Pass-through University of Virginia	P01HL132819	93.839	—	379,748
Pass-through University of Washington	R01HL141781	93.839	—	197
Total CFDA No. 93.839			1,465,536	11,017,083
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	1R61HL138657-01 REVISED	93.840	—	(1,615)
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	R33HL138657	93.840	—	992,016
Pass-through All India Institute of Medical Sciences	U01HL138635	93.840	—	63,341
Pass-through Seattle Biomedical Research Institute	U01HL142103	93.840	—	11,054
Pass-through University of Washington	R01HL137808	93.840	—	53,263
Total CFDA No. 93.840			—	1,118,059
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR048266-15	93.846	—	57,719
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR064307-05	93.846	—	19,246
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR067786-04	93.846	—	26,279
Arthritis, Musculoskeletal and Skin Diseases Research	F30AR069472	93.846	—	37,237
Arthritis, Musculoskeletal and Skin Diseases Research	F32AR074249	93.846	—	64,139
Arthritis, Musculoskeletal and Skin Diseases Research	K23AR075888	93.846	—	1,717
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR047901	93.846	—	(632)
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR048266	93.846	3,606	224,841
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR048615	93.846	—	225,171
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR050501	93.846	—	460,879
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR061987	93.846	—	402,772
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR068157	93.846	—	804,693
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070091	93.846	—	668,913
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070736	93.846	—	383,578
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070898	93.846	68,582	621,837
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR071397	93.846	—	334,645
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR073874	93.846	—	418,239
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR071529	93.846	—	132,059
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR071536	93.846	22,738	137,463
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR072222	93.846	—	167,309
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR073593	93.846	—	200,677
Pass-through Georgia Institute of Technology	R01AR071026	93.846	—	14,724
Pass-through Louisiana State University	R01AR073277	93.846	—	2,993
Pass-through University of Alabama Birmingham	1R01AR072697-01	93.846	—	18,569
Pass-through University of Michigan	U01AR073485	93.846	—	12,839
Pass-through University of Oregon	R01AR069297	93.846	—	58,144
Total CFDA No. 93.846			94,926	5,496,050
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R01DK055679-16 REVI	93.847	—	41
Diabetes, Digestive, and Kidney Diseases Extramural Research	3DP3DK108245-01S1	93.847	38,044	(17)
Diabetes, Digestive, and Kidney Diseases Extramural Research	4K24DK096574-10	93.847	—	374
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK102851-05	93.847	—	22,797
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK041707-22	93.847	—	82,222
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059390-15 REVISED	93.847	—	2,770
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059888-14REVISED	93.847	—	39
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK074731-07	93.847	—	76,688
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK089763-04	93.847	—	39
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK092722-07	93.847	—	266,735
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098231-05 REVISED	93.847	—	(49)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK104125-03	93.847	—	12,139
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK107300-04	93.847	13,140	368,140
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK112946-02	93.847	—	398,810
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK112108-02	93.847	—	40,158
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK038842-29	93.847	—	(1,736)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK062470-15	93.847	191,748	215,580
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK117570	93.847	—	40,383
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK122745	93.847	—	13,882
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK120195	93.847	—	22,275
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK109025	93.847	—	96,039

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK114391	93.847	\$ —	29,483
Diabetes, Digestive, and Kidney Diseases Extramural Research	K08DK111998	93.847	—	163,780
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK113241	93.847	—	192,536
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK118189	93.847	5,928	174,357
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122115	93.847	—	40,097
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122199	93.847	—	20,898
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK123384	93.847	—	78,665
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK124647	93.847	—	42,670
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	73,935	727,158
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK044234	93.847	—	311,945
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK047987	93.847	—	502,965
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK054514	93.847	—	145,643
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK080684	93.847	137,742	469,939
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK087694	93.847	181,832	820,201
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK107719	93.847	—	217,754
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK108070	93.847	83,098	235,056
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK110409	93.847	—	455,391
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK111678	93.847	—	558,483
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK114891	93.847	1,707	179,036
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115213	93.847	—	537,747
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115937	93.847	144,508	283,687
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK116799	93.847	—	542,335
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119229	93.847	—	774,619
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK122701	93.847	—	176,392
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125187	93.847	—	9,031
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK117246	93.847	—	82,704
Diabetes, Digestive, and Kidney Diseases Extramural Research	R18DK118467	93.847	—	359,378
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK119997	93.847	—	224,908
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK122229	93.847	26,335	139,414
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK123616	93.847	—	415
Diabetes, Digestive, and Kidney Diseases Extramural Research	R25DK101390	93.847	—	27,620
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK044234	93.847	—	4,646
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK096231	93.847	79,500	113,833
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK007656	93.847	—	214,692
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK108735	93.847	—	267,752
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK062470	93.847	386,687	908,935
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK106994	93.847	—	102,173
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK116099	93.847	—	302,991
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119793	93.847	—	360,044
Pass-through Augusta University Research Institute Inc	U24DK115255	93.847	—	41,387
Pass-through Children's Hospital of Philadelphia	R01DK110749	93.847	30,016	104,238
Pass-through Fdtn for Atlanta Veterans Educ and Res	U01DK098246	93.847	—	77,789
Pass-through Kaiser Foundation Research Institute	R01DK085070	93.847	—	25,649
Pass-through Mayo Clinic	RC2DK118619	93.847	—	655,665
Pass-through Mount Sinai School of Medicine	U01DK119200	93.847	—	49,102
Pass-through Natl Jewish Health	R01DK107735	93.847	—	(5,730)
Pass-through Northern California Inst of Res and Edu	01DK109823	93.847	—	545
Pass-through Ohio State University	U01DK108327	93.847	—	(551)
Pass-through Research Institute at Nationwide Children's Hospital	U01DK100866	93.847	—	38,519
Pass-through Translational Genomics Research Inst	R01 DK107735	93.847	—	95,208
Pass-through University of Alabama Birmingham	R01DK115473	93.847	—	36,669
Pass-through University of Alabama Birmingham	U01DK106858	93.847	—	21,760
Pass-through University of Kansas Medical Center	R01DK099611	93.847	—	5,449
Pass-through University of Kansas Medical Center	R01DK113111	93.847	—	81,336
Pass-through University of Maryland, Baltimore	R01DK110375	93.847	—	47,671
Pass-through University of Michigan	R01DK089763	93.847	—	285,215
Pass-through University of Pittsburgh	R01DK109365	93.847	—	2,944
Pass-through University of South Florida	UC4DK117009	93.847	—	84,206
Pass-through Vanderbilt University Medical Center	R01DK120814	93.847	—	25,155
Pass-through Virginia Commonwealth University	U01DK061731	93.847	1,872	57,528
Pass-through Weill Cornell Medical College	R01DK056626	93.847	—	57,197
Pass-through Weill Cornell Medical College	R01DK103046	93.847	—	144,649
Pass-through Wright State University	670895-1 P0059981	93.847	—	24,846
Pass-through Yale University	R01DK121326	93.847	—	14,699
Total CFDA No. 93.847			1,396,092	14,427,837
Kidney Diseases, Urology and Hematology Research	5T32DK00765620	93.849	—	206
Total CFDA No. 93.849			—	206
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS110312	93.853	—	42,476
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS112740	93.853	—	155,119
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS112948	93.853	—	3,232
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS106896-01 REVISED	93.853	—	12,549
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS104801-01A1	93.853	—	159,759
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS104953-01A1	93.853	—	(19,876)
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106346-01	93.853	—	203,276
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R56NS099092-01A1	93.853	—	8,959
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R56NS102980-01	93.853	—	4,828
Extramural Research Programs in the Neurosciences and Neurological Disorders	2R56NS045962-09	93.853	—	(5,347)
Extramural Research Programs in the Neurosciences and Neurological Disorders	32NS096050	93.853	—	351,442
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS092122-03S1 REVISED	93.853	67,147	225,323
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS093362-04S1	93.853	—	207,328
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098648-03	93.853	—	50
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098663-02	93.853	—	40,887
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101786-02	93.853	—	48,075
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101806-02	93.853	—	44,695
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS101932-03	93.853	—	27,867
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS110193-02	93.853	—	33,586
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS098615-03 REVISED	93.853	—	4,355
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS087121-05	93.853	—	21,694
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS083748-05	93.853	—	54,407
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS097576-02 REVISED	93.853	—	199,027
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P30NS055077-09	93.853	—	76,958
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS036654-20	93.853	—	(105)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS037112-18	93.853	—	(10,319)

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS047357-13REVISED	93.853	\$ —	125
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079858-05REVISED	93.853	—	63,238
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS084844-05 REVISED	93.853	—	(169)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085568-05	93.853	—	49,143
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088413-05	93.853	—	38
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088528-05	93.853	120,615	327,469
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088748-05	93.853	26,159	131,541
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089719-04	93.853	—	181,692
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090319-04	93.853	31,946	65,190
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090677-04	93.853	63,800	427,208
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091201-04	93.853	—	178,414
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091585	93.853	—	330,733
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS093016-04	93.853	—	85,498
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095279-04	93.853	—	366,506
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS091986-02	93.853	—	(70)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS093550-02	93.853	—	2,725
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS101167-02	93.853	141,718	181,862
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS102652-02	93.853	—	126,430
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS104410-02	93.853	—	15
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R24NS092389-03	93.853	—	234,861
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R31NS098764-03	93.853	—	7,680
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS08455-14REVISED	93.853	—	331
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS094302-03S1	93.853	—	(3,252)
Extramural Research Programs in the Neurosciences and Neurological Disorders	7R01NS083654-06 REVISED	93.853	—	39,082
Extramural Research Programs in the Neurosciences and Neurological Disorders	7U13NS087848-05	93.853	—	20,017
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS103363	93.853	—	43,163
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS103595	93.853	—	38,827
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS106755	93.853	—	42,308
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS106887	93.853	—	14,330
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS113530	93.853	—	17,482
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS113572	93.853	—	15,309
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS118867	93.853	—	2,110
Extramural Research Programs in the Neurosciences and Neurological Disorders	K00NS105218	93.853	—	36,444
Extramural Research Programs in the Neurosciences and Neurological Disorders	K00NS108539	93.853	—	14,297
Extramural Research Programs in the Neurosciences and Neurological Disorders	K08NS099474	93.853	—	177,637
Extramural Research Programs in the Neurosciences and Neurological Disorders	K08NS105929	93.853	—	189,787
Extramural Research Programs in the Neurosciences and Neurological Disorders	K23NS105944	93.853	—	150,037
Extramural Research Programs in the Neurosciences and Neurological Disorders	NS097549	93.853	876,306	1,326,248
Extramural Research Programs in the Neurosciences and Neurological Disorders	P50NS098685	93.853	—	1,085,267
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01 NS084844	93.853	—	385,664
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS036232	93.853	—	462,772
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS037112	93.853	—	407,689
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS045962	93.853	—	486,915
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS051630	93.853	212,821	345,518
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS065992	93.853	—	341,535
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS078095	93.853	—	328,096
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS083654	93.853	—	32,803
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS085387	93.853	—	184,979
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS088748	93.853	—	39,082
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS089694	93.853	—	16,062
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS092343	93.853	—	129,109
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS095181	93.853	—	371,168
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS095269	93.853	—	344,367
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS096236-04	93.853	—	17,356
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS097776	93.853	—	376,719
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS098441	93.853	—	731,625
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS099375	93.853	5,935	385,768
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100864	93.853	—	7,446
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100908	93.853	—	378,920
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100967	93.853	—	285,379
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS101701	93.853	—	518,537
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102306	93.853	86,020	303,850
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102850	93.853	—	421,461
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102871	93.853	—	346,199
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS105971	93.853	—	511,835
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS105982	93.853	—	354,891
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS107505	93.853	—	521,872
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS109237	93.853	160,152	506,695
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS109242	93.853	—	586,736
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110110	93.853	54,552	467,114
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110386	93.853	—	282,821
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111280	93.853	—	305,130
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111470	93.853	—	340,210
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111969	93.853	—	91,149
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS112308	93.853	—	70,622
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS112350	93.853	—	143,031
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS113746	93.853	—	354,526
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114130	93.853	—	199,004
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114253	93.853	37,876	191,260
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS102913	93.853	—	77,733
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106120	93.853	—	285,534
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106209	93.853	—	127,026
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106325	93.853	—	181,972
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS106554	93.853	—	23,742
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS108758	93.853	—	217,128
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS108760	93.853	—	99,408
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS110416	93.853	—	167,126
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS111765	93.853	—	148,231
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS113019	93.853	—	72,404
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114603	93.853	—	94,404
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114795	93.853	—	60,548
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114839	93.853	—	152,305
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114882	93.853	—	10,687
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114908	93.853	—	207,278
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS115758	93.853	—	62,207

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116311	93.853	\$ —	109,879
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116318	93.853	—	55,833
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116438	93.853	—	36,393
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116665	93.853	—	55,016
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116724	93.853	—	71,473
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS117113	93.853	—	15,037
Extramural Research Programs in the Neurosciences and Neurological Disorders	R33NS101167	93.853	161,729	289,615
Extramural Research Programs in the Neurosciences and Neurological Disorders	R35NS111602	93.853	—	778,501
Extramural Research Programs in the Neurosciences and Neurological Disorders	R35NS111619	93.853	—	752,399
Extramural Research Programs in the Neurosciences and Neurological Disorders	T32NS007480	93.853	22,118	294,869
Extramural Research Programs in the Neurosciences and Neurological Disorders	U24NS100673	93.853	43,060	90,657
Extramural Research Programs in the Neurosciences and Neurological Disorders	U24NS107234	93.853	—	300,337
Extramural Research Programs in the Neurosciences and Neurological Disorders	U54NS116025	93.853	697,577	1,078,724
Extramural Research Programs in the Neurosciences and Neurological Disorders	UG3NS100559	93.853	162,716	446,399
Extramural Research Programs in the Neurosciences and Neurological Disorders	UNS113879A	93.853	—	295,964
Pass-through Albert Einstein College of Medicine	K12NS080223	93.853	—	47,188
Pass-through Baylor College of Medicine	R21NS104953	93.853	—	61,398
Pass-through Case Western Reserve University	R01 NS096956	93.853	—	10,376
Pass-through Childrens Healthcare of Atlanta	R21NS103507	93.853	—	50,094
Pass-through Children's Hospital of Philadelphia	U01NS106845	93.853	—	12,520
Pass-through Children's Hospital of Philadelphia	U54NS115052	93.853	—	2,504
Pass-through Duke University	R37NS040894	93.853	—	(1,059)
Pass-through Georgia Institute of Technology	R01NS109226	93.853	—	63,354
Pass-through Georgia Institute of Technology	R01NS109978	93.853	—	15,500
Pass-through Georgia State University	R21NS111355	93.853	—	10,728
Pass-through Medical University of South Carolina	R01NS110347	93.853	—	81,033
Pass-through Medical University of South Carolina	U24NS100655	93.853	—	14,806
Pass-through Morehouse School of Medicine	R21 NS116726	93.853	—	7,732
Pass-through Mount Sinai School of Medicine	UH3NS103550	93.853	—	214,490
Pass-through Pennsylvania State University	EMUNS113912	93.853	—	20,359
Pass-through Stanford University	U01NS038455	93.853	1,500	337,337
Pass-through Univ of Arkansas for Medical Services	R03 NS103000	93.853	—	1,937
Pass-through Univ of Texas Health Sciences Ctr	R61NS113329-01	93.853	—	8,826
Pass-through University of Akron	R15NS109957	93.853	—	57,684
Pass-through University of Cincinnati	U01NS086872	93.853	—	3,545
Pass-through University of Georgia	R01NS099596	93.853	—	134,308
Pass-through University of Idaho	R01NS111283	93.853	—	37,689
Pass-through University of Miami	R01NS084288	93.853	—	69,309
Pass-through University of Michigan	IJ24NS100659-01	93.853	—	29,431
Pass-through University of North Carolina	R01NS090029	93.853	—	13,899
Pass-through University of Pennsylvania	P01NS097206	93.853	—	59,333
Pass-through University of Pennsylvania	U01NS113198	93.853	—	31,379
Pass-through University of Pittsburgh	R21NS111063	93.853	—	4,430
Pass-through University of Southern California	H50438/H49894	93.853	—	50
Pass-through University of Utah	R01NS097819	93.853	—	51,722
Pass-through University of Wisconsin-Madison	652K330	93.853	—	(30)
Pass-through University of Wisconsin-Madison	R01NS099158	93.853	—	7,235
Pass-through University of Wisconsin-Madison	R01NS108756	93.853	—	188,424
Pass-through Wright State University	R01NS107398	93.853	—	70,200
Total CFDA No. 93.853			2,973,747	28,812,273
COVID-19 - Allergy, Immunology and Transplantation Research	P01AI125180	93.855	—	608,090
COVID-19 - Allergy, Immunology and Transplantation Research	R01AI127799	93.855	—	23,522
COVID-19 - Allergy, Immunology and Transplantation Research	R01AI141327	93.855	—	16,561
COVID-19 - Allergy, Immunology and Transplantation Research	R01AI143875	93.855	—	1,436,105
COVID-19 - Allergy, Immunology and Transplantation Research	R01AI148378	93.855	—	3,820
COVID-19 - Allergy, Immunology and Transplantation Research	U19AI057266	93.855	—	119,168
COVID-19 - Allergy, Immunology and Transplantation Research	U19AI090023	93.855	—	230,667
COVID-19 - Allergy, Immunology and Transplantation Research	U19AI11048	93.855	—	107,921
COVID-19 - Allergy, Immunology and Transplantation Research	UM1AI069418	93.855	—	5,157
COVID-19 - Allergy, Immunology and Transplantation Research	UM1AI148576	93.855	—	3,117,185
COVID-19 - Allergy, Immunology and Transplantation Research	UM1AI148684	93.855	404,665	463,547
Allergy, Immunology and Transplantation Research	1F31AI138391-01	93.855	—	20,879
Allergy, Immunology and Transplantation Research	1K23AI144036-01	93.855	—	166,925
Allergy, Immunology and Transplantation Research	1R01AI139675-01	93.855	—	933
Allergy, Immunology and Transplantation Research	1R03AI139871-01	93.855	48,458	85,280
Allergy, Immunology and Transplantation Research	1R21AI130918-01	93.855	—	24,916
Allergy, Immunology and Transplantation Research	1R21AI141094-01	93.855	—	175,228
Allergy, Immunology and Transplantation Research	1U01AI132904	93.855	195,847	438,936
Allergy, Immunology and Transplantation Research	4R01AI064462-10 REVISED	93.855	—	(305)
Allergy, Immunology and Transplantation Research	4R01AI072435-11REVISED	93.855	—	(1,390)
Allergy, Immunology and Transplantation Research	4R01AI100110-05	93.855	—	3,739
Allergy, Immunology and Transplantation Research	5011649 / 8470038	93.855	—	336,450
Allergy, Immunology and Transplantation Research	5F30AI124568-03	93.855	—	1,427
Allergy, Immunology and Transplantation Research	5F31AI33950	93.855	—	40,404
Allergy, Immunology and Transplantation Research	5K08AI110528-06	93.855	—	6,811
Allergy, Immunology and Transplantation Research	5K22AI130223-02	93.855	—	64,517
Allergy, Immunology and Transplantation Research	5K23AI103044-05	93.855	—	235
Allergy, Immunology and Transplantation Research	5K23AI114407-05	93.855	—	102,708
Allergy, Immunology and Transplantation Research	5R01AI030048-24	93.855	—	(473)
Allergy, Immunology and Transplantation Research	5R01AI065429-15	93.855	—	(9,016)
Allergy, Immunology and Transplantation Research	5R01AI107960-05	93.855	57,961	57,957
Allergy, Immunology and Transplantation Research	5R01AI110334-05	93.855	45,428	54,622
Allergy, Immunology and Transplantation Research	5R01AI110680-05	93.855	120,001	545,853
Allergy, Immunology and Transplantation Research	5R01AI110701-05	93.855	—	(12)
Allergy, Immunology and Transplantation Research	5R01AI110720-05	93.855	—	60,432
Allergy, Immunology and Transplantation Research	5R01AI111557-04	93.855	—	32,335
Allergy, Immunology and Transplantation Research	5R01AI111851-04	93.855	—	352,090
Allergy, Immunology and Transplantation Research	5R01AI111948-05	93.855	—	2,917
Allergy, Immunology and Transplantation Research	5R01AI112723-04	93.855	—	180
Allergy, Immunology and Transplantation Research	5R01AI113021-05	93.855	—	450
Allergy, Immunology and Transplantation Research	5R01AI116379-05	93.855	—	566,557
Allergy, Immunology and Transplantation Research	5R01AI116933-04	93.855	—	211,884
Allergy, Immunology and Transplantation Research	5R01AI118853-04	93.855	—	6,452
Allergy, Immunology and Transplantation Research	5R21AI121860-02	93.855	—	275

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology and Transplantation Research	5R21AI122192-02	93.855	\$ —	58,535
Allergy, Immunology and Transplantation Research	5R21AI128313-02	93.855	—	31,027
Allergy, Immunology and Transplantation Research	5R21AI135711-02	93.855	—	170,470
Allergy, Immunology and Transplantation Research	5R21AI135753-02	93.855	100,074	154,029
Allergy, Immunology and Transplantation Research	5R33AI104278-05	93.855	—	(332)
Allergy, Immunology and Transplantation Research	5U01AI103408-03 REV	93.855	—	(1,403)
Allergy, Immunology and Transplantation Research	5U01AI103408-05REVISED	93.855	—	186,080
Allergy, Immunology and Transplantation Research	5U01AI115651-05	93.855	278,754	364,353
Allergy, Immunology and Transplantation Research	5U19AI051731-17	93.855	1,187,634	2,575,585
Allergy, Immunology and Transplantation Research	5U19AI057266-15	93.855	—	(1,106)
Allergy, Immunology and Transplantation Research	5U19AI090023-05	93.855	—	(582)
Allergy, Immunology and Transplantation Research	5UM1AI069418-13	93.855	1,629,634	4,687,579
Allergy, Immunology and Transplantation Research	5UM1AI124436-03REVISED	93.855	1,453,385	6,080,653
Allergy, Immunology and Transplantation Research	F30AI152342	93.855	—	31,239
Allergy, Immunology and Transplantation Research	F31AI131532	93.855	—	5,333
Allergy, Immunology and Transplantation Research	F31AI136310	93.855	—	33,291
Allergy, Immunology and Transplantation Research	F31AI145178	93.855	—	16,732
Allergy, Immunology and Transplantation Research	F31AI145750	93.855	—	48,562
Allergy, Immunology and Transplantation Research	F31AI147589	93.855	—	3,486
Allergy, Immunology and Transplantation Research	F31AI147611	93.855	—	2,110
Allergy, Immunology and Transplantation Research	F31AI150114	93.855	—	4,220
Allergy, Immunology and Transplantation Research	F31AI152459	93.855	—	6,906
Allergy, Immunology and Transplantation Research	F32AI145150	93.855	—	56,995
Allergy, Immunology and Transplantation Research	K08AI132747	93.855	—	140,025
Allergy, Immunology and Transplantation Research	K08AI139348	93.855	—	172,340
Allergy, Immunology and Transplantation Research	K22AI137306	93.855	—	128,598
Allergy, Immunology and Transplantation Research	K23AI124913	93.855	—	161,830
Allergy, Immunology and Transplantation Research	K23AI134182	93.855	—	134,871
Allergy, Immunology and Transplantation Research	K23AI143479	93.855	—	113,346
Allergy, Immunology and Transplantation Research	K23AI144040	93.855	—	136,532
Allergy, Immunology and Transplantation Research	K24AI114444	93.855	—	144,617
Allergy, Immunology and Transplantation Research	K99AI146271	93.855	—	79,257
Allergy, Immunology and Transplantation Research	P01AI125180	93.855	574,160	1,698,999
Allergy, Immunology and Transplantation Research	P30AI050409	93.855	598,077	3,526,531
Allergy, Immunology and Transplantation Research	R01AI020211	93.855	—	381,296
Allergy, Immunology and Transplantation Research	R01AI030048	93.855	—	315,692
Allergy, Immunology and Transplantation Research	R01AI051231	93.855	704,917	1,257,826
Allergy, Immunology and Transplantation Research	R01AI053668	93.855	157,772	431,870
Allergy, Immunology and Transplantation Research	R01AI064060	93.855	685,825	1,723,784
Allergy, Immunology and Transplantation Research	R01AI073707	93.855	—	388,464
Allergy, Immunology and Transplantation Research	R01AI076119	93.855	—	113,571
Allergy, Immunology and Transplantation Research	R01AI088025	93.855	17,195	407,387
Allergy, Immunology and Transplantation Research	R01AI110482	93.855	271,150	274,889
Allergy, Immunology and Transplantation Research	R01AI113021	93.855	—	38,844
Allergy, Immunology and Transplantation Research	R01AI114902	93.855	—	166,243
Allergy, Immunology and Transplantation Research	R01AI120860	93.855	87,966	328,516
Allergy, Immunology and Transplantation Research	R01AI121252	93.855	—	540,816
Allergy, Immunology and Transplantation Research	R01AI121315	93.855	226,323	690,734
Allergy, Immunology and Transplantation Research	R01AI123126	93.855	—	405,441
Allergy, Immunology and Transplantation Research	R01AI123733	93.855	—	246,959
Allergy, Immunology and Transplantation Research	R01AI124680	93.855	70,172	494,515
Allergy, Immunology and Transplantation Research	R01AI125064	93.855	—	732,199
Allergy, Immunology and Transplantation Research	R01AI125268	93.855	—	331,737
Allergy, Immunology and Transplantation Research	R01AI126322	93.855	23,237	698,312
Allergy, Immunology and Transplantation Research	R01AI127799	93.855	279,590	579,063
Allergy, Immunology and Transplantation Research	R01AI128799	93.855	10,410	476,788
Allergy, Immunology and Transplantation Research	R01AI128837	93.855	85,436	1,121,146
Allergy, Immunology and Transplantation Research	R01AI129862	93.855	161,330	401,689
Allergy, Immunology and Transplantation Research	R01AI130163	93.855	152,891	508,261
Allergy, Immunology and Transplantation Research	R01AI132766	93.855	—	33,284
Allergy, Immunology and Transplantation Research	R01AI132833	93.855	180,054	451,517
Allergy, Immunology and Transplantation Research	R01AI133706	93.855	12,313	1,030,339
Allergy, Immunology and Transplantation Research	R01AI134244	93.855	—	963,539
Allergy, Immunology and Transplantation Research	R01AI135806	93.855	23,132	286,082
Allergy, Immunology and Transplantation Research	R01AI136533	93.855	117,763	662,431
Allergy, Immunology and Transplantation Research	R01AI136581	93.855	—	278,964
Allergy, Immunology and Transplantation Research	R01AI137127	93.855	—	299,175
Allergy, Immunology and Transplantation Research	R01AI137679	93.855	532,716	657,860
Allergy, Immunology and Transplantation Research	R01AI138646	93.855	341,967	715,607
Allergy, Immunology and Transplantation Research	R01AI138783	93.855	412,581	649,757
Allergy, Immunology and Transplantation Research	R01AI139406	93.855	356,483	766,797
Allergy, Immunology and Transplantation Research	R01AI141327	93.855	49,972	322,037
Allergy, Immunology and Transplantation Research	R01AI141883	93.855	—	489,272
Allergy, Immunology and Transplantation Research	R01AI143414	93.855	—	484,258
Allergy, Immunology and Transplantation Research	R01AI143875	93.855	208,075	417,073
Allergy, Immunology and Transplantation Research	R01AI144067	93.855	—	278,251
Allergy, Immunology and Transplantation Research	R01AI145231	93.855	—	147,785
Allergy, Immunology and Transplantation Research	R01AI145640	93.855	8,006	783,316
Allergy, Immunology and Transplantation Research	R01AI146017	93.855	222,636	558,080
Allergy, Immunology and Transplantation Research	R01AI146260	93.855	—	186,804
Allergy, Immunology and Transplantation Research	R01AI147609	93.855	22,190	288,108
Allergy, Immunology and Transplantation Research	R01AI148377	93.855	—	2,092
Allergy, Immunology and Transplantation Research	R01AI148382	93.855	369,642	876,118
Allergy, Immunology and Transplantation Research	R01AI148471	93.855	—	146,630
Allergy, Immunology and Transplantation Research	R01AI148661	93.855	—	103,892
Allergy, Immunology and Transplantation Research	R01AI149297	93.855	—	91,864
Allergy, Immunology and Transplantation Research	R01AI149486	93.855	—	13,817
Allergy, Immunology and Transplantation Research	R01AI149527	93.855	—	15,534
Allergy, Immunology and Transplantation Research	R01AI149724	93.855	—	121,428
Allergy, Immunology and Transplantation Research	R01AI150774	93.855	—	3,821
Allergy, Immunology and Transplantation Research	R01AI152516	93.855	—	121,699
Allergy, Immunology and Transplantation Research	R01AI153102	93.855	—	20,614
Allergy, Immunology and Transplantation Research	R01AI47839	93.855	129,269	575,484
Allergy, Immunology and Transplantation Research	R21AI142489	93.855	—	164,859
Allergy, Immunology and Transplantation Research	R21AI142507	93.855	—	235,037

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology and Transplantation Research	R21AI144571	93.855	\$ —	955
Allergy, Immunology and Transplantation Research	R21AI145541	93.855	—	40,657
Allergy, Immunology and Transplantation Research	R21AI145650	93.855	—	120,924
Allergy, Immunology and Transplantation Research	R21AI146443	93.855	31,836	144,812
Allergy, Immunology and Transplantation Research	R21AI148847	93.855	—	100,970
Allergy, Immunology and Transplantation Research	R21AI149252	93.855	—	26,411
Allergy, Immunology and Transplantation Research	R21AI150292	93.855	—	26,595
Allergy, Immunology and Transplantation Research	R21AI154232	93.855	—	42,526
Allergy, Immunology and Transplantation Research	R21AI154352	93.855	—	31,665
Allergy, Immunology and Transplantation Research	R21AI38079	93.855	35,812	190,304
Allergy, Immunology and Transplantation Research	R37AI021150	93.855	100,331	194,555
Allergy, Immunology and Transplantation Research	R37AI049660	93.855	—	172,028
Allergy, Immunology and Transplantation Research	R37AI066998	93.855	—	639,746
Allergy, Immunology and Transplantation Research	R37AI11278	93.855	46,497	670,202
Allergy, Immunology and Transplantation Research	R38AI140299	93.855	—	121,228
Allergy, Immunology and Transplantation Research	R56AI145231	93.855	—	222,907
Allergy, Immunology and Transplantation Research	RAI150401A	93.855	—	44,617
Allergy, Immunology and Transplantation Research	RO1AI1072435	93.855	—	612,113
Allergy, Immunology and Transplantation Research	T32 AI138952	93.855	—	94,222
Allergy, Immunology and Transplantation Research	T32AI070081	93.855	—	201,738
Allergy, Immunology and Transplantation Research	T32AI074402	93.855	—	313,093
Allergy, Immunology and Transplantation Research	T32AI106699	93.855	—	34,355
Allergy, Immunology and Transplantation Research	U01AI131566	93.855	67,860	378,553
Allergy, Immunology and Transplantation Research	U01AI138909	93.855	—	566,424
Allergy, Immunology and Transplantation Research	U01AI141993	93.855	70,384	817,656
Allergy, Immunology and Transplantation Research	U01AI148069	93.855	140,241	422,273
Allergy, Immunology and Transplantation Research	U01AI150747	93.855	—	1,235
Allergy, Immunology and Transplantation Research	U19AI057266	93.855	1,186,092	2,941,079
Allergy, Immunology and Transplantation Research	U19AI090023	93.855	1,689,970	2,900,398
Allergy, Immunology and Transplantation Research	U19AI110483	93.855	1,097,615	2,165,393
Allergy, Immunology and Transplantation Research	U19AI11121	93.855	1,003,661	2,712,783
Allergy, Immunology and Transplantation Research	U19AI117891	93.855	467,261	1,217,013
Allergy, Immunology and Transplantation Research	U24AI120134	93.855	—	383,488
Allergy, Immunology and Transplantation Research	UH3AI122320	93.855	278,204	984,490
Allergy, Immunology and Transplantation Research	UM1AI148576	93.855	—	267,371
Allergy, Immunology and Transplantation Research	UM1AI148684	93.855	497,769	1,246,424
Allergy, Immunology and Transplantation Research	5R01AI047498-13	93.855	—	(966)
Allergy, Immunology and Transplantation Research	5R01AI064060-10	93.855	—	(14)
Allergy, Immunology and Transplantation Research	5R01AI071852-03	93.855	—	35
Allergy, Immunology and Transplantation Research	5R33AI121684-04	93.855	160,905	361,091
Allergy, Immunology and Transplantation Research	R01AI064462	93.855	—	499,867
Allergy, Immunology and Transplantation Research	R01AI148378	93.855	—	561,147
Allergy, Immunology and Transplantation Research	R21AI136563	93.855	7,991	184,619
Pass-through Albert Einstein College of Medicine	P30AI124414	93.855	—	6,343
Pass-through Albert Einstein College of Medicine	R01I114304	93.855	—	120,036
Pass-through Benaroya Research Institute at Virginia	UM1AI109565	93.855	—	321,664
Pass-through Beth Israel Deaconess Medical Center	R01AI143457	93.855	—	111,307
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	189,946
Pass-through Boston Children's Hospital	R33AI116184	93.855	—	1,814
Pass-through Boston Children's Hospital	U01AI126614	93.855	—	60,332
Pass-through Brigham and Womens Hospital	R01AI138801	93.855	—	85,919
Pass-through Brigham and Womens Hospital	UM1AI068636	93.855	—	3,557
Pass-through Case Western Reserve University	1R37AI141258-01	93.855	—	468,774
Pass-through Case Western Reserve University	AI072219-11	93.855	—	27,256
Pass-through Case Western Reserve University	R21AI122380	93.855	—	1,799
Pass-through Cincinnati Childrens Hospital	U01AI144673	93.855	—	482,920
Pass-through Dana Farber Cancer Institute	R21AI129017	93.855	—	(39)
Pass-through Dana Farber Cancer Institute	R33AI129017	93.855	—	270,066
Pass-through Duke University	5R21AI136556-02	93.855	—	38,002
Pass-through Duke University	A039048	93.855	—	9,627
Pass-through Duke University	P01AI131276	93.855	—	440,785
Pass-through Duke University	PO1AI131276	93.855	—	687,264
Pass-through Duke University	UM1AI104681	93.855	—	88,337
Pass-through Family Health International	PO15004277	93.855	130,252	175,469
Pass-through Fred Hutchinson Cancer Research Center	965013	93.855	—	4,225
Pass-through Fred Hutchinson Cancer Research Center	UM1 AI06861	93.855	—	91,988
Pass-through Fred Hutchinson Cancer Research Center	UM1 AI06863	93.855	—	17,565
Pass-through Fred Hutchinson Cancer Research Center	UM1AI068614	93.855	—	896,535
Pass-through Fred Hutchinson Cancer Research Center	UM1AI068635	93.855	—	20,586
Pass-through Georgia Institute of Technology	R01AI044902	93.855	—	(19,244)
Pass-through Georgia Institute of Technology	U01AI124270	93.855	—	253,705
Pass-through Georgia State University	R01AI071002	93.855	—	158,317
Pass-through Georgia State University	R01AI116835	93.855	—	2,845
Pass-through Georgia State University	R01AI141222	93.855	—	431,405
Pass-through Georgia State University	R01AI153400	93.855	—	12,894
Pass-through Georgia State University	R03AI133172	93.855	—	9,783
Pass-through Georgia State University	SP00011272-02	93.855	—	(85)
Pass-through Georgia State University	SP00013950-01	93.855	—	43,591
Pass-through Georgia Tech Foundation	UH2AI153028	93.855	—	6,009
Pass-through Harvard University	P01AI056299	93.855	—	354,908
Pass-through Henry M Jackson Foundation	U19AI144180	93.855	—	149,686
Pass-through Johns Hopkins University	PO# 2001007978	93.855	—	(891)
Pass-through Johns Hopkins University	R01AI108695	93.855	—	86,455
Pass-through Johns Hopkins University	R21AI139784	93.855	—	72,663
Pass-through Johns Hopkins University	U01AI069918	93.855	—	149,874
Pass-through Johns Hopkins University	UH3AI133669	93.855	—	149,378
Pass-through Johns Hopkins University	UM1 AI068632	93.855	—	459
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	23,399
Pass-through Johns Hopkins University	UM2AI130836	93.855	71,484	154,862
Pass-through La Jolla Institute for Allergy	R01AI125068	93.855	—	473,553
Pass-through La Jolla Institute for Allergy	U19AI142742	93.855	—	26,775
Pass-through Massachusetts General Hospital	R01AI124718	93.855	—	15,239
Pass-through Mayo Clinic Rochester	R01AI121054	93.855	—	319,206
Pass-through Medical University of South Carolina	U01AI125159	93.855	—	238,861
Pass-through Mount Sinai School of Medicine	0255-8689-4609	93.855	—	69,500



**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Mount Sinai School of Medicine	P01AI097092	93.855	\$ —	302,970
Pass-through Mount Sinai School of Medicine	U01A163594	93.855	—	98,745
Pass-through Mount Sinai School of Medicine	U19AI118610	93.855	—	200,072
Pass-through Ohio State University	R01AI127863	93.855	—	116,272
Pass-through Regents of the University of California	R01AI125842	93.855	—	125,764
Pass-through Research Institute at Nationwide Children's Hospital	R01AI096882	93.855	—	56,869
Pass-through Research Institute at Nationwide Children's Hospital	R01AI126890	93.855	—	276,254
Pass-through Scripps Research Institute	1A1I00663	93.855	—	(25,632)
Pass-through Scripps Research Institute	R01AI145629	93.855	—	231,834
Pass-through Scripps Research Institute	U19AI142790	93.855	—	175,389
Pass-through Scripps Research Institute	UM1 AI144462	93.855	—	209,208
Pass-through Scripps Research Institute	UM1AI100663	93.855	—	482
Pass-through South Dakota State University	R01AI14188	93.855	—	129,036
Pass-through St Jude Childrens Research Hospital	U01AI144616	93.855	—	339,844
Pass-through Texas Biomedical Research Institute	R01AI111943	93.855	—	264,356
Pass-through Texas Biomedical Research Institute	R01AI123047	93.855	—	264,384
Pass-through Tulane University	R21AI140840	93.855	—	36,919
Pass-through University of Alabama	U19AI142737	93.855	—	136,415
Pass-through University of Alabama Birmingham	R01AI112566	93.855	—	(42)
Pass-through University of Alabama Birmingham	U19AI109662	93.855	—	59,556
Pass-through University of Alabama Birmingham	U19AI142759	93.855	—	496,068
Pass-through University of Alabama Birmingham	U54AI150225	93.855	—	1,308
Pass-through University of California Davis	01AI098670	93.855	—	(11,665)
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	81,093
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	47,048
Pass-through University of California San Francisco	SUM1AI110498-05	93.855	—	7,234
Pass-through University of California San Francisco	R13AI102630	93.855	—	(259)
Pass-through University of California San Francisco	U01I118594	93.855	—	89,511
Pass-through University of Georgia	R01AI125738	93.855	—	143,972
Pass-through University of Houston	R01AI125362	93.855	—	190,152
Pass-through University of Illinois	R01AI147487	93.855	—	13,926
Pass-through University of Louisiana at Lafayette	8799-01	93.855	—	6,315
Pass-through University of Louisiana at Lafayette	R01AI111907	93.855	—	18,477
Pass-through University of Maryland, Baltimore	P01AI124912	93.855	—	1,304,288
Pass-through University of Mississippi	R21AI144571	93.855	—	24,681
Pass-through University of Nebraska	R01AI129745	93.855	—	595,720
Pass-through University of Nevada	R01AI122266	93.855	—	25,193
Pass-through University of North Carolina	UM1AI126619	93.855	—	942,873
Pass-through University of North Carolina Chapel Hill	R01AI136990	93.855	—	608,291
Pass-through University of North Carolina Chapel Hill	U01AI114378	93.855	—	24,719
Pass-through University of North Carolina Chapel Hill	U19AI100625	93.855	—	(5,281)
Pass-through University of North Carolina Chapel Hill	UAI100625C	93.855	—	28,836
Pass-through University of Pennsylvania	P01AI131338	93.855	—	1,011,196
Pass-through University of Pennsylvania	R01AI139188	93.855	—	76,771
Pass-through University of Pennsylvania	U19AI131130	93.855	—	180,679
Pass-through University of Texas Southwestern	R01AI141101	93.855	—	78,171
Pass-through University of Utah	R01AI123425	93.855	—	3,087
Pass-through University of Virginia	R01AI154242	93.855	—	1,927
Pass-through University of Washington	R01AI142647	93.855	—	377,261
Pass-through University of Washington Seattle	U19AI083019	93.855	—	(536)
Pass-through University of Wisconsin-Madison	R01AI148707	93.855	—	2,883
Pass-through University of Wisconsin-Madison	U01AI102456	93.855	—	122,867
Pass-through Vanderbilt University	U19AI095227	93.855	—	95,576
Pass-through Vanderbilt University	U19AI117905	93.855	—	78,500
Pass-through Wayne State University	R21AI140033	93.855	—	31,715
Pass-through Yale University	R01AI112970	93.855	—	19,263
Total CFDA No. 93.855			19,699,256	96,904,675
Microbiology and Infectious Diseases Research	R01HD097843	93.856	—	44,359
Pass-through Baylor College of Medicine	HHSN2722013000151	93.856	—	411,946
Pass-through University of Florida	RF1AG052476	93.856	—	360,072
Total CFDA No. 93.856			—	816,377
Biomedical Research and Research Training	R01AI150451	93.859	—	244,604
Biomedical Research and Research Training	1F32GM128407-01REVISED	93.859	—	68,590
Biomedical Research and Research Training	1R01GM125842-01A1	93.859	35,417	44,900
Biomedical Research and Research Training	2R01GM100151-05	93.859	—	168
Biomedical Research and Research Training	2T32GM008490-26	93.859	—	463,032
Biomedical Research and Research Training	3T32GM008169-30S1	93.859	—	119
Biomedical Research and Research Training	52T32GM008169-32	93.859	—	1,135,184
Biomedical Research and Research Training	5F32GM125350-02	93.859	—	67,506
Biomedical Research and Research Training	5K99GM127671-02	93.859	—	(1,561)
Biomedical Research and Research Training	5R01GM069971-12 REVISED	93.859	—	3,072
Biomedical Research and Research Training	5R01GM091875-17	93.859	—	19,533
Biomedical Research and Research Training	5R01GM093278-09S1	93.859	—	68,688
Biomedical Research and Research Training	5R01GM110663-04	93.859	—	(39)
Biomedical Research and Research Training	5R01GM114561-03 REVISED	93.859	—	(2,183)
Biomedical Research and Research Training	5R01GM117946-04	93.859	118,644	210,581
Biomedical Research and Research Training	5R35GM122549	93.859	—	492,046
Biomedical Research and Research Training	F31GM130112	93.859	—	44,746
Biomedical Research and Research Training	F31GM131609	93.859	—	44,225
Biomedical Research and Research Training	F31GM134649	93.859	—	13,774
Biomedical Research and Research Training	F32GM126734	93.859	—	38,684
Biomedical Research and Research Training	F32GM133091	93.859	—	77,386
Biomedical Research and Research Training	K12GM000080	93.859	42,508	1,381,073
Biomedical Research and Research Training	K23GM128221	93.859	—	188,690
Biomedical Research and Research Training	K23GM137182	93.859	—	11,495
Biomedical Research and Research Training	R00GM129460	93.859	—	106,824
Biomedical Research and Research Training	R01AI150453	93.859	112,791	431,561
Biomedical Research and Research Training	R01GM035463	93.859	—	878,395
Biomedical Research and Research Training	R01GM051173	93.859	35,760	324,053
Biomedical Research and Research Training	R01GM053640	93.859	—	389,880
Biomedical Research and Research Training	R01GM072808	93.859	—	391,111

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Biomedical Research and Research Training	R01GM083889	93.859	\$ —	387,412
Biomedical Research and Research Training	R01GM084070	93.859	—	358,557
Biomedical Research and Research Training	R01GM093278	93.859	21,828	201,537
Biomedical Research and Research Training	R01GM099142	93.859	—	4,079
Biomedical Research and Research Training	R01GM104323	93.859	—	374,713
Biomedical Research and Research Training	R01GM109501	93.859	9,025	23,494
Biomedical Research and Research Training	R01GM113228	93.859	—	2,496
Biomedical Research and Research Training	R01GM116065	93.859	23,384	229,098
Biomedical Research and Research Training	R01GM116991	93.859	—	216,361
Biomedical Research and Research Training	R01GM118012	93.859	199,517	281,130
Biomedical Research and Research Training	R01GM120271	93.859	—	301,818
Biomedical Research and Research Training	R01GM121967	93.859	—	243,240
Biomedical Research and Research Training	R01GM122083	93.859	217,048	316,080
Biomedical Research and Research Training	R01GM123136-	93.859	89,214	251,302
Biomedical Research and Research Training	R01GM124061	93.859	85,646	189,875
Biomedical Research and Research Training	R01GM124280	93.859	928	388,860
Biomedical Research and Research Training	R01GM124472	93.859	—	456,757
Biomedical Research and Research Training	R01GM129495	93.859	—	228,631
Biomedical Research and Research Training	R01GM130950	93.859	—	390,348
Biomedical Research and Research Training	R01GM131099	93.859	74,737	406,395
Biomedical Research and Research Training	R01GM132598	93.859	—	285,557
Biomedical Research and Research Training	R01GM138544	93.859	—	8,346
Biomedical Research and Research Training	R21GM127971	93.859	—	79,915
Biomedical Research and Research Training	R21GM134564	93.859	—	42,431
Biomedical Research and Research Training	R25GM125598	93.859	—	434,148
Biomedical Research and Research Training	R35GM1119426	93.859	—	355,010
Biomedical Research and Research Training	R35GM122568	93.859	—	414,810
Biomedical Research and Research Training	R35GM122591	93.859	—	335,464
Biomedical Research and Research Training	R35GM133509	93.859	—	369,966
Biomedical Research and Research Training	R35GM133719	93.859	—	207
Biomedical Research and Research Training	R35GM136407	93.859	—	143,235
Biomedical Research and Research Training	R35GM138123	93.859	—	6,759
Biomedical Research and Research Training	T32GM008367	93.859	—	292,640
Biomedical Research and Research Training	T32GM008602	93.859	—	267,972
Biomedical Research and Research Training	T32GM095442	93.859	—	161,833
Biomedical Research and Research Training	T32GM135060	93.859	—	31,903
Biomedical Research and Research Training	R01GM134245	93.859	—	253,318
Pass-through Albert Einstein College of Medicine	P01GM068036	93.859	—	(14,373)
Pass-through Georgia Institute of Technology	R01GM1118803	93.859	—	14,954
Pass-through Georgia Institute of Technology	T32GM008433	93.859	—	46,034
Pass-through Johns Hopkins University	R01GM127578	93.859	—	168,306
Pass-through North Carolina State University	R25GM130528	93.859	—	14,144
Pass-through Ohio State University	1R01GM30135-01	93.859	—	122,260
Pass-through Ohio State University	R01GM065183	93.859	—	47,769
Pass-through Pennsylvania State University	R01GM121650	93.859	—	83,788
Pass-through Scripps Research Institute	U54GM103368	93.859	—	698,993
Pass-through Univ of Texas Health Sciences Ctr	R01GM130147	93.859	—	212,390
Pass-through University of California San Diego	R01GM118609	93.859	—	340,621
Pass-through University of Georgia	P01GM085354	93.859	—	72,902
Pass-through University of Maryland, Baltimore	R01GM130617	93.859	—	15,928
Pass-through University of Texas Medical Branch	R01GM18534	93.859	—	115,730
Pass-through University of Washington	R01AI150467	93.859	—	25,620
Total CFDA No. 93.859			1,066,447	17,836,900
Child Health and Human Development Extramural Research	1F32HD096816-01	93.865	—	60,996
Child Health and Human Development Extramural Research	1R03HD097737-01	93.865	—	160,421
Child Health and Human Development Extramural Research	1R21HD089160-02	93.865	—	63,960
Child Health and Human Development Extramural Research	1R21HD095138-01	93.865	46,504	206,487
Child Health and Human Development Extramural Research	3R21HD092785-02S1	93.865	—	169,358
Child Health and Human Development Extramural Research	5F31HD088043-03	93.865	—	1,001
Child Health and Human Development Extramural Research	5K01HD079584-05	93.865	—	(777)
Child Health and Human Development Extramural Research	5K01HD080722-04	93.865	—	691
Child Health and Human Development Extramural Research	5K23HD078153-05	93.865	—	(108)
Child Health and Human Development Extramural Research	5K25HD086276-03	93.865	—	116,694
Child Health and Human Development Extramural Research	5R01HD075784-05	93.865	5,653	40,298
Child Health and Human Development Extramural Research	5R01HD085877-03 REVISED	93.865	146	207,883
Child Health and Human Development Extramural Research	5R03HD087606-02	93.865	—	44,333
Child Health and Human Development Extramural Research	5R21HD080107-02 REVISED	93.865	—	495
Child Health and Human Development Extramural Research	5R21HD086491-02	93.865	15,350	21,318
Child Health and Human Development Extramural Research	5R21HD087760-02 REVISED	93.865	—	38,285
Child Health and Human Development Extramural Research	5R21HD089056-02	93.865	1,275	33,789
Child Health and Human Development Extramural Research	5R21HD093027-02	93.865	—	89,198
Child Health and Human Development Extramural Research	5R25HD079102-05 REVISED	93.865	—	14,391
Child Health and Human Development Extramural Research	5U01HD066439-04	93.865	—	4,187
Child Health and Human Development Extramural Research	F31HD096815	93.865	—	26,643
Child Health and Human Development Extramural Research	F31HD097918	93.865	—	47,737
Child Health and Human Development Extramural Research	F31HD098816	93.865	—	42,594
Child Health and Human Development Extramural Research	F31HD100145	93.865	—	42,881
Child Health and Human Development Extramural Research	F31HD100265	93.865	—	19,218
Child Health and Human Development Extramural Research	F32HD097920	93.865	—	51,661
Child Health and Human Development Extramural Research	F32HD100176	93.865	—	6,571
Child Health and Human Development Extramural Research	HD071845	93.865	—	232,857
Child Health and Human Development Extramural Research	K01HD100588	93.865	—	101,980
Child Health and Human Development Extramural Research	K12HD072245	93.865	—	404,013
Child Health and Human Development Extramural Research	K12HD085850	93.865	—	385,142
Child Health and Human Development Extramural Research	K99HD097920	93.865	—	97,896
Child Health and Human Development Extramural Research	R00HD092625	93.865	—	212,214
Child Health and Human Development Extramural Research	R00HD093858	93.865	—	215,061
Child Health and Human Development Extramural Research	R01HD046922	93.865	8,655	607,113
Child Health and Human Development Extramural Research	R01HD082373	93.865	—	223,637
Child Health and Human Development Extramural Research	R01HD090642	93.865	219,685	349,950
Child Health and Human Development Extramural Research	R01HD090925	93.865	—	754,793
Child Health and Human Development Extramural Research	R01HD092033	93.865	—	494,215

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Child Health and Human Development Extramural Research	R01HD092580	93.865	\$ 178,576	384,261
Child Health and Human Development Extramural Research	R01HD092595	93.865	342,333	507,858
Child Health and Human Development Extramural Research	R01HD094716	93.865	—	304,549
Child Health and Human Development Extramural Research	R01HD095741	93.865	58,170	649,076
Child Health and Human Development Extramural Research	R01HD097175	93.865	248,979	415,807
Child Health and Human Development Extramural Research	R01HD099224	93.865	—	214,210
Child Health and Human Development Extramural Research	R01HD099480	93.865	94,238	304,955
Child Health and Human Development Extramural Research	R21HD100820	93.865	36,344	95,038
Child Health and Human Development Extramural Research	R21HD103030	93.865	—	17,770
Child Health and Human Development Extramural Research	UG1HD027851	93.865	—	253,546
Child Health and Human Development Extramural Research	R01HD095975	93.865	—	221,224
Child Health and Human Development Extramural Research	R21HD097491	93.865	7,819	125,190
Child Health and Human Development Extramural Research	U54NS091859	93.865	—	1,207,094
Pass-through Bradley Hospital	7127549	93.865	—	15,667
Pass-through Case Western Reserve University	R01HD092351	93.865	—	15,854
Pass-through Harvard School of Public Health	R01HD093761	93.865	—	25,450
Pass-through Mclean Hospital	R21HD097524	93.865	—	55,328
Pass-through Medical University of South Carolina	P2CHD086844	93.865	—	(32)
Pass-through Michigan State University	R01HD096033	93.865	—	18,173
Pass-through Mount Sinai School of Medicine	R01HD099231	93.865	—	26,621
Pass-through New York University	14-A0-00-002901-01	93.865	—	61
Pass-through Northwestern University	5K12HD073945-08	93.865	—	98,944
Pass-through Northwestern University	R01HD099344	93.865	—	562
Pass-through Phoenix Children's Hospital	R01HD088528	93.865	—	58,954
Pass-through Research Institute at Nationwide Children's Hospital	R01HD091347	93.865	—	1,379
Pass-through Seattle Children's Research Institute	R01HD086978	93.865	58,328	109,142
Pass-through Tulane University	U01HD052104	93.865	—	37,923
Pass-through Tulane University	U01HD052104	93.865	—	(638)
Pass-through Univ of Massachusetts Medical School	U54HD082013	93.865	—	322,756
Pass-through University of Cape Town	R01HD083040	93.865	—	59,944
Pass-through University of Georgia	R01HD080749	93.865	—	2,296
Pass-through University of Georgia	R01HD090126	93.865	7,065	11,022
Pass-through University of Miami	R01HD101352	93.865	—	32,997
Pass-through University of North Carolina Chapel Hill	R01HD094009	93.865	—	60,162
Pass-through University of North Carolina Chapel Hill	U19HD089881	93.865	—	1,997,387
Pass-through University of North Carolina Chapel Hill	U24HD089880	93.865	—	687,381
Pass-through University of North Carolina Chapel Hill	U24HD089980	93.865	—	(49,091)
Pass-through University of Pittsburgh	P2CHD086943	93.865	—	19,675
Pass-through University of Washington	R01HD089831	93.865	—	155,717
Pass-through Wayne State University	R01HD099178	93.865	—	6,935
Pass-through Weill Cornell Medical College	R21HD099000	93.865	—	11,770
Pass-through Women & Infants Hospital of Rhode Island	R01HD084515	93.865	—	119,845
Total CFDA No. 93.865			1,329,120	14,191,838
Aging Research	P30AG064200	93.866	53,463	342,799
Aging Research	R21AG065977	93.866	—	96,201
Aging Research	1R21AG054206-01A1	93.866	—	97,027
Aging Research	1R21AG058866-01	93.866	—	179,860
Aging Research	1R56AG060757-01	93.866	119,291	79,766
Aging Research	1RF1AG051538-01A1	93.866	—	477,258
Aging Research	1RF1AG057247-01	93.866	—	(14,334)
Aging Research	1RF1AG057471-01	93.866	303,267	2,696,097
Aging Research	1RF1AG057965-01A1 REVISED	93.866	38,418	235,253
Aging Research	1RF1AG060285-01A1 REVISED	93.866	43,784	362,353
Aging Research	3U01AG052460-03S1	93.866	—	733,048
Aging Research	5K01AG042498-06	93.866	—	7,475
Aging Research	5R01AG023695-10	93.866	—	283,697
Aging Research	5R01AG042127-06 REVISED	93.866	—	94,768
Aging Research	5R21AG055995-02 REVISED	93.866	—	93,785
Aging Research	5R21AG058445-02	93.866	22,751	99,460
Aging Research	F32AG064862	93.866	—	50,004
Aging Research	K23AG065452	93.866	—	73,331
Aging Research	P30AG066511	93.866	—	190,869
Aging Research	P50AG025688	93.866	122,434	2,340,886
Aging Research	R01AG047408	93.866	44,565	201,023
Aging Research	R01AG049752	93.866	—	317,124
Aging Research	R01AG054046	93.866	—	416,846
Aging Research	R01AG054079	93.866	173,166	896,016
Aging Research	R01AG054991	93.866	87,606	553,431
Aging Research	R01AG055634	93.866	—	351,546
Aging Research	R01AG056533	93.866	210,136	742,966
Aging Research	R01AG057714	93.866	25,461	526,770
Aging Research	R01AG058704	93.866	414,194	669,974
Aging Research	R01AG061175	93.866	—	678,389
Aging Research	R01AG061179	93.866	13,659	378,468
Aging Research	R01AG061971	93.866	130,852	512,323
Aging Research	R01AG062577	93.866	7,728	381,509
Aging Research	R01AG062581	93.866	—	34,416
Aging Research	R01AG062691	93.866	—	584,555
Aging Research	R01AG064464	93.866	—	286,963
Aging Research	R01AG065177	93.866	—	443,352
Aging Research	R01AG066203	93.866	—	317,119
Aging Research	R01AG068247	93.866	—	27,511
Aging Research	R03AG056448	93.866	—	23,147
Aging Research	R03AG066559	93.866	—	19,769
Aging Research	R13AG047064	93.866	—	25,706
Aging Research	R21AG054903	93.866	—	287,061
Aging Research	R21AG064405	93.866	—	148,297
Aging Research	R21AG065815	93.866	—	3,730
Aging Research	R34AG058835	93.866	78,164	147,021
Aging Research	R56AG019206	93.866	—	150,726
Aging Research	R56AG059714	93.866	—	433,091
Aging Research	R56AG062256	93.866	113,418	12,141

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Aging Research	R56AG062633	93.866	\$ 37,730	246,409
Aging Research	RF1AG051514	93.866	23,530	416,093
Aging Research	RF1AG051633	93.866	149,141	759,719
Aging Research	RF1AG057470	93.866	252,273	1,840,836
Aging Research	U01AG046161	93.866	462,420	993,074
Aging Research	U01AG061357	93.866	67,230	1,413,554
Aging Research	U54AG062334	93.866	156,537	1,366,901
Aging Research	U54AG065187	93.866	1,752,435	2,783,831
Pass-through Baylor College of Medicine	R01AG057339	93.866	—	58,107
Pass-through Baylor College of Medicine	R01AG53960	93.866	—	187,372
Pass-through Beth Israel Deaconess Medical Center	1RF2AG062181-01	93.866	—	281,255
Pass-through Boston University	5U34AG051419	93.866	—	(1,780)
Pass-through Brown University	U54AG063546	93.866	—	17,287
Pass-through Columbia University	R01AG062624	93.866	—	8,585
Pass-through Duke University	5R01AG057235-07	93.866	—	7,657
Pass-through Duke University	R01AG057235	93.866	—	374,815
Pass-through Georgia Institute of Technology	R21AG056781	93.866	—	41,228
Pass-through Georgia State University	R01AG062310	93.866	—	94,821
Pass-through Georgia State University	SP00013539-01, R56AG0	93.866	—	88,099
Pass-through Indiana University	U01AG057195	93.866	—	43,061
Pass-through Mayo Clinic	R21AG062580	93.866	—	12,839
Pass-through Medical University of South Carolina	MUSC17-030-8A840	93.866	—	11,120
Pass-through Medical University of South Carolina	R01AG046543	93.866	—	15,116
Pass-through Northwestern University	R01AG030611	93.866	—	13,449
Pass-through Northwestern University	R01AG046352	93.866	—	15,666
Pass-through Northwestern University	U2CAG057441	93.866	—	75,577
Pass-through Northwestern University	U2CAG060426	93.866	—	14,307
Pass-through Oregon Health and Science University	R01AG056102	93.866	—	40,888
Pass-through Paragon Nanolabs	20180930-EMORYUNIV-A	93.866	—	74,987
Pass-through Rush University Medical Center	R01AG015819	93.866	—	48,358
Pass-through Univ of Texas Health Sciences Ctr	R01AG059993	93.866	—	15,735
Pass-through University of Alabama Birmingham	R01AG061800	93.866	—	301,046
Pass-through University of California San Diego	R01AG062387	93.866	—	242,341
Pass-through University of Florida	R01AG064786	93.866	—	93,570
Pass-through University of Florida	RF1AG057247	93.866	—	6,576
Pass-through University of Georgia	R01AG059260	93.866	—	16,809
Pass-through University of Minnesota	R01AG04893	93.866	—	278
Pass-through University of Minnesota	R21AG059068	93.866	—	24,205
Pass-through University of Minnesota	R21AG061372	93.866	—	5,136
Pass-through University of Pittsburgh	RF1 AG051538	93.866	—	19,139
Pass-through University of Southern California	CTAADN1032	93.866	—	32,770
Pass-through University of Southern California	R01AG053798	93.866	—	20,000
Pass-through University of Southern California	U19AG024904	93.866	—	127,507
Pass-through University of Southern California	U24AG057437	93.866	—	68,621
Pass-through University of Washington	U01AG016976	93.866	—	48,154
Pass-through University of Washington Saint Louis	RAG056639A	93.866	—	47,467
Pass-through University of Wisconsin-Madison	R01AG058680	93.866	—	18,076
Total CFDA No. 93.866			4,903,653	30,521,254
Vision Research	5R01EY014852-11	93.867	—	42
Vision Research	5R01EY025978-03 REVISED	93.867	33,893	118,537
Vision Research	5UG1EY013287-15	93.867	—	127,559
Vision Research	F31EY028855	93.867	—	42,621
Vision Research	K23EY030158	93.867	—	63,281
Vision Research	P30EY006360	93.867	—	673,961
Vision Research	R01EY014852	93.867	—	259,885
Vision Research	R01EY021592	93.867	—	237,828
Vision Research	R01EY027711	93.867	265,840	533,989
Vision Research	R01EY028450	93.867	90,266	518,038
Vision Research	R01EY028859	93.867	127,323	521,842
Vision Research	R01EY029594	93.867	12,982	472,734
Vision Research	R01EY029724	93.867	—	225,037
Vision Research	R21EY028320	93.867	—	127,008
Vision Research	T32EY007092	93.867	195,546	275,766
Vision Research	UG1EY025553	93.867	55,933	145,529
Vision Research	5U10EY013287-12REVISED	93.867	—	(23,008)
Pass-through Georgia Institute of Technology	K8501-G1	93.867	—	(125)
Pass-through Georgia Institute of Technology	R01EY016435	93.867	—	49,951
Pass-through Johns Hopkins University	U10EY024527	93.867	—	4,908
Pass-through Morehouse School of Medicine	01EY022216	93.867	—	342
Pass-through Morehouse School of Medicine	R01EY026291	93.867	—	92,333
Pass-through New England College of Optometry	R01EY025307	93.867	—	620
Pass-through Pennsylvania State University	EMUEY023533	93.867	—	1,852
Pass-through University of Alabama Birmingham	R01EY028578	93.867	—	25,434
Pass-through University of California San Francisco	UG1EY023939	93.867	—	14,026
Total CFDA No. 93.867			781,783	4,509,990
Medical Library Assistance	5R01LM012372-02	93.879	—	96
Medical Library Assistance	G13LM013010	93.879	—	38,939
Medical Library Assistance	K01LM012924	93.879	—	198,214
Medical Library Assistance	R01LM013049	93.879	94,819	155,599
Medical Library Assistance	R01LM013323	93.879	—	227,925
Medical Library Assistance	R21LM013014	93.879	—	117,733
Total CFDA No. 93.879			94,819	738,506
Grants for Training in Primary Care Medicine and Dentistry	T08HP28571	93.884	—	202,508
Pass-through Grady Memorial Hospital	T08HP29995	93.884	—	168,423
Total CFDA No. 93.884			—	390,931

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
HIV Emergency Relief Project Grants Pass-through Fulton County	VS14448/PO11817S1085	93.914	\$ —	(285)
Total CFDA No. 93.914			—	(285)
HIV Care Formula Grants Pass-through University of Washington	HED23192	93.917	—	14,064
Total CFDA No. 93.917			—	14,064
COVID-19 - Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H7CHA37221	93.918	—	54,350
Total CFDA No. 93.918			—	54,350
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS004977-04	93.941	172,973	609,012
HIV Demonstration, Research, Public and Professional Education Projects	U01PS005112	93.941	—	149,329
HIV Demonstration, Research, Public and Professional Education Projects	U01PS005181	93.941	159,686	1,313,044
Total CFDA No. 93.941			332,659	2,071,385
COVID-19 - Geriatric Education Centers	T1MHP39056	93.969	—	13,050
Geriatric Education Centers	U1Q33070	93.969	260,691	729,181
Total CFDA No. 93.969			260,691	742,231
International Research and Research Training	5D43TW007124	93.989	—	214,261
International Research and Research Training	D43TW009127	93.989	11,336	227,780
International Research and Research Training	D43TW010934	93.989	28,005	211,353
International Research and Research Training	D43TW011404	93.989	18,695	73,049
International Research and Research Training	R01TW010664	93.989	74,032	131,061
International Research and Research Training	U2RTW010114	93.989	208,238	314,606
Pass-through Addis Ababa University	D43TW010143	93.989	—	91,417
Pass-through Addis Ababa University	R25TW011214	93.989	—	33,802
Pass-through Georgia State University	R01TW010666	93.989	—	44,435
Pass-through Natl Ctr for Tuberculosis and Lung Diseases	R21TW011157	93.989	—	45,325
Pass-through Universidad Peruana Cayetano Heredia	U01TW010107	93.989	—	5,794
Pass-through Vanderbilt University	D43TW009337	93.989	—	75,204
Pass-through Vanderbilt University	VUMC 54582	93.989	—	(41)
Pass-through Vanderbilt University Medical Center	D43TW009337	93.989	24,840	156,313
Total CFDA No. 93.989			365,146	1,624,359
Contract	00HCVJCG-2018-25346	93.RD	—	105,950
Contract	200-2011-41278	93.RD	—	495,969
Contract	200-2016-M_88579	93.RD	—	28
Contract	200-2017-92309	93.RD	—	59,928
Contract	200-2017-95890	93.RD	—	731
Contract	200-2017-M-95879	93.RD	—	62,056
Contract	75D30118C02645	93.RD	52,752	189,573
Contract	75D30118P01681	93.RD	—	66,777
Contract	75D30119C06635	93.RD	—	229,829
Contract	75D30119C06765	93.RD	—	118,131
Contract	75D30119C06772	93.RD	—	142,147
Contract	75D30119P06269	93.RD	—	40,184
Contract	75D30119P06520	93.RD	—	17,194
Contract	75D30119P06734	93.RD	—	20,544
Contract	75D30120P07242	93.RD	—	50,449
Contract	75D30120P08041	93.RD	—	45,546
Contract	HHSN258201800013C	93.RD	—	52,341
Contract	HHSN0100201900015C	93.RD	60,000	135,209
Contract	HHSN261201800003I	93.RD	—	2,940,977
Contract	HHSN268201700205A	93.RD	—	1,931
Contract	HHSN268201800209P	93.RD	—	197,445
Contract	75N93019C00058	93.RD	183,490	995,621
Contract	75N93020D00005	93.RD	—	779,670
Contract	HHNS272201300006C	93.RD	49,743	1,471,733
Contract	HHNS272201300018	93.RD	—	6,523
Contract	HHNS272201300018I	93.RD	—	495,486
Contract	HHNS272201300018I	93.RD	642,032	5,419,198
Contract	HHNS272201300018I/HHNS272	93.RD	—	331,530
Contract	HHNS272201400004C	93.RD	1,953,307	5,822,341
Contract	75N94020D00009	93.RD	—	893
Contract	HHNS2752014000001I	93.RD	—	(11)
Contract	HHNS275201500001I	93.RD	—	183,165
Contract	20FED2000031PSE	93.RD	—	12,171
Contract	U10CA180886	93.RD	—	14,904
Pass-through Children's Healthcare of Atlanta	75D30119C06345	93.RD	—	32,794
Pass-through Children's Hospital of Philadelphia	PO# 6417	93.RD	—	266
Pass-through Council of State and Territorial Epidem	OPP1110830	93.RD	—	27,036
Pass-through Fred Hutchinson Cancer Research Center	HHNS250201500009C	93.RD	—	18,078
Pass-through Hennepin Healthcare Research Institute	18Q145-HHSN261201500003I	93.RD	—	117,814
Pass-through Leidos Biomedical Research	HHNS261200800001E	93.RD	99,516	94,980
Pass-through Leidos Biomedical Research	D30119C06088	93.RD	—	173,186
Pass-through Mayo Clinic	75N93019C00051	93.RD	—	416,112
Pass-through Mount Sinai School of Medicine	N93019C00051	93.RD	—	593,317
Pass-through Mount Sinai School of Medicine	HHNS268201200001I	93.RD	—	14,438
Pass-through New England Research Institutes	8421.EMORY.01	93.RD	—	19,934
Pass-through NORC at the University of Chicago	HHSD2002013M53955B	93.RD	—	67,149
Pass-through NORC at the University of Chicago				

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through NORC at the University of Chicago	HHSD2002013M54955B	93.RD	\$ —	333,857
Pass-through Univ of Arkansas for Medical Services	75N91019D000024	93.RD	—	41,430
Pass-through Univ of Arkansas for Medical Services	HHSN261200800001E	93.RD	—	(81)
Pass-through University of Alabama Birmingham	HHSN2722013000121	93.RD	—	292
Pass-through University of Alabama Birmingham	HHSN2722013000121	93.RD	—	4,571
Pass-through University of Georgia	N93019C000052	93.RD	—	183,744
Pass-through University of North Carolina Chapel Hill	2538	93.RD	—	54,156
Pass-through Veterans Medical Research Foundation	688D97020	93.RD	—	5,116
Total CFDA No. 93.RD			3,040,840	22,704,352
U.S. Department of Health and Human Services Total			74,898,681	450,046,529
U.S. Agency for International Development:				
USAID Foreign Assistance for Programs Overseas	AID114A1700003	98.001	749,995	1,225,135
Pass-through Intl Aids Vaccine Initiative	AID-OAA-A-16-00032	98.001	3,702	906,765
Pass-through Natl Academy of Sciences	AID-391-A-17-00001	98.001	—	83,106
Total CFDA No. 98.001			753,697	2,215,006
Cooperative Development Program (CDP):				
Pass-through Queensland Institute of Medical Research	2AID-OAA-F-16-00094	98.002	—	642
Total CFDA No. 98.002			—	642
U.S. Agency for International Development Total			753,697	2,215,648
Total Research and Development Cluster			84,640,221	488,772,744
Student Financial Assistance Cluster (notes 2 and 3):				
U.S. Department of Education:				
Federal Work Study Program		84.033	—	1,615,887
Federal Supplemental Education Opportunity Grant Program		84.007	—	1,175,379
Federal Pell Grant Program		84.063	—	7,629,631
Federal Direct Loan Program		84.268	—	79,069,410
Federal Direct PLUS Loan Program		84.268	—	45,345,792
Federal Perkins Loan Program		84.038	—	7,497,009
Total U.S. Department of Education			—	142,333,108
Total Student Financial Assistance Cluster			—	142,333,108
U.S. Department of Housing and Urban Development				
Contract				
Pass-through Atlanta Regional Commission	ARC-AH AG2027	14.CTR	—	15,591
Total CFDA No. 14.CTR			—	15,591
U.S. Department of Housing and Urban Development Total			—	15,591
U.S. Department of State				
Academic Exchange Programs - Humphrey Fellowship Program				
Pass-through Institute of International Education	S-ECAGD-19-CA-0047	19.010	—	20,362
Total CFDA No. 19.010			—	20,362
U.S. Department of State Total			—	20,362
National Endowment for Humanities				
Promotion of the Humanities_Federal/State Partnership				
Pass-through Georgia Humanities Council	SO-263604-19	45.129	(5,000)	(5,000)
Total CFDA No. 45.130			(5,000)	(5,000)
National Endowment for Humanities Total			(5,000)	(5,000)
U.S. Department of Veterans Affairs				
Contract				
36C24719C0118		64.CTR	—	550,965
Total CFDA No. 64.CTR			—	550,965
U.S. Department of Veterans Affairs Total			—	550,965
U.S. Department Of Energy:				
Office of Science Financial Assistance Program				
Pass-through Southface Energy Institute	DE-EE0007575	81.049	—	16,286
Total CFDA No. 81.049			—	16,286
U.S. Department Of Energy Total			—	16,286
U.S. Department of Health and Human Services:				
National Family Caregiver Support, Title III, Part E				
Pass-through Atlanta Regional Commission	2001GAOAF	93.052	—	15,617
Total CFDA No. 93.052			—	15,617
Global AIDS	6NU2GGH001815-02-02	93.067	—	532
Global AIDS	NU2GGH001443	93.067	219,880	338,404
Global AIDS	NU2GGH001815	93.067	—	45,023
Total CFDA No. 93.067			219,880	383,959
Birth Defects and Developmental Disabilities – Prevention and Surveillance	6 NU50DD004932-04-01	93.073	—	40,418
Total CFDA No. 93.073			—	40,418
Prevention of Disease, Disability, and Death by Infectious Diseases	NU38PS004646	93.084	273,334	483,585
Total CFDA No. 93.084			273,334	483,585
Maternal and Child Health Federal Consolidated Programs	UH7MC30772	93.110	—	88,973
Maternal and Child Health Federal Consolidated Programs	UH7MC30772-03-00	93.110	75,400	416,428
Pass-through Hemophilia of Georgia	H30MC24046	93.110	—	52,500
Pass-through Hemophilia of Georgia	H30MC24049	93.110	—	19,825
Total CFDA No. 93.110			75,400	577,726

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Emergency Medical Services for Children Pass-through Rhode Island Hospital Total CFDA No. 93.127	U03MC33155	93.127	\$ — —	62,319 62,319
AIDS Education and Training Centers Pass-through University of Washington Total CFDA No. 93.145	6 U1OHA33252-01-01	93.145	— —	55,451 55,451
Health Program for Toxic Substances and Disease Registry: Pass-through Amer Academy of Pediatrics Total CFDA No. 93.161	NU61TS000237	93.161	— —	95,557 95,557
Disabilities Prevention: Pass-through Georgia State University Total CFDA No. 93.184	U58DD001138	93.184	4,650 4,650	17,300 17,300
Scaling the National Diabetes Prevention Program to Priority Populations Pass-through American Diabetes Association Total CFDA No. 93.261	NU58DP006364	93.261	— —	3,641 3,641
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security Total CFDA No. 93.318	19NU14GH001238	93.318	— —	397,711 397,711
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Pass-through Public Health Foundation Enterprises Total CFDA No. 93.323	NU50CK000539	93.323	— —	2,055 2,055
Sickle Cell Treatment Demonstration Program Pass-through Carolinas Healthcare System Total CFDA No. 93.365	6 U1EMC31108-03-01	93.365	— —	30,427 30,427
Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises Pass-through CDC Foundation Pass-through Natl Network of Public Health Institutes Total CFDA No. 93.391	NU1ROT000017 NU1ROT000004	93.391 93.391	— 209,034 209,034	90,585 348,447 439,032
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health Pass-through CDC Foundation Pass-through Natl Assoc of Chronic Disease Directors Total CFDA No. 93.421	CDC Grant NO.1 FS4 NU38OT000286	93.421 93.421	— — —	9,154 70,656 79,810
Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke Pass-through Adcare Educational Institute Pass-through Alabama Department of Public Health Pass-through Arkansas Dept of Health Pass-through Connecticut Department of Health Pass-through Minnesota Department of Health Pass-through Nebraska Department of Health and Human Pass-through South Dakota Department of Health Pass-through Tennessee Department of Health Pass-through Wyoming Department of Health Total CFDA No. 93.426	NU58DP006518 NU58DP006527 NU58DP006556 NU58DP006530 NU58DP006522 NU58DP006548 NU58DP006526 NU58DP006552 NU58DP006551	93.426 93.426 93.426 93.426 93.426 93.426 93.426 93.426 93.426	— — — — — — — — —	6,504 7,223 9,433 8,021 24,229 8,811 26,651 43,479 9,588 143,939
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke Pass-through Kentucky Department for Public Health Pass-through North Carolina Dept of Hlth and Human Services Pass-through Utah Department of Health Total CFDA No. 93.435	NU58DP006612 NU58DP006635 NU58DP006609	93.435 93.435 93.435	— — —	7,283 18,678 12,396 38,357
COVID-19 - COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Total CFDA No. 93.461		93.461	— —	11,487,321 11,487,321
PPHF: Racial and Ethnic Approaches to Community Health Program financed solely by Public Prevention and Health Funds Pass-through Georgia Dept of Public Health Total CFDA No. 93.738	NU58DP006580	93.738	— —	29,044 29,044
Medical Assistance Program Pass-through Georgia Department of Behavioral Health Pass-through Georgia Department of Behavioral Health Pass-through Georgia Department of Behavioral Health Total CFDA No. 93.778	44100-907-0000070367 44100-907-0000099734 4410-907000133937	93.778 93.778 93.778	— — —	13,799 16,058 186,573 216,430
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities Pass-through Georgia Dept of Public Health Total CFDA No. 93.817	40500-033-16161809	93.817	244,747 244,747	371,964 371,964

**EMORY UNIVERSITY AND ITS SUBSIDIARIES**  
Supplementary Schedule of Expenditures of Federal Awards  
Year ended August 31, 2020

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
National Ebola Training and Education Center	NU38CK000481	93.825	\$ —	142,249
Total CFDA No. 93.825			—	142,249
HIV Emergency Relief Project Grants				
Pass-through Fulton County	2 HA89HA00007-29-00	93.914	—	263,857
Pass-through Fulton County	2H9HA00007-28-00	93.914	—	6,467
Pass-through Fulton County	6 H89HA00007-26-01	93.914	—	499,273
Total CFDA No. 93.914			—	769,597
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H76HA07848	93.918	—	680,847
Total CFDA No. 93.918			—	680,847
HIV Prevention Activities Health Department Based				
Pass-through Georgia Dept of Public Health	40500-037-20203126	93.940	—	293,945
Total CFDA No. 93.940			—	293,945
Assistance Programs for Chronic Disease Prevention and Control				
Pass-through Ohio Department of Health	NU58DP006544	93.945	—	626
Total CFDA No. 93.945			—	626
Block Grants for Prevention and Treatment of Substance Abuse				
Pass-through Georgia Department of Behavioral Health	44100-906-0000118070	93.959	—	41,747
Pass-through Georgia Department of Behavioral Health	44100-907-0000100119	93.959	—	(1,052)
Pass-through Georgia Department of Behavioral Health	B08TI010061-20; FY20 SAPT BG	93.959	—	429,387
Total CFDA No. 93.959			—	470,082
CDC's Collaboration with Academia to Strengthen Public Health				
Pass-through Assoc for Prevention Teaching and Res	NU36O000008	93.967	—	5,125
Total CFDA No. 93.967			—	5,125
Contract	1,990,029	93.CTR	—	39
Contract	200-2008-24753/0001	93.CTR	(2,730)	(2,730)
Contract	200-2015-87862 00007	93.CTR	2,730	1,101,003
Contract	200-2016-M-91197	93.CTR	—	(22)
Contract	75D30120POT855	93.CTR	—	422,056
Contract	PO # 200-2017-M-95264	93.CTR	—	19
Pass-through Assoc for Prevention Teaching and Res	18-16-TH01	93.CTR	—	1,025
Pass-through Assoc of State & Territorial Dental	ASTDD072215/AMND 4	93.CTR	—	11,616
Pass-through Connecticut Department of Health	DPHM1-0000066204	93.CTR	—	7,459
Pass-through Connecticut Department of Health	PO. DPHM1-0000068805	93.CTR	—	964
Pass-through Georgia Department of Community Health	2,017,001	93.CTR	—	277,687
Pass-through Georgia Dept of Public Health	40500-036-17161798	93.CTR	—	(38)
Pass-through Georgia Dept of Public Health	40500-036-18161798	93.CTR	—	(20,000)
Pass-through Georgia Dept of Public Health	40500-036-20161798	93.CTR	—	66,505
Pass-through Green River District Health Department	20-314-389-24	93.CTR	—	54,080
Pass-through Leidos Biomedical Research	75N91019D00024	93.CTR	123,179	253,727
Pass-through NORC at the University of Chicago	7843.Emory.01	93.CTR	—	110
Pass-through North Carolina Dept of Hlth and Human Services	PO #NC10528502	93.CTR	—	6,866
Total CFDA No. 93.CTR			123,179	2,180,366
U.S. Department of Health And Human Services Total			1,150,224	19,514,500
Total Expenditures of Federal Awards			\$ 85,785,445	651,218,556

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.



**EMORY UNIVERSITY AND ITS SUBSIDIARIES**

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2020

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
2 HA89HA00007-29-00	FULTON COUNTY	17RW2018A-MH, FY 18 Ryan White Part A	\$ 171,661	263,857
2017001	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Pro	903,355	277,687
2H9HA00007-28-00	FULTON COUNTY	17RW2018A-MH, FY 18 Ryan White Part A	—	6,467
40500-033-16161809	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	167,134	281,964
40500-036-16161891	GEORGIA DEPT OF PUBLIC HEALTH	Statistical Support for Syndromic Surveillance	—	490
40500-036-17161798	GEORGIA DEPT OF PUBLIC HEALTH	Georgia Coverdell Acute Stroke Registry	—	(38)
40500-036-19161798	GEORGIA DEPT OF PUBLIC HEALTH	Georgia Coverdell Acute Stroke Registry	13,296	(20,000)
40500-036-21161799	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	2,975,097	640,356
40500-037-20203126	GEORGIA DEPT OF PUBLIC HEALTH	Emory Prevention Clinic	293,951	293,945
42700-040-0000072848	GEORGIA DEPARTMENT OF HUMAN SERVICES	2019 Summer Child Advocacy Program	45,659	3,058
42700-040-0000088042	GEORGIA DEPARTMENT OF HUMAN SERVICES	2020 Summer Child Advocacy Program	29,543	97,000
44100-906-0000118070	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Fetal Alcohol and Drug Screening project: MASCD	124,989	41,747
44100-907-0000099734	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Emory Neuro Developmental Exposure Clinic (ENEC)	190,000	2,342
44100-907-0000100119	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Fetal Alcohol and Drug Screening project: MASCD	(2,495)	(1,052)
4410-907000133937	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2019-2020 Emory Neuro Developmental Exposure Clinic (ENEC)	95,000	186,573
6 H89HA00007-26-01	FULTON COUNTY	17RW2018A-MH, FY 18 Ryan White Part A	581,070	499,273
B08T1010061-20; FY20 SAPT BG	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2019-2020 Fetal Alcohol and Drug Screening project: MASCD	416,660	429,387
NU58DP006580	GEORGIA DEPT OF PUBLIC HEALTH	Evaluation of the REACH Grant	49,006	29,044
VS14448/PO11817S108584RD	FULTON COUNTY	Ryan White Comprehensive AIDS Resources	—	(285)
			<u>\$ 6,053,926</u>	<u>3,031,815</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND  
EXPENDITURES OF STATE OF GEORGIA AWARDS**

## EMORY UNIVERSITY AND ITS SUBSIDIARIES

### Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2020

#### (1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University and its subsidiaries (the University) and is presented on the accrual basis of accounting. The Schedule presents all grants, contracts, and similar agreements entered into directly between agencies and departments of the federal government and subawards to the University from nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The Schedule also presents awards passed through from the University to other nonfederal subrecipient organizations. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred (i.e., on an accrual basis) by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

#### (2) Basis of Accounting

Expenditures for federal student financial assistance programs are recognized as incurred and include grants to students under the Federal Pell Grant and Federal Supplemental Educational Opportunity Grant Programs, student earnings under the Federal Work Study Program, and administrative cost allowances, where applicable. Expenditures for loans related to the Federal Direct Student Loan Programs (FDSLP) are reported in the Schedule when disbursed.

New loans made during the fiscal year and loans from previous fiscal years for which the University has continuing compliance requirements to adhere to related to the Federal Perkins Loan Program are reported in the Schedule. Expenditures for other federal awards are recognized as incurred using the cost accounting principles contained in Uniform Guidance. Under these cost principles, certain types of expenses are not allowable or are limited as to reimbursement.

COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured (CFDA 93.461) includes reimbursements for health care services rendered through August 31, 2020.

#### (3) Federal Loan Programs

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the FDSLP and revolving loan programs, such as the Federal Perkins Loan Program.

## EMORY UNIVERSITY AND ITS SUBSIDIARIES

### Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2020

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>CFDA number</u>	<u>Amount</u>
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 8,492,064
Unsubsidized Stafford Loan Program	84.268	<u>70,577,346</u>
Total Direct Stafford Loan Program		79,069,410
Federal Direct PLUS Loan Program	84.268	<u>45,345,792</u>
Total Federal Direct Student Loan Programs		<u>\$ 124,415,202</u>

The Federal Perkins Loan Program is administered directly by the University, and balances and transactions relating to this program are included in the University's consolidated financial statements. The amount presented on the Schedule represents the Federal Perkins Loans outstanding as of August 31, 2019. Federal Perkins Loans outstanding at August 31, 2020 totaled \$5,653,185. No new loans were awarded or disbursed during the year ended August 31, 2020.

The University is responsible for the performance of certain administrative duties with respect to the FDSLP. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2020. These loans are not included in the University's consolidated financial statements.

#### (4) Matching

Under the Federal Supplemental Educational Opportunity Grant Program, the University matched \$391,793 in funds awarded to students for the year ended August 31, 2020 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study Program, the University matched \$737,145 in total compensation to students for the year ended August 31, 2020 in addition to the federal share of expenditures included in the Schedule.

#### (5) Administrative Cost Allowance

The University recorded an administrative cost allowance of \$72,125 for the year ended August 31, 2020. This amount is included in the Schedule as federal expenditures under the Federal Work Study Program.

#### (6) Indirect Costs

For the year ended August 31, 2020, the University did not elect to use the 10% de minimis indirect cost rate permitted by the Uniform Guidance.

## **UNIFORM GUIDANCE REPORTS**



KPMG LLP  
Suite 2000  
303 Peachtree Street, N.E.  
Atlanta, GA 30308-3210

**Independent Auditors' Report on Compliance For Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards**

The Board of Trustees  
Emory University:

**Report on Compliance for Each Major Federal Program**

We have audited Emory University's (the University) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended August 31, 2020. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

*Management's Responsibility*

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

*Auditors' Responsibility*

Our responsibility is to express an opinion on compliance for the University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of the Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Emory University's compliance with those requirements and performing such other procedures as we consider necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the University's major federal programs. However, our audit does not provide a legal determination of the University's compliance.

*Opinion on Each Major Federal Program*

In our opinion, Emory University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2020.

**Report on Internal Control Over Compliance**

Management of Emory University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing



procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

#### **Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards**

We have audited the consolidated financial statements of Emory University and subsidiaries as of and for the year ended August 31, 2020, and have issued our report thereon dated December 18, 2020, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

**KPMG LLP**

Atlanta, Georgia  
July 22, 2021

## EMORY UNIVERSITY AND ITS SUBSIDIARIES

### Schedule of Findings and Questioned Costs

Year ended August 31, 2020

#### (1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
  - Material weaknesses: **No**
  - Significant deficiencies: **None reported**
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
  - Material weaknesses: **No**
  - Significant deficiencies: **None reported**
- (e) Type of auditors' report issued on compliance for major programs: **Unmodified**
- (f) Any audit findings, which are required to be reported under Section 2 CFR 200.516(a) of Uniform Guidance: **No**
- (g) Major programs:
  - **Research and Development cluster** – various CFDA numbers
  - **COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured** – CFDA number 93.461
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

#### (2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards*

None

#### (3) Findings and Questioned Costs Relating to Federal Awards

None